Molecular imaging of dopamine synthesis and release by Shotbolt, John
1 
 
 
Molecular imaging of dopamine 
synthesis and release 
 
 
 
Dr John Paul Shotbolt MA MBBS MRCPsych 
 
 
 
Department of Medicine 
Imperial College London  
 
 
 
Thesis submitted for the degree of Doctor of Philosophy 
 
2 
 
Abstract 
 Positron emission tomography (PET) can be used to measure striatal dopamine synthesis and 
release, both of which have been shown to be elevated in schizophrenia. One study has 
demonstrated that first degree relatives of schizophrenia patients exhibit increased dopamine 
synthesis capacity, suggesting this could be an endophenotype or susceptibility marker. 
However, the specific relation to schizophrenia was not tested, as the index cases were not 
studied. In this thesis, I directly tested the hypothesis that both members of twin pairs 
discordant for schizophrenia show similar increases in dopamine synthesis capacity. I found 
that striatal dopamine synthesis capacity is not elevated in individuals at genetic risk of 
schizophrenia or in stable patients with chronic schizophrenia, suggesting that it is not a 
vulnerability marker for schizophrenia, and is associated with active psychosis only.   
 
I also tested whether dopamine synthesis capacity is elevated in otherwise healthy people 
who report hallucinations. No elevation was found, suggesting that the underlying 
neurobiology is distinct from schizophrenia. 
 
I then considered whether it would be possible to examine similar relationships with 
measurements of dopamine release. Methodologies for this measurement were still limited: 
antagonist radioligands such as [
11
C] raclopride have been used, but the dynamic range for 
the measure is small, confounding precision.  I hypothesised that agonist radioligands could 
provide a more sensitive measure. [
11
C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-
naphtho[1,2-b][1,4]oxazin-9-ol ([
11
C]-(+)-PHNO) is a D2/D3 agonist PET radioligand. I 
directly compared the sensitivity of [
11
C]-(+)-PHNO to amphetamine challenge with that of 
the antagonist ligand [
11
C] raclopride. Mass carry-over and cerebellar binding were potential 
problems with [
11
C]-(+)-PHNO. I therefore designed a study to quantify these factors. I found 
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that [
11
C]-(+)-PHNO is superior to [
11
C]raclopride for studying acute fluctuations in 
dopamine in the striatum. Use of [
11
C]-(+)-PHNO will allow quantification of smaller 
changes in dopamine release, although mass effects and displaceable cerebellar binding are 
potential confounding factors. 
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Chapter 1. Schizophrenia and the dopamine system  
1.1. Schizophrenia  
Schizophrenia is a psychiatric disorder that affects around 1% of the population. The illness 
is characterised by perceptual disturbances, such as auditory hallucinations and delusional 
beliefs. Cognitive decline and negative symptoms such as apathy and social withdrawal are 
also common. Classically the age of onset is in the patient’s late teens or early 20’s. The 
disease usually follows a relapsing and remitting course. As a result of this the economic 
burden of the disease is significant. In addition the individual’s ability to work is also 
severely compromised, as is social functioning. 
 
1.2. History of the disorder 
The nature of ‘schizophrenia’ has historically always been controversial. One early accepted 
system was based on Greisinger’s ideas that only affective disorders could constitute a 
primary disease process, and that what would now be described as chronic schizophrenia 
could only occur secondarily (i.e. after a primary affective disorder) (Greisenger, 1861). 
Kraepelin turned against this idea in 1886, and used the term ‘dementia praecox’ to 
distinguish the illness from the affective psychoses, introducing the so-called ‘Kraepelian 
dichotomy’. However, he eventually agreed that dementia praecox and affective psychosis 
could coexist, and therefore the possibility of a ‘unitary psychosis’ could not be excluded. 
 
The term ‘schizophrenia’ was actually developed by Eugen Bleuler. He maintained the 
separation from the affective psychoses while recognising that affective symptoms could co-
exist. His concept was based on the assumption that the external clinical manifestations 
masked an inner clinical unity, analogous to the modern concept of an endophenotype. 
Bleuler’s primary symptom was cognitive, namely loosening of associations. He also 
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believed that the core symptoms of disorders of affect, ambivalence, autism, attention and 
will were present in every case. He regarded other symptoms such as catatonia, delusions, 
hallucinations and behavioural problems as accessory psychological reactions not caused by 
the underlying biological process.  Kurt Schneider composed a list of psychopathological 
symptoms which could be used to differentiate schizophrenia from affective psychosis with a 
degree of reliability. These ‘first-rank’ symptoms included thoughts experienced as spoken 
aloud or echoed, voices commenting on the patient’s thoughts in the form of a ‘running 
commentary’ in the third person,  passivity phenomena (i.e.,  experiencing bodily functions 
movements or emotions as being under the control of some external force or agency), 
delusional atmosphere (i.e., a pervasive feeling that something strange is about to happen) 
and delusional perception (i.e., a  normal percept is imbued with enormous personal, 
unexplainable and often bizarre significance). Modern international classification systems 
such as the International Classification of Diseases (ICD) and the Diagnostic and Statistical 
Manual of Mental Disorders (DSM) have generally drawn on these early classifications to 
attempt to reach an international agreement.  These reflect our current understanding of the 
concept of schizophrenia. To make the diagnosis, ICD-10 requires either one of the 
Schneiderian first-rank symptoms, or bizarre delusions, or two or more symptoms including 
persistent hallucinations, thought disorder, catatonic behaviour, negative symptoms or 
significant and persistent behavioural change. The features must be present for one month or 
longer. DSM-IV requires at least two of the symptoms of delusions, hallucinations, 
disorganised speech, disorganised catatonic behaviour or negative symptoms, to be present 
for one month or longer. Only one of these is required if the delusions are bizarre or third-
person auditory hallucinations or running commentary are present. In addition six months of 
social or occupational dysfunction are required to make the diagnosis. Both classification 
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systems exclude schizoaffective and mood disorders, and disorders secondary to general 
medical condition and substance misuse.  
  
1.3. The neurodevelopmental hypothesis of schizophrenia 
Both Kraepelin and Bleuler noticed the presence of abnormal neurological and behavioural 
signs in the childhood histories of adult patients, as did other researchers working in the early 
part of the twentieth century. Fish and Hagin (Fish and Hagin, 1972) described a constellation 
of delays and disruptions in neurological development which predicted the later emergence of 
schizophrenia symptoms, proposing abnormal brain development as the cause. Watt (Watt, 
1972) recognised early childhood social abnormalities in patients with adult-onset 
schizophrenia, and again put forward abnormal brain development as the cause. However 
despite this body of work the pervasive view amongst psychiatrists at the time was that 
schizophrenia was caused by a pathological process that occurs around early adult life, and 
that progression of the condition is an expression of progression of the underlying pathology. 
This viewpoint was consistent in many ways to Kraepelin’s classification of schizophrenia as 
an early dementia (‘dementia praecox’). 
 
A conceptual shift began to take place in the mid-1980s, when the possibility of abnormal 
brain development came back into favour and the neurodevelopmental hypothesis was 
embraced by academic psychiatry. Several strands of evidence led to this paradigm shift. 
Firstly, longitudinal studies showed that a degree of recovery was possible in schizophrenia, 
thus undermining the Kraepelian concept of a degenerative disease (Harding et al.  1992; 
Tsuang et al.  1979). Also, in patients who did not have good outcomes, the pattern of 
neuropsychological impairment was not one of a progressive deterioration (Aylward et al.  
1984). Secondly, the development of neuroimaging technologies led to the finding of 
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increased ventricular size (Johnstone et al.  1976). The fact that this finding was present from 
the beginning of the illness and was stable throughout in most longitudinal studies further 
suggested that a degenerative process was not responsible (Jaskiw et al.  1994; Weinberger et 
al.  1979).    Concurrent post-mortem histological studies did not find evidence of 
neurodegeneration. 
 
As part of the refinement of the hypothesis it was proposed that abnormalities of cortical 
development increase the risk for the emergence of schizophrenia in adulthood. This 
neurodevelopmental hypothesis suggested that the emergence of the syndrome depended on 
the interaction of early developmental abnormalities, triggered by genetic and/or 
environmental factors, with the normal brain maturational changes that take place in early 
adulthood. Further support for the hypothesis came from studies that found an association 
between schizophrenia, obstetric complications and in utero adversity. More recently the 
failure to discover genetic associations with high risk ratios and the fact that disease 
concordance in monozygotic twins is far from 100% have led to the suggestion that 
epigenetic factors are significant in the etiology of the condition. 
 
1.4. Heritability 
Schizophrenia clearly aggregates in families. Genetic epidemiological surveys reveal robust 
evidence for heritability at around 80% (Cannon et al.  1998; Cardno and Gottesman, 2000; 
Sullivan et al.  2003). Schizophrenia is increasingly thought to be a complex genetic disorder. 
Specific risk loci are yet to be identified. One hypothesis to explain this is that the condition 
results from a combination of relatively common genes with small effects and some rare 
alleles with large effect. Work in psychiatric genetics began with linkage studies in families 
with a high disease density, with a view to detecting high penetrance genes by examining 
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functional candidate genes. This progressed to larger scale linkage studies as well as studies 
of microscopic chromosomal abnormalities. No strongly replicated findings have emerged 
from whole genome association studies. Positional cloning studies have been more fruitful, 
and a small number of susceptibility genes have been implicated in multiple studies (Ross et 
al.  2006). Those for which the evidence is strongest include DISC1, NRG1, DTNBP1, 
DAOA and COMT. However, despite this evidence, there have been no specific risk alleles 
that can be unequivocally implicated as causal. In addition the strength and consistency of the 
genetic evidence is lower than for genes known to be involved in a number of other complex 
diseases.  It is notable that none of the genetic loci identified in whole genome association or 
linkage studies to date appear to be related specifically to dopaminergic neurotransmission, 
abnormalities of which appear strongly implicated in schizophrenia based on decades of 
pharmacological studies (see below).   
 
More recently, genome-wide association studies have identified common genetic variations 
that meet modern standards for replication and significance in human genetics (Kim et al.  
2011). Further larger studies are required to identify more risk loci. In addition, as mentioned 
above, epigenetic factors may have a role in the etiology of schizophrenia. A genome-wide 
analysis of DNA methylation from a sample of MZ pairs discordant for major psychosis 
found numerous disease-associated differences in DNA methylation (Dempster et al.  2011). 
Many of the differences were located in regions close to genes that have been previously 
associated with psychosis. 
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1.5. Dopamine pharmacology and the dopamine hypothesis of schizophrenia 
1.5.1. Dopamine pharmacology  
Dopamine is a monoaminergic neurotransmitter. Its neurotransmitter role was first described 
by Carlsson (Carlsson et al.  1957; Carlsson et al.  1958). Dopamine is synthesised in the 
brain from L-tyrosine, which is converted to L-3,4-dihydroxyphenylalanine (L-DOPA) by 
tyrosine hydroxylase and then to dopamine by L-aromatic acid decarboxylase (AADC). After 
synthesis dopamine is transported into presynaptic vesicles where it is stored (Figure 1). 
 
Figure 1. Prototypic dopaminergic terminal with cycle of synthesis, storage, release and 
removal of dopamine (from Cooper et al. 1996) 
 
 
 Upon depolarisation of the neurone, dopamine is released into the synaptic cleft and binds 
post-synaptically to one of five G-protein linked dopaminergic receptors, D1-5. Dopamine 
receptors were initially divided into D1 and D2 subgroups by Kebabian and Calne (Kebabian 
and Calne, 1979). Subsequently cloning studies have subdivided them further into the ‘D1-
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like’ family consisting of D1 and D5 receptors and a ‘D2-like’ family consisting of D2, D3 and 
D4 receptors. Dopamine receptors belong to the G-protein coupled superfamily.  G-proteins 
are membrane receptors that have 7 transmembrane spanning α–helices (Figure 2). Dopamine 
binding to the ‘binding groove’ on the extracellular portion of the receptor activates the G-
proteins, which initiate secondary messenger signalling pathways. The downstream effect 
will be either inhibitory or stimulatory, depending on the type of G-protein linked to the 
receptor – dopamine D1 and D5 receptors are linked to stimulatory G-proteins, whereas 
dopamine D2-like receptors (D2, D3 and D4) are linked to inhibitory G-proteins (Neve et al.  
2004).  
It is generally accepted that the D1-like receptors are found exclusively post-synaptically on 
dopamine-receptive cells. In contrast, D2 and D3 dopamine receptors are expressed both 
postsynaptically on dopamine target cells and presynaptically on dopaminergic neurons 
(Sokoloff et al. 2006; Rankin et al. 2010). 
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Figure 2. The dopamine receptor showing seven transmembrane α-helices (from CNS 
forum.com) 
 
Common to all G protein-linked receptors is the fact that the affinity of D2-like receptors for 
agonists is affected by the coupling of the receptors with G proteins. The high-affinity sites 
(D2 high) are G protein-coupled, whereas the low-affinity sites (D2 low) are G protein 
uncoupled. It has been suggested from in vitro homogenate binding studies that 
approximately 50% of D2 receptors are configured in the G-protein coupled D2 high state 
(Sibley et al.  1982). In anaesthetised primates  was estimated at 71% (Narendran et 
al. 2005), while a subsequent study in humans found a somewhat lower estimate of ~60% 
(Narendran et al. 2010). It has been hypothesised that the for the D2 receptor is 
elevated in schizophrenia (Seeman et al.  2006; Seeman, 2011). 
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1.5.2. Dopamine receptor location 
 
Dopamine receptors are broadly distributed throughout the brain. D1 receptors are expressed 
at high density in nigrostriatal, mesolimbic, and mesocortical areas, such as the caudate and 
putamen (striatum), nucleus accumbens, substantia nigra, olfactory bulb, amygdala, and 
frontal cortex, as well as at lower levels in the hippocampus, cerebellum, thalamic areas and 
hypothalamus. D5 receptors are expressed at low levels in multiple regions, including 
pyramidal neurons of the prefrontal cortex, the premotor cortex, the cingulate cortex, the 
entorhinal cortex, substantia nigra, hypothalamus, the hippocampus, and the dentate gyrus. 
(Missale et al. 1998; Gerfen, 2000; Sokoloff et al. 2006). 
 
The highest levels of D2 receptors are found in the striatum, the nucleus accumbens, and the 
olfactory tubercle. D2 receptors are also expressed at significant levels in the substantia nigra, 
ventral tegmental area, hypothalamus, cortical areas, septum, amygdala, and hippocampus 
(Missale et al. 1998; Gerfen, 2000; Vallone et al. 2000; Seeman, 2006). The D3 receptor is 
more limited in distribution, its highest level of expression is in the limbic areas, such as in 
the shell of the nucleus accumbens, the olfactory tubercle, and the islands of Calleja 
(Sokoloff et al. 2006; Missale et al. 1998). The D3 receptor is also found in the striatum, the 
substantia nigra pars compacta, the ventral tegmental area, the hippocampus, the septal area, 
the thalamus and hypothalamus, and in various cortical areas. The D4 receptor has the lowest 
level of expression in the brain, and is found in the frontal cortex, amygdala, hippocampus, 
hypothalamus, globus pallidus, substantia nigra pars reticulata, and thalamus (Missale et al. 
1998; Rondou et al. 2010). 
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The actions of D2-like receptors are much more complex than D1 receptors because they are 
located both as heteroreceptors on post-synaptic membranes, and as autoreceptors  (Missale 
et al. 1998; Sibley, 1999, Sokoloff, 2006). The splice variants of the D2 dopamine receptor, 
D2L and D2S, have different neuronal distributions, D2S being predominantly presynaptic 
and D2L being postsynaptic. D2L differs from D2S by the presence of an additional 29 
amino acids within the third intracellular loop. This region is implicated in the receptor 
interaction with G-proteins and indeed D2L and D2S possess different coupling affinities for 
these proteins (Montmayeur et al. 1993; Guiramand et al. 1995). The D2L, but not D2S, 
requires the presence of the alpha-subunit of the inhibitory G-protein to elicit greater 
inhibition of adenylyl cyclase activity.  
 
The different roles of the postsynaptic and presynaptic D2 receptors are probably determined 
by the different contributions of these isoforms (Usiello et al. 2000; De Mei et al. 2009). 
Presynaptic autoreceptors generally provide negative feedback, with activation of the 
receptor by elevated neurotransmitter levels leading to a reduction in the neuronal firing rate 
and  neurotransmitter synthesis (Wolf and Roth, 1990; Missale et al. 1998; Sibley, 1999). D2 
autoreceptors are generally activated by a lower concentration of dopamine agonist than 
necessary to activate postsynaptic receptors; the same dopamine agonist can induce a 
biphasic effect, thus causing decreased activity at low doses and activation at high doses.  
 
D2 receptors are the predominant type of autoreceptors that are involved in the presynaptic 
regulation of the firing rate, synthesis of dopamine and release of dopamine. However D3 
autoreceptors may also contribute to the presynaptic regulation of tonically released 
dopamine, thereby complementing the D2 autoreceptor’s role in regulating the neuronal firing 
rate, synthesis of dopamine, and phasic release of dopamine (De Mei et al. 2009). 
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1.5.3. The dopamine hypothesis 
The classical dopamine hypothesis of schizophrenia postulates that the positive symptoms are 
associated with an excess of subcortical dopamine. This dopaminergic excess subcortically 
results in the hyperstimulation of D2 receptors, which is thought to lead to positive symptoms. 
This classical hypothesis was based on two observations, firstly that prolonged exposure to 
D2 receptor agonists induces psychotic symptoms and secondly that all drugs with proven 
antipsychotic action block D2 receptors to some degree. In the early 1990s the classical 
hypothesis was reformulated to include an explanation to account for the negative and 
cognitive symptoms of the disorder (Davis et al.  1991). This arose from the observations that 
cognitive impairment is associated with lesions to the prefrontal cortex (PFC), and that 
experimentally induced dopamine depletion in the PFC in animals results in cognitive 
impairment.  The dopaminergic deficit in the PFC is thought to result in the hypostimulation 
of D1 receptors, which leads to the negative and cognitive symptoms. The revised dopamine 
hypothesis thus postulates coexistence of a dopamine excess subcortically and a dopamine 
deficit cortically.  This hypothesis has been supported by evidence from neurochemical 
imaging studies. This evidence is discussed below. 
1.5.4. Increased dopamine synthesis 
Ten studies have investigated pre-synaptic striatal dopaminergic function in schizophrenia 
through quantification of the uptake of the PET radiotracers L-[ -
11
C]-DOPA or 6-
[
18
F]fluoro-L-DOPA (
18
F-DOPA). Eight out of the ten studies reported elevated striatal 
DOPA uptake in patients with schizophrenia, including all the studies in patients in the acute 
psychotic phase of the illness (reviewed in Howes et al.  2009a). The two studies that did not 
report an elevation were in chronic, remitted patients (Dao-Castellana et al.  1997; Elkashef et 
al.  2000). Overall, these studies support the hypothesis that striatal hyperdopaminergia is 
important in the aetiology of psychosis in schizophrenia (Davis et al.  1991; Howes and 
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Kapur, 2009b). The neurotransmitter basis of the genetic vulnerability to schizophrenia has 
been examined using PET. A recent study examining striatal dopamine synthesis capacity in 
first degree relatives of patients with schizophrenia found that this group had higher striatal 
[
18
F]-DOPA uptake values than unrelated controls at low genetic risk (Huttunen et al.  2008). 
Furthermore, elevated striatal dopaminergic function has also been reported both in people 
who are vulnerable to schizophrenia because they have prodromal signs of the disorder 
(Howes et al.  2009c), or they have schizotypal personality disorder (Abi-Dargham et al.  
2004). Furthermore a recent study examining subjects with prodromal signs of the disorder 
have shown that those individuals who progress to frank psychosis have higher [18F] DOPA 
Ki values in the striatum, and specifically the  associative striatum subdivision, than a 
comparison group of healthy controls. In addition dopamine synthesis capacity was also 
greater in the group who made the transition to psychosis than in the non-transition group 
(Howes et al. 2011a). The same group found a significant longitudinal increase in dopamine 
synthesis capacity in the sensorimotor striatum in prodromal individuals who develop 
psychosis (Howes et al. 2011b). 
These findings suggest that hyperactivity of the striatal dopaminergic system is also present 
in individuals at risk for schizophrenia, and that this hyperactivity increases further in those 
patients who make the transition to psychosis.  In the Huttunen paper, it is suggested that the 
magnitude of the dopaminergic elevation seen in the well relative is similar to that seen in 
patients with schizophrenia. However, crucially they did not examine dopamine function in 
the unwell schizophrenia probands, but made the comparison with a group of previously 
studied unrelated patients.  
 
If the Huttunen hypothesis is correct, hyperactivity of the striatal dopamine system may 
represent an endophenotype which is present both in individuals with schizophrenia and those 
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at risk of developing the disorder. An endophenotype is defined as an internal phenotype lying 
intermediate between the genes and the disease itself. This concept is based on the assumption that 
genes involved in endophenotypic variation are likely to represent more elementary phenomena than 
those involved in complex psychiatric diagnostic entities. It is used interchangeably with the term 
‘intermediate trait,’ which is also used to describe a heritable quantitative phenotype believed to be 
closer in the chain of causality to the genes underlying the disease. 
 
1.5.5. Increased subcortical dopamine release in schizophrenia after challenge 
Change in subcortical endogenous dopamine levels can be measured using in vivo molecular 
imaging techniques in competition studies. The standard paradigm is to perform baseline and 
post challenge PET scans using a D2/3 radioligand. The challenge agent is usually the potent 
dopamine releasing agent amphetamine, although this is problematic as it can make psychotic 
symptoms worse. Examination of the differences in radioligand binding potential between the 
two scans gives a measure of dopamine release. It has been consistently demonstrated in 
several studies that dopamine release is significantly higher in schizophrenia patients when 
compared to normal controls. Moreover the amount of amphetamine released after challenge 
correlates with the deterioration of psychotic symptoms (Laruelle et al.  1999), lending 
weight to the dopamine hypothesis.  
 
Until now antagonist radiotracers such as [
11
C] raclopride have been used to measure 
dopamine release. Agonist radiotracers such as [
11
C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-
2H-naphtho[1,2-b][1,4]oxazin-9-ol ([
11
C]-(+)-PHNO) should be should be more affected by 
acute fluctuations in synaptic dopamine (DA) than that of antagonist radiotracers such as 
[
11
C]raclopride. If this is the case, use of agonist radiotracers will allow detection of smaller 
changes in endogenous dopamine levels, and could perhaps enable the use of alternative 
challenge agents in place of amphetamine. 
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1.5.6. Increased baseline occupancy by dopamine in schizophrenia 
Baseline receptor occupancy by endogenous dopamine can be measured using a dopamine 
depleting agent such as α-methyl-para-tyrosine (AMPT). AMPT blocks tyrosine 
hydroxylase, thus preventing new dopamine synthesis. Endogenous dopamine is depleted 
from the synapse, and a greater number of D2 receptors are available to the radioligand. 
Again a two scan design is required, a baseline scan followed by a post-depletion scan. The 
difference in radioligand binding between the scans provides a measure of baseline 
occupancy. It has been demonstrated that the increase in availability of D2 receptors was 
significantly greater after AMPT treatment in schizophrenia when compared to normal 
controls (Abi-Dargham et al.  2000). In addition,  patients who showed higher levels of 
occupancy by endogenous dopamine at baseline showed greater improvement in psychotic 
symptoms after 6 weeks of antipsychotic treatment. 
 
A consistent assumption within the field has been that aberrant dopamine neurotransmission 
in the limbic striatum is a major factor in the pathophysiology of schizophrenia. However, a 
case-control study comparing drug-naive patients with schizophrenia and healthy controls 
(Kegeles et al.2010) has demonstrated that the associative striatum was the area where 
baseline dopamine levels were significantly greater in patients compared to controls. The 
other striatal subdivisions (including the limbic striatum) did not demonstrate significant 
differences from controls. Moreover, of the associative striatum sub-divisions, this effect was 
most pronounced in the precommisural dorsal caudate (preDCA) (15% [8%] in patients vs 
9%[8%] in healthy controls, P=0.03). ).   
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This localisation of the elevated dopaminergic activity to the associative striatum was 
consistent with the findings of Howes et al. in prodromal subjects (Howes at al. 2009c, 
2011a). 
 
The associative striatum is functionally conncted to the dorsolateral prefrontal cortex 
(DLPFC), the neocortical area most implicated in the pathophysiologic mechanism of 
schizophrenia, with the preDCA area of the associative striatum receiving the largest 
corticostriatal projections from the DLPFC.  The results are consistent with the theory that 
disruption of the DA transmission in the associative striatum may impact on DLPFC 
function. 
 
1.5.7. Dopamine in cortical regions 
D1 receptors are the commonest receptor subtype in this area. In a study looking at D1 
availability in patients with schizophrenia and healthy controls (Abi-Dargham et al.  2002), a 
significant increase in D1 receptors was found in the dorsolateral prefrontal cortex (DLPFC). 
Although D1 receptors were elevated almost universally in the cortex, these increases did not 
reach statistical significance in other cortical regions.   
The increase was not caused by previous antipsychotic medication and was not associated 
with clinical symptomatology. The DLPFC is important in working memory, which provides 
the ability to manipulate information in order to perform complex tasks. Working memory 
impairment is a core feature of schizophrenia. The n-back task was devised to test working 
memory (Cohen et al.  1994). In the task, subjects are presented with a series of letters 
sequentially, and are asked to respond if the letter was the same as the one presented either 
one, two or three letters back. The task requires subjects to remember what they are seeing 
and to continuously update this as new letters are presented. The finding that working 
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memory is impaired in schizophrenia has been robustly demonstrated (Gold et al.  1997; Park 
and Holzman, 1992). A relationship was demonstrated between the pathological cortical up-
regulation in D1 receptors in schizophrenia patients and working memory performance (n-
back task) in the study described above examining D1 receptor availability in patients with 
schizophrenia and healthy controls (Abi-Dargham et al.  2002). This relationship was not 
found in controls. It may be that the upregulation of D1 receptors is a result of compensation 
for the dopamine deficit in the cortex. This is consistent with other evidence suggesting that 
schizophrenia is associated with a deficit in prefrontal dopaminergic functioning. A 
relationship between low CSF homovanillic acid and poor performance on tasks involving 
the DLPFC in schizophrenia has been demonstrated (Kahn et al.  1994; Weinberger et al.  
1988), and there is a positive effect of DA dopamine agonists on DLPFC activation during 
these tasks (Daniel et al. 1989; Dolan et al. 1995). An alternative explanation is that the D1 
upregulation is a primary phenomenon (ie not related to a dopamine deficit), and that the 
working memory problem results from increased postsynaptic sensitivity to dopamine 
released during the task. If this were the case then an improvement in working memory in 
schizophrenia patients might be expected following administration of specific D1 antagonists. 
However, while working memory has not been specifically examined, therapeutic trials of D1 
antagonists in schizophrenia generally show no effect or a worsening in clinical condition (de 
Beaurepair et al.  1995; den Boer et al.  1995; Karle et al.  1995; Karlsson et al.  1995). 
 
1.6. Questions addressed in this thesis 
As described above, it is apparent that the current in vivo imaging findings robustly 
demonstrate that both presynaptic striatal dopamine synthesis capacity and post-synaptic 
dopamine release is increased in schizophrenia.  One of the main aims of this thesis is to 
examine further the relationship between dopamine synthesis capacity, risk of psychosis and 
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schizophrenia.  In the first study presented here, striatal [
18
F]DOPA uptake is investigated in 
twin pairs discordant for schizophrenia to test the hypothesis that unaffected members of twin 
pairs discordant for schizophrenia show elevations in striatal [
18
F]DOPA uptake of a similar 
magnitude to their co-twin with schizophrenia, as proposed by Huttunten (Huttunen et al.  
2008).  
 
This work with relatives of schizophrenia patients then led me to consider the role of 
dopamine dysfunction in other sub-clinical populations. The psychosis phenotype appears to 
exist in the population as a continuum, but it is not clear if sub-clinical psychotic symptoms 
in the normal population and psychosis in schizophrenia share the same underlying 
neurobiology. To examine this question, I investigated whether the dopaminergic dysfunction 
seen in schizophrenia is also present in well functioning people with auditory verbal 
hallucinations. 
 
Having focussed initially on striatal dopamine synthesis in schizophrenia and psychosis, I 
then consider the measurement of dopamine release. As discussed above, it has been robustly 
demonstrated that patients with high levels of positive psychotic symptoms show increased 
dopamine release following an amphetamine challenge when compared to normal controls. 
The use of amphetamine in actively psychotic patients is controversial and challenging as it 
can make symptoms worse. I wanted to test the hypothesis that agonist radiotracers such as 
[
11
C]-(+)-PHNO are more affected by acute fluctuations in synaptic dopamine (DA) than 
antagonist radiotracers such as [
11
C]raclopride. If  [
11
C]-(+)-PHNO allows quantification of 
smaller changes in dopamine release then patient groups where increases in release, if 
present, might be expected to be smaller in magnitude to those seen in schizophrenia patients 
could be studied. In addition, alternative safer challenge agents could be used in place of 
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amphetamine in future studies in psychosis and schizophrenia. A well characterised agonist 
ligand would also enable estimations to be made of the the proportion of D2 receptors that are 
configured in D2 high state ( ) in vivo. 
Finally, during the course of the thesis it became apparent that mass-carry over and cerebellar 
binding was a potential problem with [
11
C]-(+)-PHNO. In order to quantify mass-carry over I 
performed a test-retest study, and also used aripiprazole, a D2/3 blocking agent, to quantify 
any displaceable cerebellar binding. 
1.7 Summary of hypotheses 
 
Aim 1:  Investigation of striatal [
18
F]DOPA uptake in twin pairs discordant for schizophrenia  
 
Hypothesis 1: Unaffected members of twin pairs discordant for schizophrenia show elevations in 
striatal [
18
F]DOPA uptake of a similar magnitude to their co-twin with schizophrenia 
Aim 2: Investigated of whether the dopaminergic dysfunction seen in schizophrenia is also present in 
well functioning people with auditory verbal hallucinations. 
 
Hypothesis 2: Well functioning people with schizophrenia show an elevation in striatal [
18
F]DOPA 
uptake, similar to patients with with schizophrenia 
 
Aim 3: Within-subject comparison of [(11)C]-(+)-PHNO and [(11)C]raclopride sensitivity to acute 
amphetamine challenge in healthy humans.  
Hypothesis 3: [
11
C]-(+)-PHNO will be more sensitive to detect acute fluctuations in synaptic 
dopamine (DA) than [
11
C]raclopride.  
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Aim 4: Characterisation of the quantification parameters of the D2/3 agonist radiotracer [
11
C]-(+)-
PHNO. 
 Hypothesis 4a: [
11
C]-(+)-PHNO  PET scans are usually conducted under non-tracer conditions, hence 
significant mass carry-over may be expected in consecutive scans conducted with a minimal  time 
interval. 
Hypothesis 4b: There is a significant displaceable binding component in the cerebellum, which, if not 
accounted for, could lead to a bias in the quantification of [
11
C]-(+)-PHNO. 
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Chapter 2. PET fundamentals 
In this chapter I describe the general principles behind positron emission tomography (PET). 
The subsequent chapters describing the different studies include experiment-specific 
methods.  
2.1. PET physics 
Positron emission tomography (PET) is a nuclear medicine imaging technique used to 
produce an image of functional processes in the body. At the start of a scan a molecule of 
interest labelled with a positron emitting radionucleide is injected into the subject. This 
molecule is based on a biologically active molecule, and becomes concentrated in the tissue 
of interest. The decay of the positron emitting radionucleide produces a positron which 
travels a short distance (usually less than 3 mm) before encountering an electron. This 
encounter results in an annihilation event, producing a pair of annihilation (gamma) photons 
travelling at 180 degrees to each other (see Figure 3).  
Figure 3. An annihilation event producing two photons travelling at 180 degrees to each 
other (adapted from (Cherry 2001)) 
 
35 
 
This coincidence detection of the annihilation photons makes it possible to localize the source 
of the photons along a straight line of coincidence (also called the line of response).  The 
photons are detected when they reach scintillation detector crystals, usually made of bismuth-
germanium oxide. There may be up to 25,000 scintillation detectors arranged in a ring around 
the source of radioactivity. A burst of light is created when the crystal absorbs the photon. 
This light is enhanced and detected by photomultiplier tubes. When two photons are detected 
within a short time interval it can be assumed that they were created during the same 
annihilation event, and that this event took place on the line of coincidence between the two 
detectors. During a scan several million coincident events are detected forming a large 
number of lines of coincidence. These are recorded as a two-dimensional matrix known as 
the sinogram. Prior to the reconstruction of a three dimensional image the sinogram data must 
be corrected for irregular absorption of photons by body tissues (termed attenuation 
correction), scatter in the tissue and detectors, accidental coincidence events, detector dead 
time and detector efficiency corrections before it can be analyzed. The image can then be 
reconstructed using a filtered back-projection algorithm (see ((Phelps 2006) for further 
information). Following reconstruction the PET data is formatted as a series of three 
dimensional images acquired during contiguous time periods known as frames. Data from a 
particular region of interest can be collated over the range of time frames to create a time-
activity curve (TAC) from which physiological parameters can be estimated using 
appropriate biomathematical models. The basic principle is that the kinetics of a labelled 
compound in blood and tissue, which can be estimated from PET data, will be dependent on 
the availability of specific binding sites in the region examined. The availability of the target 
molecule for the binding of a ligand can be estimated via the application of an appropriate 
model to tissue and blood data collected during a PET study. 
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Radionuclides used in PET scanning are usually isotopes with short half – lives, such as 
carbon-11 (~20 minutes), nitrogen-13 (~10 mins), oxygen-15 (~2 mins) and fluorine-18 
(~110 mins). These radionuclides are either incorporated into compounds that are used in 
normal metabolism such as glucose and water (radiotracers), or into molecules that bind to 
receptors (radioligands). Large numbers of radiotracers and radioligands have been 
developed to examine different aspects of brain chemistry. For example brain metabolism has 
been studied using [
18
F] fluorodeoxyglucose ([
18
F] FDG), a glucose analogue taken up by 
metabolically active cells and phosphorylated by hexokinase in the first step of the glycolysis 
pathway. The phosphorylated [
18
F] FDG is unable to leave cells or progress down the 
glycolysis pathway, and consequently its levels provide an index of metabolic activity. In 
addition specific radioligands have allowed assessment of a large number of aspects of 
neurotransmitter function, for example synthesis ([
18
F] DOPA), release ([
11
C]raclopride) and 
receptor density ([
11
C]raclopride, [
11
C] FLB 457). 
  
2.2. Basic pharmacokinetic concepts 
The Michaelis Menten equation can be derived from the law of mass action (Laruelle et al. 
2003); 
L  + R                  LR 
It describes the interaction at equilibrium between a receptor and a ligand and takes the form 
 
Where B is the concentration of bound ligand, Bmax is the density of receptors and F is the 
concentration of free ligand. A plot of the equation as bound vs free is hyperbolic with an 
asymptote at Bmax. Therefore if enough ligand is added to saturate all the receptors then 
Kon 
Koff 
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B=Bmax. In PET studies, when the radioligand is administered at tracer dose, F is negligible in 
comparison to Kd, and the equation simplifies to; 
 
The initial slope of the curve at time zero (B/F) is a therefore a constant that reflects the ratio 
Bmax/Kd. In PET this constant is termed ‘binding potential’ or BP. Differences in binding 
potential between individuals could be either a reflection of receptor numbers (Bmax) or 
receptor affinity, or both. In general it is assumed that differences in BP reflect differences in 
Bmax if affinity remains constant (which is often assumed).  BP is the most reported outcome 
measure in PET neuroreceptor studies. These studies use PET to measure the initial slope of 
the saturation binding curve,  or BP. BP can also be conceptualised as the ratio of the 
specific binding to another reference concentration, which is assumed to approximate to non-
displaceable binding.  
 
Discrepancies have arisen in the literature as a result of the use of different reference 
concentrations of the radioligand. In this thesis consensus in nomenclature proposed by a 
group of eminent molecular imagers has been used (Innis et al. 2007). BPF denotes the ratio at 
equilibrium of the specifically bound radioligand in tissue to the free concentration in tissue, 
which is assumed to be equal to the free concentration in plasma, provided that the ligand 
crosses the blood-brain barrier by diffusion only. BPP denotes the ratio at equilibrium of 
specifically bound radioligand to that of total parent radioligand in plasma (i.e., free plus 
protein bound, excluding radioactive metabolites). BPND denotes to the ratio at equilibrium of 
specifically bound radioligand to that of nondisplaceable radioligand in tissue. BPND  is the 
commonest measurement used in reference tissue methods. It compares the concentration of 
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radioligand in regions that are receptor-rich to those that are at least assumed to be receptor-
free.  
 
This nomenclomature therefore provides information about what is represented in the binding 
potential measurement under discussion.  BP without any subscript denotes the ‘true’ in vitro 
measurement of Bmax/Kd. The term BPF denotes the ratio of displaceable binding to free 
radioligand at equilibrium. BPP is not corrected for the fraction of ligand that is bound to 
plasma proteins (fP), consequently it follows that BPP is equal to the product of BPF and fP. 
BPND is not corrected for the free fraction of ligand in the nondisplaceable tissue 
compartment (fND), therefore BPND is equal to the product of BPF and fND. 
 
Volume of distribution is another commonly derived parameter in PET studies. The term 
‘volume of distribution’ is used in pharmacology to denote the ratio of the dose administered 
to the concentration of a substance in the systemic circulation at equilibrium. The unit of this 
quantity is a real volume expressed in litres and is conceptually the total volume of all the 
compartments in which the injected substance is distributed. In the PET literature, the term 
volume of distribution is different to the pharmacological volume of distribution.  It is 
equivalent to the partition coefficient of the radioligand between the tissue and the plasma at 
equilibrium. A large volume of distribution is equivalent to a large partition coefficient 
between compartments. In dynamic PET studies we do not measure steady-state 
concentrations directly, but instead estimate the values of rate constants between 
compartments (see below). The distribution volume can then be derived from the rate 
constants. 
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2.3. Kinetic analysis of neuroreceptor binding using PET 
2.3.1. Compartmental models 
Most quantitative dynamic PET studies of radioligand binding to neuroreceptor sites in the 
brain use models derived from the three-tissue compartment (3TC) model described by 
Mintun et al. (Mintun et al. 1984). The compartments consist of the free, specifically bound 
and non-specifically bound pools (Figure 4). Specific binding refers to the interaction of the 
radioligand with a receptor. It is saturable in that it increases with radioligand concentration 
until all the receptors are occupied and no further binding can occur. Non-specific binding 
refers to all other binding for example to cell membranes. It is non-saturable and will increase 
indefinitely with increasing ligand concentration. The model describes the exchange of 
radioligand between plasma and the tissue compartments in terms of plasma clearance and 
fractional rate constants (microparameters, Figure 4, K1, k2-6). This model is based on both 
the physiological and pharmacological properties of the system. Consequently the 
microparameters can be interpreted in terms of blood flow, transport across the blood-brain 
barrier, non-specific binding and receptor concentration and affinity.  In practice, due to the 
noise present in typical PET data, it is impossible to identify the full 3TC model with six 
parameters within individual regions. Usually only one or two compartments are identifiable. 
For example, rapid equilibration may take place between the free and non-specific 
compartments may occur, giving rise to a two-tissue compartment (2TC) model. In this 
situation only a fraction of the compartment in exchange with plasma is free. This ‘free-
fraction’ in the tissue must be used in interpretation of the binding microparameters.   
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Figure 4. The Standard Neuroreceptor Compartment Model     
 
 
As a result of the difficulty in independently observing the different compartments, which 
essentially relate to the states of the radioligand in the same tissue, the analysis of PET data 
usually relies on estimation of more robust macroparameters such has the total volume of 
distribution in the tissue (Koeppe et al. 1991). These analyses can be based on a specific a 
priori defined compartmental model, or may derive from a general compartmental model, 
applied to provide estimates of macroparameters without assignation of a specific 
compartmental structure (Gunn et al. 2001). A comparison of target and reference tissue 
regions can then be used to estimate binding potential;- 
 
      
 
(BP=binding potential, VT=volume of distribution, ROI=region of interest, REF=reference tissue) 
 
 
Arterial  
Plasma (Ca) 
Cp(t) 
Free tracer 
(Ct) 
Non 
specific 
binding 
(CNS) 
 
Specific 
(Cs) 
K1 
k2 
k3 
k4 
k5 k6 
41 
 
These approaches have proved their utility in PET, allowing quantification of regional 
receptor concentration, exogenous drug occupancy and endogenous neurotransmitter release. 
 
2.3.2. PET Input function  
The term input function describes a measure of the delivery of radioligand to the brain. The 
input function can be measured directly by measuring the metabolite-corrected concentration 
of the ligand in arterial plasma over time. Alternatively it can be derived indirectly via 
examination of the radioactivity in a tissue devoid of specific binding as in the simplified 
reference tissue model (SRTM) and other reference tissue models (see below). 
 
2.4. The simplified reference tissue model (SRTM) 
An arterial input kinetic model requires the determination of an arterial input function to 
quantify K1 and k2. This requires arterial cannulation and blood sampling during the PET 
scan, which is time-consuming and may be painful for the subject. If a region can be found 
where there is no specific binding, then a reference tissue model can be applied to derive an 
input function. The simplified reference tissue model (STRM), first developed by 
Lammertsma and colleagues (Lammertsma and Hume 1996), is one of the most successful 
examples of a reference tissue model. This model uses the reference region free tracer (Cf) 
time activity curve as an indirect input function. The technique makes more assumptions than 
use of a measured input function, and should to be used with caution. For example, if there is 
specific binding in the reference region this will produce an underestimation of specific 
binding in the target region. In addition the presence of more than one nondisplaceable 
compartment in the reference region without any specific binding can complicate reference 
tissue models. Their accuracy should therefore be quantified for each individual radioligand. 
 
42 
 
2.5. Patlak analysis for modelling irreversible ligands such as [18F] DOPA 
In order to model the tissue distribution of irreversible ligands such as [
18
F]-DOPA a complex 
multiple compartmental approach is needed. In practice, the number of microparameter 
estimations generated means that modelling irreversible ligands in this way produces 
unreliable results. An alternative is to use graphical methods to estimate parameters by fitting 
a straight line to the transformed experimental data. In the case of [
18
F]-DOPA PET, the 
influx constant (Ki) is calculated using the Patlak analysis (Patlak et al. 1983). With this 
method, uptake of [
18
F]-DOPA is calculated by assuming that there are a number of reversible 
compartments in rapid equilibrium with the blood (e.g. brain parenchyma) and at least one 
irreversible compartment in which the radiotracer is trapped (e.g. [
18
F]-DOPA is transported 
across the blood–brain barrier via the large neutral amino acids system and is subsequently 
decarboxylated via L-aromatic amino acid decarboxylase into [
18
F]-dopamine, which is then 
trapped irreversibly in the presynaptic vesicles). 
 
In these circumstances it is only the accumulation of tracer in the irreversible compartment 
that has an effect on the apparent distribution volume. The Patlak analysis uses a linear 
regression model to graphically fit the influx constant occurring between the two 
compartments (ie the plasma and the irreversible compartments). The y axis of plot contains 
the apparent distribution volumes, i.e. the ratio of concentrations of the tracer in tissue and in 
plasma. On x axis is normalized plasma integral, i.e. the ratio of the integral of tissue 
concentration and the plasma concentration (Figure 5). 
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Figure 5. Patlak analysis compartment model. There can be any number of reversible compartments, where the 
tracer can come and go. After some time, tracer concentations in these compartments start to follow the tracer 
concentration changes in plasma (ratio does not change). Then, any change in the total tissue concentration 
(measured by PET) per plasma concentration represents the change in irreversible compartment(s) (from Turku 
PET centre web pages;   http://www.turkupetcentre.fi) 
 
 
 
When equilibrium is achieved between the reversible compartments and plasma the Patlak 
plot becomes linear (Figure 6). The slope of the linear phase represents the net transfer rate Ki 
(influx constant). Ki represents the amount of accumulated tracer in relation to the amount of 
tracer that has been available in plasma. 
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Figure 6.  The Patlak plot becomes linear after the tracer concentrations in reversible compartments and in 
plasma are in equilibrium. The slope of the linear phase of plot is the net uptake (influx) rate constant Ki. Ki is in 
units min
-1
, or (mL tissue)/((mL plasma)*min). Note that although x axis has time units (min or sec), the values 
do not represent the PET sample times (from Turku PET centre web pages;   http://www.turkupetcentre.fi) 
 
 
The cerebellum can be used as a reference region to model the reversible tissue region in 
[
18
F]-DOPA PET analysis. This region has negligible levels of dopaminergic neurones, 
therefore irreversible uptake into dopaminergic synapses should also be negligible. It is 
assumed that the reference region contains only reversible compartments which achieve 
equilibrium with plasma. The cerebellum can also be used as a reference region for [
11
C]-
raclopride and potentially the agonist ligand [
11
C]-PHNO, as it can be generally assumed that 
levels of D2 and D3 receptors are negligible. This assumption is evaluated directly in chapter 
6.   
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2.6. Wavelet-based kinetic modelling 
It has been documented that wavelet-based kinetic modelling increases the signal-to-noise 
ratio of Ki maps for [
18
F] DOPA by a factor of three without significant loss of resolution 
(Turkheimer et al. 2006).  This methodology is based on the observation that the 
physiological properties of the components of a living organ at different spatial or temporal 
resolutions share a degree of similarity. It follows from this that the kinetic parameters of a 
small area of tissue have a quantitative resemblance to the same parameters when averaged 
over a larger area inclusive of that region. This observation has been developed into a method 
for generating parametric maps from PET studies. Initially a multi-resolution deconstruction 
of the PET dynamic acquisition is created. Subsequently the kinetic parameters are calculated 
starting with the lowest resolution and then proceeding to higher levels using the estimates 
from the lowest resolution as priors. This method has a statistical advantage over traditional 
pixel-by-pixel estimations because the higher quality of the parameter estimates at lower 
resolutions, where noise is low, can be used to smooth out estimates at higher resolutions, 
where noise is a more significant problem.  
 
2.7. Sources of artefact in PET radioligand studies  
2.7.1. Head movement 
 
Improvements in scanner resolution and attempts to measure small differences in receptor 
binding mean that subject head movement during the scan is now one of the most significant 
obstacles to capitalising on other technological advances in the field. Head movement is 
potentially more of a problem in studies using a pharmacological challenge agent due to 
psychological or motor effects on the subject during the scan. If movement does occur then 
the signal measured may be increased or decreased depending on radioligand concentration in 
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tissues around the defined region of interest. As a result changes in binding may go 
undetected or alternatively produced as artefact.  
 
In order to minimise head movement multiple physical approaches have been used, including 
individually moulded thermoplastic masks. However while partially effective they do not 
reduce head movement entirely (Green et al. 1994; Ruttimann et al. 1995). A more 
technologically advanced approach is to measure head position during a scan using laser 
positioning, then correct for any movements when the sinogram data is generated. This is an 
experimental approach and few centres have been able to implement this routinely. 
 
It is possible to reduce the influence of head movement by performing post-hoc realignment 
of the data. This is performed by realigning frames either to an initial frame or to a frame 
chosen for its high signal to noise ratio. This technique is termed frame-by frame (FBF) 
realignment (Mawlawi et al. 2001). The technique has several potential limitations. Firstly, 
changes in radioligand distribution occur over the duration of the scan. Early frames represent 
radioligand delivery, while later frames represent binding of radioligand to receptors. This 
may lead to a different distribution of radioligand between early and late frames, and for this 
reason attempts to align early frames with later ones or vice versa may result in artefactual 
between frame movements. Secondly the method is unable to correct for movement that takes 
place within-frames, which may be as long as ten minutes, and lastly does not account for 
movement that occurs between the transmission and emission scans, which may lead to an 
incorrect attenuation correction being applied. 
 
Montgomery and colleagues used an [
11
C]-raclopride dataset to determine the effect of FBF 
realignment on test-retest reliability and noise characteristics. FBF realignment greatly 
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improved both the accuracy and the test-retest reliability of the [
11
C]-raclopride analysis, for 
example the variability of the ventral striatal signal dropped from 13.5% without realignment 
to 7.3% using FBF realignment (Montgomery et al. 2006).  
 
2.7.2. Region of interest analysis 
 
Generally, quantitative measures from PET images are obtained only from certain regions; 
these are termed regions of interest (ROIs). Measurements are taken from the count values in 
the region. Obtaining an appropriate ROI is one of the most basic steps in most approaches to 
image quantification. A geometric shape, such as an oval or circle, may be appropriate in 
some circumstances. It is always possible to interactively trace the ROI, and this is still a 
common approach. However, interactive approaches are associated with significant inter-
rater and intra-observer variability and are time-intensive. For these reasons automated 
model-based methods have been introduced and can be useful. If the expected shape of the 
ROI is known, then model-based approaches can be used to locate the ROI by fitting a model 
of the object to the image. A conceptually straightforward way of obtaining the model is to 
manually define anatomical regions of interest on numerous images and find the average 
shape of the ROI. Registration techniques may be used to fit the model to the new image 
containing the object. The model is transformed and scaled over all possible locations in the 
new image, and may even be non-linearly warped in order to match the new image. After an 
ideal, nonlinear transformation of a data set of an individual brain to the reference brain of an 
atlas, brains are identical in size, shape, sulcal pattern, and asymmetry. One common method 
of examining the strength of the match is the sum of the squares of the differences between 
the template and the image, which should be small when there is a good match. In a more 
complicated approach, an iterative adaptation of the boundaries of the model may be used to 
best fit the ROI. Constraints on the boundary can be used to that they do not stretch far 
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beyond the original model and they maintain a smooth surface. The goal of fitting the model 
to the image in this way is to be able to use the boundaries of the transformed model as the 
boundaries of the ROI in the new image. However, even with automated registration 
approaches there remains potential for confounding factors due to micro-structural 
cytoarchitectural variation. Registration minimizes the macroanatomical differences as 
confounds for comparisons between brains, but does not eliminate effects of microstructural 
differences. Any brain atlas based exclusively on macroanatomical landmarks for the 
identification of the position and extent of cortical areas can still be subject to  misalignment 
of the cytoarchitectonically defined cortical region borders, the magnitude of which is 
difficult to estimate a priori (See Amunts and Zilles (2006) for further discussion).  
    
2.7.3. Scanner stability; factors affecting PET measure variance and bias 
 
Changes in radiotracer uptake between scans can be due to several factors, including response 
to therapy, biological variability and systemic variability in measurement from differences in 
hardware, reconstruction, ROI analysis and subject positioning. The combined impacts of 
PET hardware, subject positioning and data processing and analysis on the reproducibility of 
tracer uptake quantification have not been well examined.  If PET measurements are to be 
used as end points in multi-centre trials, it will become vital to understanding the variance 
and bias intrinsic to serial PET scan measurements. However, encouragingly a recent study 
examining this issue found that, at least in the short term, scanner variability is low compared 
to other sources of error (Doot et al. 2010). This analysis included effects of repositioning; no 
significant differences in standard deviations for PET outcome measures were found for 
objects ≥10 mm in diameter when measuring a stationary or repositioned phantom when 
using the same reconstruction settings. In addition, the results suggested that it may be 
feasible to use PET/CTs from different vendors and sites in clinical trials if they are properly 
cross-calibrated. 
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2.7.4. Blood flow 
 When PET imaging is used to determine the effect of drugs on endogenous neurotransmitter 
levels, one of the concerns in quantifying change in binding potential (BP) is the effect that 
any change in cerebral blood flow (rCBF) may have on the estimation of BP values. This is a 
particular concern with activation studies, both pharmacological (eg use of an amphetamine 
challenge) and behavioural. The consequences of increased rCBF are potential changes in the 
rate constants K1 and k2, thus altering rate of radioligand delivery and washout. With regard 
to the amphetamine study described in this thesis, as it is a comparison study of the change in 
binding potential of two ligands to the same dose of amphetamine, it may be assumed that 
any blood flow induced changes in binding potential will affect both ligands in similar ways 
and will thus not affect the comparison.      
 
2.8. Displacement PET studies 
There have been a large number of studies that have shown that in vivo neuroreceptor 
imaging with PET or SPECT is a potential tool for measuring changes in the synaptic 
concentration of endogenous neurotransmitters. It has been hypothesised that the mechanism 
underlying this technique is competition between the radioligand and endogenous 
neurotransmitters at the receptor site. This concept is supported by the finding that changes in 
synaptic concentrations of transmitter levels as measured by microdialysis correlate well with 
changes in neurotransmitter receptor occupancy, as indexed by change the binding potential 
of the radioligand. The use of this technique to measure DA neurotransmission has been well 
validated and has also has been applied to measure changes in DA transmission in clinical 
conditions, most notably schizophrenia. The model used to describe the behaviour of 
radioligands in competition experiments is the classic occupancy model, which is described 
mathematically by the Michaelis-Menten equation (Section 2.2.1 above). According to the 
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model, when levels of endogenous ligand increase, the binding of the radioligand decreases, 
and vice versa (see Figure 7 below). 
 
Figure 7. Classic occupancy model adapted from Laruelle (Laruelle 2000) 
 
In situations where the presence of the endogenous ligand is relevant a variation of the 
Michaelis-Menten equation is used;- 
 
Where Fi is the concentration of the endogenous ligand, with affinity for the receptor of Kdi. 
It can be seen that as Fi increases, then the BP of the radioligand will decrease.   
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However, the successful application of the occupancy model to the dopamine system has not 
translated to other neurotransmitter systems. In addition a number of observations have been 
made that are not compatible with the model. Firstly the amphetamine-induced reductions in 
BP of the D2 ligands [
123
I]IBZM and [
11
C]raclopride persist for a time after the short lived 
elevations in DA concentration after amphetamine have subsided (Laruelle 2000). Secondly 
other non-benzamide D2 ligands such as [
3
H]spiperone and [
3
H]pimozide are either not 
affected by changes in endogenous dopamine (Niehoff et al. 1979; De Jesus et al. 1986) or 
the direction of change is different to that predicted by the occupancy model, that is inhibition 
of DA release resulted in a paradoxical decrease in radioligand-specific binding (Chugani et 
al. 1988), whereas stimulation of DA release resulted in a paradoxical increase in 
radioligand-specific binding (Bischoff and Gunst 1997). 
 
 Receptor internalisation has been proposed as a mechanism to explain why these deviations 
from the behaviour expected from the occupancy model occur.  This concept was introduced 
by Chugani et al. who proposed that the paradoxical behavior of [
3
H]spiperone uptake 
following an agonist challenge resulted from agonist-promoted receptor internalization, 
resulting in an effective "trapping" of [
3
H]spiperone within endocyctic vesicles (Chugani et 
al. 1988).  This internalisation of the receptor complex could make the receptor differentially 
accessible to ligands with different properties (e.g., lipophilicity). There is evidence that 
spiperone is able to diffuse more readily into the intra-cellular compartment than raclopride.  
This would explain the different results obtained with these two ligands as spiperone binding 
is not affected by internalisation. Other factors may also be important, such as sodium levels 
and pH. It is possible that binding of benzamides such as raclopride is more affected by the 
low sodium and pH environment inside the endosome than spiperone. 
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Support for the theory that target internalisation plays an important role in the mechanism of 
changes in radioligand signal, is provided by data from mechanistic pre-clinical studies.  The 
affinity of different radioligands to both surface and internalised receptors was measured in 
human embryonic kidney cells transfected with D2 receptors (Guo et al. 2010). Agonist 
stimulation led to around half of cell surface D2 receptors to undergo internalisation. The 
affinity of the different ligands for the internalised receptors was reduced, by an average of 
2.1 fold, which would lead to a significant reduction of the binding of radioligands in 
neuroimaging studies. If all receptors are assumed to be on the cell surface in baseline 
conditions, and that after agonist treatment 50% of the receptors undergo internalisation, then 
BP would be reduced by 25%. The differences in affinity shift for the radioligands tested in 
this study were not proportional to the magnitude of the changes in binding seen in vivo 
following modulation of synaptic DA levels. This suggests that other factors may be 
contributing to the long-lasting changes in ligand binding seen in vivo, such as receptor 
modification or degradation. 
 
Skinbjerg et al. examined whether the prolonged decrease in in vivo binding of D2 PET 
radioligands following amphetamine administration is due to receptor internalisation by using 
arrestin3 knockout mice (Skinbjerg et al. 2010). These mice are incapable of D2 receptor 
internalisation. In a study using wild type mice as a comparison group, radioligand binding 
following amphetamine challenge returned to normal after 4 hours in the arrestin3 mice, but 
remained decreased in the wild-types.  This result provides further evidence to suggest that 
the prolonged decrease in binding is due to D2 receptor internalisation rather than competitive 
displacement. 
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Chapter 3. Striatal dopamine synthesis capacity in twins discordant for schizophrenia 
 
3.1. Introduction 
Ten studies have investigated pre-synaptic striatal dopamine synthesis capacity in 
schizophrenia through quantification of the uptake of the PET radiotracers L-[ -
11
C]-DOPA 
or 6-[
18
F]fluoro-L-DOPA ([
18
F] DOPA). Eight out of the ten studies reported elevated striatal 
DOPA uptake in patients with schizophrenia, including all the studies in patients in the acute 
psychotic phase of the illness (reviewed in Howes et al.  2009a).The two studies that did not 
report an elevation were in chronic, remitted patients (Dao-Castellana et al.  1997; Elkashef et 
al.  2000). Overall, these studies support the hypothesis that elevated striatal dopamine 
synthesis capacity is important in the pathogenesis of psychosis in schizophrenia (Cannon et 
al.  1998; Howes and Kapur, 2009b). However, it is not clear whether elevated dopamine 
synthesis capacity is a trait marker or endophenotype present in people at increased risk for 
developing schizophrenia as well in the disorder, or is simply a state marker associated with 
psychotic symptoms. The term vulnerability marker is used here to convey an association 
with increased risk of developing the disorder.  
 
Abnormalities in the dopamine system representing potential endophenotypes have been 
examined using PET. In one study, unaffected monozygotic (MZ) co-twins of patients with 
schizophrenia exhibited increased caudate dopamine D2 receptor density compared to 
unaffected dizygotic (DZ) co-twins and healthy control twins (Hirvonen et al.  2005). A 
recent study examining striatal dopamine synthesis capacity in first degree relatives of 
patients with schizophrenia found that this group had higher striatal [
18
F]DOPA uptake values 
than unrelated controls at low genetic risk (Huttenen et al. 2008). Furthermore, elevated 
striatal dopaminergic function has also been reported in people who are vulnerable to 
schizophrenia because they have prodromal signs of the disorder (Howes et al.  2009c), or 
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because they have schizotypal personality disorder (Abi-Dargham et al.  2004). These 
findings suggest that hyperactivity of the striatal dopaminergic system is also present in 
individuals at risk for schizophrenia. By reference to data from previously scanned unrelated 
patients with schizophrenia, Huttenen et al. proposed that the elevation in [
18
F]DOPA uptake 
they observed in unaffected first degree relatives of patients with schizophrenia was of the 
same magnitude as that in schizophrenia (Huttunen et al.  2008). However, because in their 
first degree relative study they did not image the relative with schizophrenia for comparison, 
it is unclear if this is really the case. This is an important point as if the dopaminergic 
elevation was of the same magnitude then this would imply that elevated striatal dopamine 
synthesis capacity is an endophenotype occurring in both the well and the unwell relative, 
and is not directly related to the onset of schizophrenia itself. It would clearly suggest that 
other factors aside from dopaminergic overactivity are important in the genesis of the 
symptoms of schizophrenia. 
 
In order to clarify this point, striatal [
18
F]DOPA uptake was investigated in twin pairs 
discordant for schizophrenia to test the hypothesis that unaffected members of twin pairs 
discordant for schizophrenia would show elevations in striatal [
18
F]DOPA uptake of a similar 
magnitude to their co-twin with schizophrenia. 
 
3.2. Methods and Materials 
3.2.1. Subjects 
Six DZ and one MZ twin pairs discordant for schizophrenia were recruited (mean [SD] age, 
43[12] years; age range, 30-63 years; 71% male). Recruitment of discordant twin pairs was 
from the IOP twin database. Control twins were recruited from by advertisement in London 
free newspapers. Twin zygosity was established by DNA analysis. A control group of 10 DZ 
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normal twin pairs was also recruited (mean [SD] age, 39[14] years; age range, 25-62 years; 
50% male). A power calculation using the effect size of the increase in [
18
F]-FDOPA uptake 
from a previous study of patients with schizophrenia at the same centre indicated that a 
minimum sample size of six twin pairs was required (McGowan et al.  2004). All subjects 
gave written informed consent for the study, which was approved both by the Hammersmith 
Research Ethics Committee and the Administration of Radioactive Substances Advisory 
Committee, UK. 
 
All subjects with schizophrenia met DSM –IV criteria for the disorder. Healthy control 
subjects were required to have no personal history of psychiatric illness or any first degree 
relatives with schizophrenia. The patients with schizophrenia were taking antipsychotic and 
other psychotropic medication as shown in Table 1. The mean Chlorpromazine equivalent 
dose of treatment was 216 mgs, range 200 to 366 mgs. (See (Woods, 2003) for equivalent 
dose calculation). Patients were asked to omit their regular medication on the morning of the 
PET scan. One of the healthy co-twins was taking propranolol 80mgs and escitalopram 
10mgs for anxiety. None of the other subjects was taking or had taken any psychotropic 
medication.  Urine drug testing confirmed that none of the subjects had taken illicit drugs 
prior to the scan. Subjects were asked not to smoke on the day of the scan. 
 
3.2.2. Clinical and neuropsychological measures 
All subjects were assessed at the time of scanning using the Positive and Negative Syndrome 
Scale (PANSS) for schizophrenia (Table 1 and 2) (Kay et al.  1987). The presence of 
psychiatric diagnoses was assessed using the Structured Clinical Interview for DSM-IV 
(Spitzer et al.  1992). Demographic and recreational substance use variables were assessed by 
clinical interview. 
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Table 1. Demographic, medication and substance use data for the 7 discordant twin pairs  
Pair 
Well/ Gender Age 
Age 
Diagnosed 
L/R Handed Medication Drug use Smoker? PANSS 
 
 
Unwell 
  
 
    
Pos Neg Gen Total 
1 Scz M 48 27 R 
Olanzapine 
15mgs 
Previous cannabis 12 /day 8 10 22 40 
    
 
 
Temazepam 
10mgs       
1 HCT M 48 - L 
 
Previous cannabis 15-20/ day 7 7 16 30 
    
 
  
Cocaine 1 year ago x1 
     
    
 
  
Ecstacy 3x  
     
2 Scz M 63 19 R 
Amisulpride 
200mgs bd 
Nil No 9 13 22 44 
2 HCT M 63 - L 
 
Nil No 7 7 16 30 
3 Scz M 30 27 R 
Risperidone 
depot 37.5mgs 
2 weekly 
Cocaine 7 years ago No 18 17 31 66 
    
 
  
Ecstasy 7 years ago 
     
    
 
  
Previous Cannabis 
     
3 HCT F 30 - R 
 
Ecstasy 1 year ago 
Previous Cannabis 
Ex-smoker 7 7 16 30 
    
 
        
4 Scz M 55 20 R 
Aripiprazole 
20mgs  
Previous Cannabis   No 12 13 18 43 
    
 
 
Amisulpride 
200mgs od 
LSD years ago x1 
     
    
 
 
Procyclidine 
10mgs od       
    
 
 
Temazepam 
10mgs od       
4 HCT F 55 - R 
 
Nil No 7 7 16 30 
5 Scz F 35 14 R 
 
Nil No 25 24 56 105 
    
 
 
Risperidone 
2mgs bd       
5 HCT F 35 - L 
 
Nil No 7 7 16 30 
6 Scz M 33 24 R 
Depixol 80mgs 
2 weekly 
Previous Cannabis 25 /day 9 13 21 43 
    
 
  
Previous Cocaine 
     
6 HCT M 33 - R 
 
Previous Cannabis  No 8 7 18 33 
7* Scz M 37 30 R 
Fluoxetine 
20mgs Nil 
 
No 9 14 27 50 
    
 
 
Diazepam 
5mgs      
7* HCT M 37 - R 
Propranolol 
80mgs Nil 
 
No 7 7 18 32 
    
 
 
Escitalopram 
10mgs      
 
*MZ twin pair. 
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3.2.3. Positron Emission Tomography (PET) scanning and image analysis 
PET data were acquired using the ECAT/EXACT3D PET scanner (Siemens/CTI, Knoxville, 
USA). High resolution images of the whole brain were reconstructed from 95 planes with a 
slice spacing of 2.425 mm. The scanner has a spatial resolution of 4.8±0.2 mm and a 
sensitivity of 69 cps/Bq/ml. Approximately 150 MBq of 6-[
18
F]fluoro-L-DOPA (
18
F-DOPA) 
was administered by bolus intravenous injection thirty seconds after the start of the emission 
scan. The emission data were acquired in list mode over 95 minutes and rebinned into 26 
time frames (comprising a 30-second background frame, four 60-second, three 120-second, 
three 180-second, and finally fifteen 300-second frames) and reconstructed using the 3D re-
projection algorithm. 
  
3.2.4. Image analysis 
A frame-by-frame realignment and denoising method was employed to correct for head 
movement in the scanner (Turkheimer et al.  1999). Non-attenuation corrected images were 
used to reduce the influence of redistribution of radiotracer producing erroneous 
realignments. These images are considered to be more useful for the realignment algorithm 
because they include a significant scalp signal in comparison to attenuation corrected images 
(Bose et al.  2008). Frames were realigned to a single, ‘reference’ frame acquired 7 minutes 
post-injection using a mutual information algorithm and the transformation parameters were 
then applied to the corresponding attenuation-corrected dynamic images (Studholme et al.  
1997). 
 
These realigned frames were then summated, creating a movement corrected dynamic image 
to be used in the analysis. Standardized regions in Montreal Neurologic Institute (MNI) space 
were defined in the cerebellum (the reference region) using a probabilistic atlas
 
and in the 
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whole striatum delineated using previously described criteria to create an ROI map 
(Hammers et al. 2003; Martinez et al. 2003). SPM5 (www.fil.ion.ucl.ac.uk/spm) was then 
used to normalise the ROI map together with the  tracer specific ([
18
F]-DOPA) template  (the 
template aids normalisation) to each individual PET summation image (McGowan et al.  
2004). This procedure allowed ROIs to be placed automatically on individual [
18
F]-DOPA 
PET dynamic images. Striatal subdivisions were delineated as previously described 
generating limbic (LS), associative (AST) and sensorimotor (SMST) subregions of the whole 
striatal ROI (Martinez et al.  2003). These ‘functional’ subdivisions reflect the topographical 
arrangement of corticostriatal projections. Projections to the LS are from limbic areas such as 
the hippocampus and amygdala, projections to the AST originate in associative areas such as 
the dorsolateral prefrontal cortex, and projections to the SMST come from motor and related 
areas such as primary motor cortex, premotor cortex and supplementary motor cortex. Influx 
constants (Ki values) for the whole striatal ROI and the functional sub-divisions were 
calculated relative to uptake in the reference region for left and right sides combined using a 
Patlak graphical approach (Patlak et al.  1983). 
  
 Voxel-based statistical image analyses were performed to confirm the results obtained from 
the conventional ROI analysis. Wavelet-based kinetic modelling was deployed to the scans to 
produce maps of the uptake constant for [
18
F] DOPA (Ki) using the cerebellum as a reference 
region. It has been documented that wavelet-based methodology increases the signal-to-noise 
ratio of Ki maps for [
18
F] DOPA by a factor of three without significant loss of resolution 
(Turkheimer et al.  2006). Statistical analyses of parametric images were performed using 
SPM5 (Wellcome Department of Cognitive Neuroscience, London, UK) and Matlab6.5 
(Mathworks, Natick, Mass). An explicit anatomical mask confining the analyses to striatal 
areas was used. The results of the voxel-based analysis were analysed both corrected for 
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multiple comparisons (p<0.05, Family Wise Error rate) and using a liberal threshold value of 
P<0.001 (uncorrected). 
 
3.2.5. Statistical analysis 
Any differences between patients and their healthy co-twins from controls on radiochemical 
and clinical measures, and whether [
18
F]DOPA uptake in healthy co-twins was intermediate 
between patients and unrelated healthy controls, were investigated using a regression analysis 
in STATA version10 statistical software (Stata Corp, College Station, Texas). Planned 
contrasts were performed to test our hypotheses by comparing discordant patients and their 
non-psychotic co-twins with each other and against unrelated healthy DZ control twins. 
  
Familial correlations violate the assumption of independence made in standard regression 
models. Generalized estimating equations (GEE) were used to account for the lack of 
independence within the twin pairs; specifically an exchangeable correlation structure was 
assumed to account for the within-family correlation. GEE provides unbiased estimates of the 
marginal effects, even if the assumed correlation structure is misspecified (Hardin, 2003; 
Rabe-Hesketh, 2010). To safeguard against a possible misspecification in the 
variance/covariance matrix, robust Hubert White sandwich estimators were used to adjust 
standard errors, and hence confidence intervals and p-values (Williams, 2000).  
 
The relationship between whole striatal Ki values, striatal subdivision Ki values and 
symptom scores was explored using Pearson’s product moment correlation coefficient. Intra-
class correlation coefficients (ICCs) for striatal Ki were calculated for values the healthy 
control twin group and the discordant twin group. 
3.3. Results 
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3.3.1. Demographic data and clinical characteristics 
No significant differences existed between groups on age (p=0.825), gender (Χ2=3.17, df=2, 
p=0.205), cigarette (Χ2=1.00, df=2, p=0.607), cannabis (Χ2=2.97, df=2, p=0.227)  and alcohol 
(Χ2=0.09, df=2, p=0.954)  use. The cannabis use was occasional in all subjects, and at least 12 
months had elapsed between last use and the PET scan. There were no current stimulant users in 
any of the groups.  In the pairs discordant for schizophrenia, the mean duration of 
discordance was 15±13 years. 
As expected, there was a significant effect of group on current psychotic symptom ratings 
(see Table 2). There was no relationship between whole striatal Ki values and age (r=-0.68, 
p=0.7). 
 
3.3.2. Striatal dopaminergic function 
We found no significant group effects on [
18
F] DOPA Ki values for any of the ROIs 
examined (Table 2). Mean (SD) Ki values for combined whole striatum for the unwell twins, 
well twins and healthy twin controls were 0.0143 (0.0012), 0.0140 (0.0013) and 
0.0142(0.0014) respectively. There was also no significant effect of group when the left and 
right striata were analysed separately. Excluding the MZ twin pair made no difference to the 
findings.  The distribution of Ki values was similar for the well and unwell twins (Figure 8). 
The highest Ki values were found in the healthy control twin group. The voxel-based analyses 
corroborated the ROI analysis findings, with no significant differences between groups 
groups when corrected for multiple comparisons, and this remained the case even when the 
liberal threshold (p<0.001, uncorrected) was use. Within the schizophrenia group, there was 
no significant correlation between the severity of symptoms as indexed by the total PANNS 
score and whole striatal Ki values (r=-0.1, p=0.59) or Ki values in the associative (r=-0.05, 
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p=0.77), sensorimotor (r=-0.1, p=0.54) or the limbic (r=-0.15, p=0.4) striatal subdivisions. In 
addition there were no significant correlations between positive symptoms alone, negative 
symptoms alone and [
18
F]-DOPA Ki values in the whole striatum or in its functional 
subdivisions. The ICCs for the normal and discordant twin pairs were low and of similar 
magnitude (For whole striatum; normal pairs= 0.087, discordant pairs= 0.094).  
 
Figure 8. Comparison of whole (left and right sides combined) striatal [
18
F]DOPA uptake 
constants (Ki/min)  
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Table 2. Actual mean PANNS scores and Marginal Mean Differences of planned 
comparisons between Groups on PANSS and Ki values. DC: discordant. Bold indicates 
significance  
 
Measure DC twins with 
schizophrenia 
N=6 
Non-psychotic  
DC twins 
N=6 
Healthy Control 
dizygotic twin pairs 
N=20 
PANSS total 56.8(25.4) 30.5(1.3) 30.1(0.5) 
PANSS positive 13.5(6.7) 7.2(0.4) 7(0) 
PANSS negative 15(4.9) 7(0) 7(0) 
PANSS general 28.3(14.2) 16.3(0.8) 16.1(0.4) 
Marginal Mean Differences  DC twins with 
schizophrenia 
v. 
control twins 
 
mean difference 
 (P value) 
Non-psychotic  
DC twins 
v. 
control twins 
 
mean difference 
 (P value) 
DC twins  
with schizophrenia 
 
vs. Non-psychotic  
DC twins  
 
mean difference 
 (P value) 
    
PANSS total 26.07548 (p< 0.0005) .2715708 (0.598) .2715708 (p< 0.0005) 
PANSS positive 5.995143 (0.003) 0.0048574 (0.982) 5.990285 (0.003) 
PANSS negative 7.88137  (p< 0.0005) -0.0242269 (0.609) -.0242269 (p< 0.0005) 
PANSS general 12.158  (0.002) 0.338823 (0.338) 11.81917 (0.004) 
Ki value for Whole striatum 0.0000748 (0.859) -0.0002147 (0581) 0.0002895 (0.425) 
Ki value for Whole R striatum 0.00 (0 .591) 0.00 (0.491) 0.00 (0.217) 
Ki value for Whole L  striatum 0.00 (0.770) 0.00 (0.463) 0.00 (0.638) 
Ki value for Associative 
striatum 
0.0003312 (0.490) -0.0000544 (0.893) 0.0003856 (0.338) 
Ki value for Limbic striatum -0.0005923 (0.423) -0.0003689 (0.582) -0.0002234 (0.782) 
Ki value for Sensorimotor 
striatum 
0.0000354 (0.936) -0.0002905 (0.387) .0003259  (0.421) 
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3.4. Discussion 
In this study there was no evidence for increased striatal dopamine synthesis in the well co-
twins from twin pairs discordant for schizophrenia compared with healthy control twins, in 
contrast to a previous finding in first degree relatives of patients with schizophrenia 
(Huttunen et al.  2008).  None of the unaffected co-twins of schizophrenia patients in this 
study had a PANNS rating of >2 on any item (a PANSS rating of 3 or greater indicates a 
definite symptom, whilst 1 indicates the symptom is absent, and 2 indicates questionable 
pathology/ upper extreme of normal limits).  As the unaffected co-twins in our study were 
asymptomatic, whereas the relatives in the previous study by Huttunen had appreciable 
symptom levels (mean PANSS score=39.8, median 39, range 30-63), one possible 
interpretation of these findings is that elevated dopamine synthesis capacity is linked to the 
expression of psychotic symptoms rather than a vulnerability to psychosis per se.  
The absence of a correlation between whole striatal Ki values and age is unexpected but 
consistent with some (Eidelberg et al.  1993; Ishikawa et al.  1996; Sawle et al.  1990) but not 
all previous studies (Bhatt et al.  1991; Cordes et al.  1994; Martin et al.  1989) Nevertheless, 
age is not a potential confound in this study, because the main comparison is between the 
patients and their well co-twins who are the same age. 
 
Based on previous work in this area, it was concluded that the probability that any of the 
discordant pairs would become concordant for schizophrenia in the future was low, as an 
average of 15 years had elapsed since the onset of the illness in the probands (Belmaker et al.  
1974). The possibility that the well co-twins in this study had not inherited the risk genes for 
schizophrenia cannot be excluded, bearing in mind that the mostly DZ group only share 50% 
of genes with their co-twin with schizophrenia. We included both DZ and MZ twins in the 
primary analysis because our main hypothesis was that familial vulnerability to schizophrenia 
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was associated with elevated striatal dopamine synthesis capacity, as suggested by Huttenen 
et al. (2008). Excluding the MZ twins made no difference to our finding. Between twin-pair 
ICC values for Ki values across all ROIs were similar in both twin groups, suggesting that 
having a co-twin with schizophrenia does not alter concordance in [
18
F] DOPA Ki values.   
 
In addition no elevation of striatal [
18
F] DOPA uptake was found in the twins with 
schizophrenia. However, none of the patients was acutely unwell at the time of scanning. 
Thus the finding is consistent with previous findings that elevated dopaminergic function in 
schizophrenia is particularly associated with the acute development of psychotic symptoms 
(Laruelle et al.  1999). The findings of elevated striatal dopaminergic function reported in 
people with prodromal signs of the disorder (Howes et al.  2009b, and 2011a), schizotypal 
personality disorder (Abi-Dargham et al.  2004) can be conceptualised as the onset of a 
pathological process that leads to frank psychosis. Indeed a significant longitudinal increase 
in dopamine synthesis capacity in the sensorimotor striatum has been reported in prodromal 
individuals who develop psychosis (Howes et al. 2011b). The elevated striatal dopamine 
activity in the prodromal patients therefore represents the onset of the state that subsequently 
leads to psychosis, rather than being a trait which represents a vulnerability marker. The 
hyperactivity of the striatal dopaminergic system then increases further in those patients who 
make the transition to psychosis.  
 
It is possible that the absence of elevated striatal dopamine synthesis in our patients and 
relatives at rest reflects normal tonic presynaptic tonic dopamine release.  However, phasic 
dopamine release in response to stress or a reward could be elevated and may potentially 
represent a vulnerability marker. 
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The study was powered to detect a between- group difference in mean striatal Ki values of 
0.0011/min (the effect size previously reported in patients scanned on the same scanner 
(Howes et al.  2009c). Whilst the possibility of smaller differences cannot be excluded, the 
data do not give any indication of group differences. Whilst our sample was recruited from 
general clinics, its relatively small sample size means it is possible we have recruited an 
unusual sub-group of patients, which could limit the generalisability of the findings to 
schizophrenia. All of the patients had received long-term treatment with antipsychotic 
medication prior to the scan, and, although subjects omitted treatment on the day of the scan 
itself, it remains possible that dopamine synthesis was influenced by prior treatment. 
However, the data in the literature on the effect of antipsychotic medication on dopamine 
synthesis capacity is equivocal. One study reported a reduction in FDOPA uptake following 5 
weeks pretreatment with Haloperidol (Grunder et al., 2003). Two studies have found no 
change in dopamine synthesis capacity after a single dose of risperidone {Mamo et al, 2004; 
Ito et al., 2009), although an increase was found in the putamen but not the caudate following 
three days of haloperidol (Vernaleken et al, 2006). Another possibility is that antipsychotic 
treatment-induced structural changes might have influenced our results. The literature 
suggests that the striatal nuclei may increase in size following chronic antipsychotic use 
{Navari et al., 2009, Smieskova et al., 2009). This would, if anything, mitigate against our 
finding, because, as larger structures are less susceptible to partial volume effects (reference 
needed), the schizophrenia group would be less susceptible to underestimation of striatal 
dopamine synthesis capacity.  Nevertheless, if it is possible to recruit them, studies in drug 
naïve discordant twins are needed to exclude an effect of medication. 
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3.5. Conclusions 
Striatal dopamine synthesis capacity is not elevated in stable patients with chronic 
schizophrenia or in their unaffected co-twins.  These findings suggest that genetic 
vulnerability to psychosis and a shared in utero environment are not associated with elevation 
in dopamine synthesis capacity per se. It can also be inferred that elevated striatal dopamine 
synthesis is related to the active psychotic phase of the illness, rather than a endophenotypic 
marker for schizophrenia. This relationship with the active psychotic phase is consistent with 
the literature: of the ten studies reported elevated striatal DOPA uptake in patients with 
schizophrenia, the two studies that did not report an elevation were in chronic, remitted 
patients (Dao-Castellana et al.  1997; Elkashef et al.  2000). 
 
Statement of student’s contribution to this chapter. 
For this study the discordant and control twins were scanned under a generic PET psychiatry 
group [18F]-DOPA protocol. This was developed prior to my commencement on the 
Wellcome Fellowship programme. Similarly ARSAC and REC approvals were obtained for 
the generic protocol. I recruited the discordant twin pairs was from the IOP twin database. 
Control twins were recruited from by advertisement in London free newspapers, in 
collaboration with the PET psychiatry group’s dedicated recruiter. I performed screening and 
scanning of all subjects for this study. Image analysis scans was performed by myself and 
Caroline Copeland, an MSc student. Data analysis was performed by myself, with advice 
from Dr Oliver Howes, Dr Sheena Owens and Dr Timi Touloupoulou. Results interpretation 
was performed by myself, with additional advice from Dr Oliver Howes, Professor Robin 
Murray and Dr Marco Picchioni. Twin zygosity testing was carried out at the Institute of 
Psychiatry by the twin research group. 
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Chapter 4. Striatal dopamine synthesis capacity in healthy individuals with auditory verbal 
hallucinations 
4.1. Introduction 
Auditory verbal hallucinations (AVH) are characteristic of psychotic disorders. However they 
are by no means specific for these disorders. Approximately 4% of otherwise healthy subjects 
also experience regular AVH (Johns, 2005). These healthy subjects experience similar 
hallucinations to psychotic patients, although the frequency is generally lower and the content 
more positive (Honig et al.  1998). A recent study screened 104 of these healthy individuals 
with AVH  for Axis I and II disorders and found them to be free of other psychotic 
symptoms, such as delusions and negative symptoms (Sommer et al.  2008). The fact that 
they have never used antipsychotic medication makes them an ideal subgroup to investigate 
the isolated form of hallucinations.  
 
Kapur (Kapur et al.  2005) proposed a model to link the phenomenology and pharmacology 
of psychosis. He hypothesized that psychosis arises from aberrant assignment of salience to 
objects and associations, and that it is a result of dopamine dysregulation. This leads to the 
attribution of salience to irrelevant stimuli. These overvalued irrelevant stimuli are then 
linked in an incorrect manner in an attempt of the individual to make sense of his confusing 
experiences, which results in the formation of a delusion. Psychosis, however, consists of 
several symptoms: delusions, hallucinations, catatonia and formal thought disorder. While 
Kapur’s model provides an excellent explanation of how dopamine dysregulation can lead to 
delusions, it is less suitable to explain the occurrence of hallucinations. It is currently unclear 
if hallucinations are associated with increased dopamine metabolism. The vast majority of 
patients with psychosis present with delusions and hallucinations (and some degree of formal 
thought disorder). Since very few patients experience hallucinations in the complete absence 
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of other psychotic symptoms, the specific association between dopamine hyperactivity and 
hallucinations has never been assessed. Previous studies have examined the association of 
dopamine synthesis capacity with psychotic symptoms, but none have studied AVH in 
isolation.  
 
A cohort of healthy subjects with AVH had been acquired at the UMC (University Medical 
Center) Utrecht since 2005. Over 120 subjects were collected, who were free of psychiatric 
and somatic pathology and experienced hallucinations at least once every month. These 
individuals were screened for psychiatric disorders and detailed descriptions were obtained 
about their hallucinations, cognition and personality traits (Sommer et al.  2008).  
 
In this pilot study we aimed to measure the synthesis of dopamine (as indexed by [
18
F]DOPA 
uptake) in the striatum of these healthy subjects with hallucinations. These data were 
compared to healthy control subjects. The hypothesis under investigation was that if healthy 
subjects with hallucinations showed similar increases dopamine synthesis to psychotic 
patients, then hallucinations are likely to be related, and possibly the result of increased 
dopamine metabolism. On the other hand, if dopamine synthesis in the healthy hallucinating 
subjects was similar to that in the controls, then it may be concluded that hallucinations in 
isolation are not associated with increased dopamine synthesis. 
  
4.2. Methods and Materials 
4.2.1. Subjects 
Healthy subjects with AVH were recruited from the Neuroscience Division of the University 
Medical Centre in Utrecht.  This study was a collaboration between the UMC Utrecht and the 
Medical Research Council (MRC) Clinical Sciences Centre (CSC), Hammersmith Hospital 
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Campus, Imperial College London. The subjects for this were recruited from both centres. 
The Dutch healthy subjects with AVH were initially recruited through an online 
questionnaire on a website designed to attract healthy subjects with hallucinations for 
research purposes. (‘‘Explore your mind’’—http://www.verkenuwgeest.nl). On this Web site, 
potential subjects were asked to complete a self-report questionnaire based on the Launay and 
Slade Hallucinations Scale designed to quantify the tendency to hallucinate in healthy 
individuals (Launey et al. 1981). People with high scores were invited to further assessment, 
including an interview administered by a trained psychiatrist to determine whether they met 
criteria for a psychiatric disorder using the Comprehensive Assessment of Symptoms and 
History (CASH) (Andreasen et al. 1992) and the Structured Clinical Interview for Personality 
Disorders (SCIDP) (Spitzer et al.1992). A database of more than 120 subjects with isolated 
hallucinations (at least once per month), but no psychiatric or somatic pathology had already 
been recruited at the time of the start of this study. Control subjects were recruited in the UK 
at the MRC CSC by London-wide advertisement. All data on these subjects had been 
collected prior to the start of this study using the same protocol. All participants were 
reimbursed for any travel, accommodation and living expenses associated with their 
participation.  Subjects were recruited for this study from this database and screened for 
suitability in Dutch by research collaborators from Utrecht, Marlene LeCessie, Kelly 
Diederen and Kirstin Daalman. Suitable subjects were flown over to the UK and I checked 
screening information in English where possible, and with an interpreter when it was not, 
prior to scanning. 
 
A power calculation using the effect size of the increase in [
18
F]DOPA uptake from a 
previous study of patients with schizophrenia at the same centre indicated that a minimum 
sample size of 12 subjects per group was required to detect a mean difference in Ki values of 
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0.001 Ki/min (SD 0.001) with a probability of α <0.05 (one tailed), and power of 80% 
(McGowan et al.  2004). The power calculation was performed using web-based software 
(Lenth, RV, 2006). 
 
Subjects had to fulfil the following inclusion criteria to participate in the study: 1) persistent 
auditory verbal hallucinations experienced at least once a month for over 1 year; 2) no Axis I 
or II diagnosis of current or past psychiatric disorder or substance dependence other than past 
depressive or anxiety disorder in complete remission or nicotine dependence; 4) no alcohol or 
drug abuse for at least 3 months; 5) no history of drug or alcohol abuse preceding the onset of 
the auditory verbal hallucinations. The frequency criterion of once a month was used to 
ensure that the subjects recruited had regular hallucinations. It was assumed that if there were 
long periods between hallucinations then the likelihood of finding a difference between non-
hallucinators would be reduced. 
 
Sixteen subjects with persistent auditory hallucinations participated in the study (11 females; 
mean [SD] age/y at scanning = 43.9 [8.9], 5 smokers, cigarettes smoked/d:mean [SD] = 6.6 
[4.9] and median Interquartile Range [IQR] = 5 [7]). The subjects did not meet DSM-IV 
criteria for psychosis not otherwise specified despite having persistent auditory verbal 
hallucinations because the symptoms were not associated with occupational, social or 
psychological dysfunction. Five had a family history of a psychotic disorder. All but one of 
the healthy subjects with AVH were good English speakers. However all questionnaires and 
consent forms were translated into Dutch. For the subject who did not speak English an 
interpreter was present during the consent process.  
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Healthy controls (control group) were recruited via advertisement and were matched to the 
hallucinating group on the basis of age (within 5 years). Prior to inclusion, they received a 
psychiatric interview using the CASH and SCIDP to determine if they met the following 
inclusion criteria: (1) no history of current or past hallucinations in any form or any other 
psychotic symptom; (2) no diagnosis of current or past psychiatric disorder, personality 
disorder, or substance dependence other than past depressive or anxiety disorder in complete 
remission or nicotine dependence; (3) no alcohol or drug abuse for at least three months; and 
(4) no known family history of schizophrenia or other psychotic disorder in a first or second 
degree relative (determined using the Family Interview for Genetic Studies 
http://www.nimhgenetics.org/interviews/figs/). Sixteen matched controls participated in the 
study (mean [SD] age/y = 42.8 [10.9]; 10 females, 4 smokers, cigarettes smoked/d: mean 
[SD] = 7.4[3.9] and median [IQR] = 8 [7.4]). The control group were scanned using the same 
PET camera and [18F]-DOPA protocol as the hallucinator group. None of the control scans 
were performed more than 6 months prior to the start of the study. 
  
All subjects gave written informed consent for the study, which was approved both by the 
Hammersmith Research Ethics Committee and the Administration of Radioactive Substances 
Advisory Committee, UK. 
 
None of the AVH subjects or the healthy controls was taking or had taken any psychotropic 
medication.  Urine drug testing confirmed that none of the subjects had taken illicit drugs 
prior to the scan. 
 
4.2.2. Clinical and neuropsychological measures 
The presence of psychiatric diagnoses was assessed in both AVH subjects and healthy 
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controls using the Structured Clinical Interview for DSM-IV (Spitzer et al.  1992). 
Demographic and recreational substance use variables were assessed by clinical interview. 
AVH subjects were also assessed on the Peters Delusion Inventory (PDI) (Peters et al.  1999), 
Schizotypal Personality Questionnaire (SPQ) (Raine, 1991) and the Global Assessment of 
Function (GAF) scale (Endicott et al.  1976). The clinical measures are reported in Table 3. 
 
Table 3: Clinical characteristics of the hallucinator group 
 
 
 Mean (sd) Range Appproximate description of 
the group mean score 
Age of onset of 
hallucinations 
13.3 (11.3) 4-44  
Voice frequency rating 3.6 (1.1) 2-6 Voices occur at least once/hour 
Voice duration rating 1.9 (0.8) 1-4 Voices last for several minutes at a time 
Voice location rating 2.0 (1.1) 1-4 Voices sound outside the head but close to 
ears or head 
Voice loudness rating 1.9 (0.6) 1-3 About the same loudness as own voice 
Voice origin rating 3.3 (0.9) 1-4 Holds >50% (but<100%) conviction that 
voices originate from external causes 
Voice distress rating 0.2 (0.4) 0-3 Voices not distressing at all 
Voice disruption rating 0.06 (0.3) 0-1 No disruption to life, able to maintain 
family and social relationships 
SPQ score 26.4 (11.4) 12-54 Similar to general population mean score 
(26.9)(Raine 1991) 
PDI conviction 15.4 (7.1) 6-37 Lower than general population mean score 
(20.4)(Peters et al. 1999) 
PDI distress 4.0 (8.2) 0-34 Lower than general population mean score 
(15.5)(Peters et al. 1999) 
PDI preoccupation 16.3 (7.5) 6-30 Slightly higher than general population 
mean score (15.4) )(Peters et al. 1999) 
GAF score 83.4 (7.2) 70-95 Good functioning in all areas, no more than 
everyday problems 
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4.2.3. Positron Emission Tomography (PET) scanning 
PET data were acquired using the ECAT/EXACT3D PET scanner (Siemens/CTI, Knoxville, 
USA). High resolution images of the whole brain were reconstructed from 95 planes with a 
slice spacing of 2.425 mm. The scanner has a spatial resolution of 4.8±0.2 mm and a 
sensitivity of 69 cps/Bq/ml. Approximately 150 MBq of 6-[
18
F]fluoro-L-DOPA ([
18
F]DOPA) 
was administered by bolus intravenous injection thirty seconds after the start of the emission 
scan. The emission data were acquired in list mode over 95 minutes and rebinned into 26 
time frames (comprising a 30-second background frame, four 60-second, three 120-second, 
three 180-second, and finally fifteen 300-second frames) and reconstructed using the 3D re-
projection algorithm.  
 
4.2.4. Image analysis 
  A frame-by-frame realignment and denoising method was employed to correct for head 
movement in the scanner (Turkheimer et al.  1999). Non-attenuation corrected images were 
used to reduce the influence of redistribution of radiotracer producing erroneous realignments 
(Dagher et al. 1998). These images are considered to be more useful for the realignment 
algorithm because they include a significant scalp signal in comparison to attenuation 
corrected images (Bose et al.  2008). Frames were realigned to a single, ‘reference’ frame 
acquired 7 minutes post-injection using a mutual information algorithm and the 
transformation parameters were then applied to the corresponding attenuation-corrected 
dynamic images (Studholme et al.  1997). 
 
These realigned frames were then summated, creating a movement corrected dynamic image 
to be used in the analysis. Standardized regions in Montreal Neurologic Institute (MNI) space 
were defined in the cerebellum (the reference region) using a probabilistic atlas
 
and in the 
74 
 
whole striatum delineated using previously described criteria to create an ROI map 
(Hammers et al.  2003; Martinez et al.  2003). SPM5 (www.fil.ion.ucl.ac.uk/spm) was then 
used to normalise the ROI map together with the  tracer specific ([
18
F]DOPA) template  (the 
template aids normalisation) to each individual PET summation image (McGowan et al.  
2004). This procedure allowed ROIs to be placed automatically on individual [
18
F]DOPA 
PET dynamic images. Striatal subdivisions were delineated as previously described 
generating limbic (LS), associative (AST) and sensorimotor (SMST) subregions of the whole 
striatal ROI (Martinez et al.  2003). These ‘functional’ subdivisions reflect the topographical 
arrangement of corticostriatal projections. Projections to the LS are from limbic areas such as 
the hippocampus and amygdala, projections to the AST originate in associative areas such as 
the dorsolateral prefrontal cortex, and projections to the SMST come from motor and related 
areas such as primary motor cortex, premotor cortex and supplementary motor cortex. Influx 
constants (Ki values) for the whole striatal ROI and the functional sub-divisions were 
calculated relative to uptake in the reference region for left and right sides combined using a 
Patlak graphical approach (Patlak et al.  1983).  
 
Voxel-based statistical image analyses were performed to confirm the results obtained from 
the conventional ROI analysis. Wavelet-based kinetic modelling was deployed to the scans to 
produce maps of the uptake constant for [
18
F]DOPA (Ki) using the cerebellum as a reference 
region. It has been documented that wavelet-based methodology increases the signal-to-noise 
ratio of Ki maps for [
18
F]DOPA by a factor of three without significant loss of resolution 
(Turkheimer et al.  2006).  Statistical analyses of parametric images were performed using 
SPM5 (Wellcome Department of Cognitive Neuroscience, London, UK) and Matlab6.5 
(Mathworks, Natick, Mass). An explicit anatomical mask confining the analyses to striatal 
areas was used. The results of the voxel-based analysis were analyzed corrected for multiple 
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comparisons (P < 0.05, family-wise error rate) and using a liberal threshold value of P <0 
.001 (uncorrected). 
 
4.2.5. Statistical analysis 
After confirming homogeneity of variance with Levene’s test, independent t tests were used 
to compare demographic and PET variables and striatal dopamine synthesis capacity between 
groups, and a Mann–Witney U test was used to compare nonparametric variables (cigarettes 
smoked/day and gender) between groups. Where there was a significant difference in the 
sociodemographic or PET variables, this was used as a covariate in a univariate analysis with 
striatal dopamine synthesis capacity as the dependent variable and group as the fixed factor. 
A two-tailed significance level of P = 0.05 was used throughout.The relationship between 
whole striatal Ki values and symptom scores was explored using Pearson’s product-moment 
correlation coefficient. 
  
4.3. Results 
4.3.1. Demographic data and clinical characteristics 
16 healthy subjects with AVH were scanned. There was no significant difference in the age (t 
= 0.3, df = 30, P = 0.8), cigarettes smoked/day (Z = 0.6, P = 0.5), or gender distribution 
between the two groups (Z = 0.4, P = 0.7) or in the specific activity of [18F]-DOPA 
administered (mean [SD] specific activity/GBq/lmol, in the hallucinating group = 0.034 
[0.02] and 0.035 [0.02] in the control group; t = 0.7, df = 28, P = 0.9). There were no current 
stimulant users in any of the groups.By chance, the hallucinating group received a small but 
significantly greater injected dose (mean [SD] injected dose /MBq in the hallucinating group 
= 184 [4.6] and in the control group = 179 [4.3]; t = 3.1, df = 29, P=0.005).However,there 
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was no relationship between injected dose and striatal dopamine synthesis capacity in either 
group (r <0 .2 and P >0 .5 in both groups). 
 
4.3.2. Striatal dopaminergic function 
There was no significant difference in the dopamine synthesis capacity between groups in 
either the whole striatum (Figure 9) or its functional sub-divisions (Table 4). The parametric 
analysis showed no difference between groups. 
 
In the hallucinator group, there was no relationship between whole striatal dopamine 
synthesis capacity and total scores on the PSYRATS auditory hallucinations rating scale (ρ=-
0.15, p=0.6), PDI (ρ=-0.14, p=0.6) or SPQ (ρ=0.13, p=0.63) ratings, or their sub-scales. 
 
Table 4: Striatal dopamine synthesis capacity (Ki
cer
 value/min) in the hallucinatory and 
control groups 
 
 Controls Hallucinators Statistical test 95% confidence 
interval 
Whole 
striatum 
0.0125 (0.0011) 
 
0.0128 (0.0009) t=0.68, df=30, p=0.5 -0.001 to 0.0005 
Associative 
striatum 
0.0124 (0.0012) 
 
0.0126 (0.0008) t=0.36, df=30, p=0.7 0.0009 to 0.0006 
Limbic 
Striatum 
0.0133 (0.0012) 
 
0.0135 (0.0010) t=0.34, df=30, p=0.7 -0.0009 to 0.0007 
Sensorimotor 
striatum 
0.0140 (0.0013) 0.0143 (0.0013) t=0.57, df=30, p=0.6 -0.0012 to 0.0007 
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Figure 9. Striatal dopamine synthesis capacity (Ki
cer
 value/min) for subjects in each group 
(error bars indicate sd of mean) 
 
 
 
4.4. Discussion 
  In this study there was no evidence for increased striatal dopamine synthesis capacity, as 
indexed by [
18
F] DOPA uptake, in the healthy subjects with AVH compared to previously 
scanned age-matched controls. The possibility of a type-II error must be considered. 
However, the study has over 98% power to detect an elevation in dopamine synthesis 
capacity of the size previously found in schizophrenia and over 80% power to detect an effect 
size similar to that reported in people with schizotypal personality disorder (power 
calculations for two-tailed independent t-tests with alpha=0.05 using effect sizes from 
previous studies) (Abi-Dargham et al. 2004; Howes et al.  2009c; McGowan et al.  2004). 
The small measured differences between the groups (Table 3), and the adequate group sizes 
(16 vs 16), essentially excludes a Type II error. 
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Another potential limitation for this study, as for the study in chapter 2, is the use of a general 
ROI atlas registered to the individual’s summated PET image. This process, while not 
susceptible to inter- and intra operator biases as with hand-drawn ROI delineation, could still 
lead to errors that potentially affect the results, particularly with small ROIs such the striatal 
subdivisions. 
    
Previous studies where elevations in striatal dopamine synthesis capacity have been found 
have examined schizophrenia patients with a range of psychotic symptoms including 
delusions, thought disorder and passivity phenomena.  It is important to note that the 
abnormal salience hypothesis of dopamine and its relationship with delusion formation in 
schizophrenia focuses solely on delusion formation, and does not adequately explain 
hallucinations. The data from this study suggest that AVH in isolation are not associated with 
increased striatal dopamine synthesis capacity. Another notable finding was the absence of 
any correlation between any of the symptom scores (SPQ, PDI and PSYRATS) and 
[
18
F]DOPA Ki values. A recent paper looking at dopamine D2/3 receptor densities with IBZM 
SPECT and their associations with schizotypal features (as measured with the SPQ) in 55 
healthy individuals found that SPQ total scores were not significantly correlated with D2/3 
receptors (Yang, 2011) However, the scores on the disorganized sub-scale were significantly 
associated with dopamine D2/3 receptor density in the right striatum. One possible explanation 
for the absence of any difference in dopamine synthesis in the right striatum in our study is 
that our subjects’ scores on the disorganised subscale of the SPQ were relatively low (6±3.6) 
when compared to those in the Yang study. 
 
Another possible explanation for the negative result is that perhaps the pathophysiology of 
AVH in our healthy hallucinator subjects differs from that in schizophrenia. It is clear that the 
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history of development of the symptom is different; all of the healthy hallucinator subjects 
report that their hallucinations began in childhood. This is distinctly different from the AVH 
seen in schizophrenia, which generally develop in late teens or early adulthood. 
 
The lack of neurochemical similarity between the healthy subjects with AVH and patients 
with schizophrenia is at variance with the findings from fMRI studies in this patient group 
during active hallucinations. A recent fMRI study comparing brain activation during 
hallucinations in 21 healthy subjects with AVH and 21 psychotic subjects (with a diagnosis 
of either schizophrenia, schizoaffective disorder or psychosis-not otherwise specified) 
(Diederen et al., 2011). The hypothesis was that if AVH are caused by comparable 
mechanisms in both groups they should observe a similar pattern of AVH-related brain 
activation. The two groups displayed common areas of activation and no significant 
differences. The areas of commonality consisted of the bilateral inferior frontal gyri, insula, 
superior temporal gyri, supramarginal gyri and postcentral gyri, left precentral gyrus, inferior 
parietal lobule, superior temporal pole, and right cerebellum. It is notable that the pattern of 
activation in this study is consistent with other imaging studies in psychotic patients (Allen et 
al. 2008, Diederen et al. 2010, Jardri et al. 2011 and Sommer et al. 2008). The literature thus 
illustrates the caution necessary in interpreting physiological data (such as fMRI) in 
neurochemical terms, simply on the basis of commonalities between anatomical location and 
prominent neurotransmitter release in the anatomical area. This while similar anatomical 
areas were involved in subjects with both conditions, neurochemical commonality (dopamine 
involvement) cannot be assumed.     
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4.5. Conclusion 
 Our study found no evidence for elevated dopamine synthesis capacity in healthy subjects 
with isolated auditory verbal hallucinations. This suggests that striatal dopaminergic 
alterations do not underlie all aspects of the psychosis continuum and other abnormalities 
underlie hallucinations. It may also be the case that the pathophysiology of AVH in healthly 
individuals is distinct from those seen in schizophrenia. Further studies are required to 
elucidate the neurochemical basis of auditory hallucinations.  
 
Statement of student’s contribution to this chapter. 
For this study the healthy subjects with AVH and the control subjects were scanned under the 
generic PET psychiatry group [18F]-DOPA protocol. This was developed prior to my 
commencement on the Wellcome Fellowship programme. Similarly ARSAC and REC 
approvals were obtained for the generic protocol. The idea for examining normal subjects 
with AVH was developed in conjunction with Dr Oliver Howes and Dr Iris Sommer. 
Recruitment of healthy subjects with AVH was from the Utrecht cohort. Subjects were 
screened in Dutch by research collaborators from Utrecht, Marlene LeCessie, Kelly Diederen 
and Kirstin Daalman. Suitable subjects were flown over to the UK and I checked screening 
information in English where possible, and with an interpreter when it was not, prior to 
scanning. The control group was recruited, screened and scanned by Dr Arsime Demjaha. I 
scanned 12 of the 16 subjects. The remainder were  scanned by Dr Michael Bloomfield.  
Image analysis scans was performed by myself and Euitae Kim. Data analysis was performed 
by myself, with advice from Dr Oliver Howes. Results interpretation was performed by 
myself and Dr Oliver Howes. Joint first authorship for the paper was considered appropriate 
as the relative contributions of Drs Shotbolt and Dr Howes were considered to be equal. 
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Chapter 5. Within-subject comparison of  [
11
C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-
naphtho[1,2-b][1,4]oxazin-9-ol ([
11
C]-(+)-PHNO) and [
11
C]Raclopride  sensitivity to acute 
amphetamine challenge in healthy humans  
 
5.1. Introduction 
Amphetamine induced reduction in the specific binding of the positron emission tomography 
(PET) and single photon emission computed tomography (SPECT) antagonist ligands such as 
[
11
C]raclopride or [
123
I]IBZM has been well validated as a measure of change in endogenous 
dopamine (DA) in both non-human primates and humans (Laruelle 2000). A dose-dependent 
relationship between amphetamine dose and changes in ligand binding (Breier et al. 1997; 
Hartvig et al. 1997; Laruelle et al. 1997), as well as a consistent relationship between the 
concentration of extracellular DA change and the change in radioligand binding (Breier et al. 
1997; Laruelle et al. 1997) have been demonstrated. Peak extracellular DA concentration 
increases of approximately 40% were required for each percent decrement in [
123
I]IBZM 
binding potential using amphetamine doses between 0.3 to 1.0 mg/kg (Laruelle et al. 1997). 
For [
11
C]raclopride, the corresponding figures were ~50% increase in extracellular DA 
concentration for each percent decrement in binding potential, using amphetamine doses of 
0.2-0.4 mg/kg. These results demonstrate the limited sensitivity of this technique with these 
tracers: large increases in extracellular DA are associated with relatively small effects on 
[
11
C]raclopride or [
123
I]IBZM binding. 
 
This low sensitivity may be due to the fact that the D2 receptor is a member of the G-protein 
coupled receptor family, and as such demonstrates a low affinity for agonists, such as DA, 
when not coupled to G-proteins (i.e. in a D2low state)(Creese et al. 1978;Creese et al. 
1979;Sibley et al. 1982;Zahniser and Molinoff 1978). Antagonists such as raclopride and 
IBZM show high affinity for the receptor regardless of state (D2low or D2high) state.  DA at 
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physiological concentrations (and other agonists) bind predominantly to D2high only. 
Consequently a much higher proportion of agonist than antagonist binding is modulated by 
changes in DA concentration. This hypothesis is consistent with the finding of a ~1.4 fold 
greater change in the binding of the agonist radioligand [
11
C]–N-propyl-norapomorphine 
([
11
C]-NPA) than that of [
11
C] raclopride, following an amphetamine challenge in the 
anaesthetised baboon (Narendran et al. 2004). A similar result was obtained in awake 
humans, where the ratio of reduction in binding potential ( ) after 
amphetamine challenge was between 1.5 and 1.9 (Narendran et al. 2010). However, not all 
studies support the notion that agonist ligands have differential binding to antagonist ligands. 
[
11
C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol
 
([
11
C](+)-
PHNO) and [
3
H]raclopride specific binding ratios were inhibited to the same degree in 
response to amphetamine challenge in an ex vivo study in conscious rats (McCormick et al. 
2008). In addition, in anaesthetised cynomologous monkeys, the D2/3 agonist apomorphine 
inhibited specific binding of the agonist ligand [
11
C]MNPA to a similar extent to 
[
11
C]raclopride (Finnema et al. 2009).  
 
[
11
C]-(+)-PHNO was originally developed as an agonist ligand for imaging the D2high receptor 
(Wilson et al. 2005). Subsequent examination demonstrated that [
11
C]-(+)-PHNO has an 
approximately 20 fold preferential affinity for the D3 over the D2high receptor (Gallezot et al. 
2012). The endogenous agonist DA also has a greater affinity for the D3 receptor than the D2 
in vitro (Schotte et al. 1992; Schotte et al. 1996), with selectivity again estimated as 
approximately 20 fold for the D3 receptor (Sokoloff et al. 1992). Thus (+)-PHNO may have a 
higher sensitivity to the effects of synaptic DA fluctuations due to its selectivity for the D3 
receptor, as well as its agonist profile. Comparisons of [
11
C]-(+)-PHNO to [
11
C] raclopride in 
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anaesthetised animals found that after an amphetamine challenge,  is  ~ 
1.5 (Ginovart et al. 2006;Narendran et al. 2006). A human study examining the effect of 
amphetamine on [
11
C]-(+)-PHNO binding potential reported significant reductions in striatal 
regions of interest (ROIs)  (ventral striatum 24.9%, caudate 13.2%, putamen 20.8%)(Willeit 
et al. 2008). These figures are larger than those reported in [
11
C] raclopride studies using 
similar doses of amphetamine, which generally lie between 5 and 15% (Drevets et al. 2001; 
Leyton et al. 2002; Munro et al. 2006; Oswald et al. 2005). However, in order to definitively 
compare [
11
C]-(+)-PHNO to [
11
C] raclopride in humans a within-subject design is required.  
 
An additional factor to explain the increased sensitivity of [
11
C]-(+)-PHNO and [
11
C]NPA to 
the effects of an amphetamine challenge in animal studies may be the effect of anaesthesia. 
The volatile anaesthetic isoflurane was demonstrated to increase significantly the effect of 
amphetamine on the specific binding of the agonist [
11
C]-(+)-PHNO, but not the antagonist 
[
3
H]-raclopride in rats (McCormick et al. 2008). In a follow-up study by the same group, the  
effect of amphetamine on the binding of the agonists (+)-PHNO and NPA, was greater than 
that on the binding of the antagonist raclopride, in rats anaesthetised with isoflurane, but of 
similar magnitude in conscious rats (McCormick et al. 2010). While these data implicate the 
effect of anaesthesia in the increased sensitivity of agonist radioligands,  it does not appear to 
be a major factor, as the increased sensitivity of both [
11
C]-(+)-PHNO and [
11
C]-NPA have 
been demonstrated in awake humans (Narendran et al. 2010; Willeit et al. 2008). 
 
Lastly, it is possible that the increased sensitivity of the agonist ligands is a consequence of 
receptor internalisation on their affinity. It has been proposed that D2/3 dopamine receptor 
internalisation could play a role in the change of the observed PET signal, rather than solely 
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the direct blockade of the receptor by dopamine (Laruelle 2000). The intracellular 
environment has lower pH and sodium ion concentration compared to the extracellular 
environment, and the affinity of benzamides (such as raclopride and IBZM) for D2 receptors 
is reduced by decreasing pH and sodium ion concentration. The effect of receptor 
internalisation in decreasing the affinity of radioligands for the D2 receptor has been 
demonstrated in a cell line expressing D2 receptors (Guo et al. 2010). This theory is supported 
by the finding that post-amphetamine, the time course of the changes in binding of PET 
ligands is considerably longer than the time course of the increase in extracellular DA levels 
as measured by microdialysis (Houston et al. 2004; Laruelle et al. 1997). The discrepancy in 
the time-course of the two measurements may be explained by DA induced receptor 
internalisation. An elegant experiment demonstrated a significantly faster recovery of 
baseline [
11
C]MNPA binding levels post-amphetamine in arrestin3 knock-out mice (unable to 
internalise the D2 receptor) than in wild-type controls, although the magnitude of the 
reduction was similar (Skinbjerg et al. 2010). If the sensitivity to the ionic environment for 
affinity for agonist ligands, such as [
11
C]-(+)-PHNO and [
11
C]-NPA, is greater in magnitude 
than that for the antagonists, greater changes in binding after an amphetamine challenge may 
be observed. This theory is not supported by the evidence from assessments of a cell line 
expressing D2 receptors, where the decrease in affinity for internalised receptors was of 
similar magnitude for agonists and antagonists (Guo et al. 2010).   
 
The aim of this study was to compare the sensitivity of [
11
C]-(+)-PHNO to changes in 
endogenous dopamine to that of [
11
C]raclopride, using a within-subject design. 
Amphetamine, the best-validated tool available, was used to induce an acute increase in 
extra-cellular dopamine levels. Amphetamine has the potential to worsen psychosis, and so is 
not ideal for use in schizophrenia studies. If [
11
C]-(+)-PHNO can be demonstrated to be more 
85 
 
sensitive to DA fluctuations than [
11
C]raclopride, it can be used to detect smaller changes in 
endogenous dopamine than currently possible. [
11
C]-(+)-PHNO could then allow for the 
examination of the effects of challenges such as nicotine or bupropion, which increase DA by 
smaller amounts than amphetamine, and for which the use of [
11
C]raclopride is not practical.  
Bupropion is a dopamine transporter (DAT) blocker, which increases striatal dopamine levels 
by inhibiting monoamine reuptake to presynaptic terminals (Ascher et al. 1995; Damaj et al. 
2004; Ferris and Beaman, 1983), blocking DA uptake.  Microdialysis studies in the rat, show 
that acute, systemic, bupropion administration reproducibly and dose-dependently increases 
striatal extracellular dopamine levels (Bredeloux et al. 2007; Brown et al. 1991; Gazzara and 
Andersen, 1997; Li et al. 2002; Nomikos et al. 1989; Sidhpura et al. 2007). If bupropion 
could be shown to show a robust change in the PET signal, as measured by a dopaminergic 
radioligand, then it could be used to probe striatal DA function despite not being a true DA 
releasing agent. 
Nicotine activates the nicotinic receptors on dopaminergic neurons in the ventral tegmental 
area (VTA) and substantia nigra (SN) (Pidoplichko et al. 1997; Wooltorton et al. 2003). The 
increase in burst firing leads to increased synaptic concentration of dopamine in the VTA and 
SN projection areas. Again, microdialysis studies in the rat have shown that nicotine 
administration increases striatal extracellular dopamine levels (Di Chiara et al. 1988, Pontieri 
at al. 1996). In addition a primate PET study found a significant effect of nicotine on [
11
C]-
raclopride BP (Marenco et al. 2004). However a previous human PET study, found no effect 
of nicotine given intranasally at a dose of 2mg on the binding of [
11
C]-raclopride  
(Montgomery et al. 2007). Given the higher sensitivity of [11C]-(+)-PHNO, it may be 
feasible that PET with [
11
C]-(+)-PHNO will enable the examination of the activity of these 
agents on the human dopaminergic system. If this proves to be feasible, these compounds 
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may also provide an alternative challenge agent for studying the human DA system, where 
amphetamine cannot be used for whatever reason. 
 
In addition, as [
11
C]-(+)-PHNO enables the examination of extra-striatal D2 and D3 receptors, 
its use will also allow the examination of DA fluctuations in extra-striatal brain regions, such 
as the substantia nigra and hypothalamus. 
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5.2. Materials and methods 
5.2.1. Human subjects  
The study was approved by the Essex 1 Research Ethics Committee and the Administration 
of Radioactive Substances Advisory Committee (ARSAC) and was conducted at the 
GlaxoSmithKline Clinical Imaging Centre, Hammersmith Hospital, London.  
 This was an open label study in healthy male subjects aged 25 to 55 years, who were free 
from clinically significant illness or disease as determined by their medical history and 
standard laboratory tests. Subjects were excluded if they had a history of drug or alcohol 
dependence or use of stimulant like illegal drugs on more than 5 occasions over a lifetime or 
any illegal drug on any occasion in the past 12 months. Each subject received four PET scans, 
two with [
11
C]-(+)-PHNO and two with [
11
C]-raclopride in counterbalanced order. Subjects 
were asked not to smoke on the day of the scan. For each ligand, a baseline scan was 
followed by a second post-amphetamine scan, where 3 hours prior to the start of the scan an 
oral dose of 0.3 mg/kg of amphetamine was administered on an empty stomach. Venous 
blood samples were taken to measure amphetamine levels at the start and end of scan 2 (3 
hours and 4.5 hours post-dosing). Subjective effects of amphetamine were measured by self 
rating with the simplified version of the Amphetamine Interview Rating Scale (Van 
Kammen, 1975) at baseline and 1, 2, 3 and 4.5 hours post-dose. Four items were investigated: 
euphoria (‘feel good’), alertness (‘feel energetic’), restlessness (‘feel like moving’) and 
anxiety (‘feel anxious’).  
The two administrations of amphetamine were separated by a minimum of 6 days. A total of 
13 healthy subjects were enrolled into the study, 10 of whom completed four PET scans and 
received two doses of amphetamine. A further 3 subjects received only two [
11
C]-(+)-PHNO 
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scans and one dose of amphetamine each (two of these dropped out of the study, and the third 
was withdrawn due to an incidental finding).  
During the course of the study emerging data suggested a very low Kd for [
11
C]-(+)-PHNO at 
the D3 receptor in vivo, (Kd
ND
 = 0.2-0.6 nM and an estimated ED50 of 0.03 ng/kg (Gallezot et 
al. 2012). This raised concerns about the possibility of (+)-PHNO occupying a significant 
proportion of the D3 receptor, and a consequent ‘carry over’ effect from the first to the second 
scan if conducted on the same day. No carry over effects would be expected at the D2 
receptors because the affinity of PHNO for the D2 receptor is approximately 20 times less 
than at the D3 receptor. 
Such a ‘carry over’ could potentially bias our results towards recording a greater [11C]-(+)-
PHNO reduction than can be attributed to DA effects. As a precaution the study design was 
changed, and subsequent subjects received their second [
11
C]-(+)-PHNO scans with a 
separation of at least 24 hrs from their baseline scan. Subjects 1-6 received both [
11
C]-(+)-
PHNO scans on the same day (“same-day subjects”), while subjects 7-13 received their [11C]-
(+)-PHNO scans on separate days (“different-day subjects”).  
5.2.2. PET data acquisition 
In total 46 PET scans were acquired on a Siemens Biograph HiRez XVI PET scanner 
(Siemens Healthcare, Erlangen, Germany). A low dose CT scan (Effective Dose = 0.2 mSv) 
was acquired for attenuation and model-based scatter correction. Subjects were injected with 
a single intravenous bolus of [
11
C]-(+)-PHNO or [
11
C]raclopride. [
11
C]-(+)-PHNO was 
prepared from the N-despropyl PHNO, (+)-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-
b][1,4]oxazin-9-ol, hydrochloride, by [
11
C]propionyl chloride acylation followed by 
reduction of the [
11
C]amide intermediate (Wilson et al. 2005 with minor modifications). The 
reaction, purification and formulation steps were fully automated to reliably produce high 
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purity [
11
C]-(+)-PHNO in a radiochemical decay-corrected yield of 16 ± 5% after a synthesis 
time of 35 minutes. [
11
C]raclopride was prepared as previously described (Ehrin et al. 1987). 
 
Following bolus administration of radioligand, dynamic emission data were acquired 
continuously for 90 minutes. The dynamic images were subsequently reconstructed, using a 
filtered back projection algorithm (direct inversion fourier transform) with a 128 matrix, a 
zoom of 2.6, a transaxial Gaussian filter of 5 mm, into 26 frames (8 x 15 s, 3 x 1 min, 5 x 2 
min, 5 x 5 min and 5 x 10 min). 
 
5.2.3. MRI data acquisition  
High resolution T1-weighted magnetic resonance images (MRI) were acquired to aid in the 
definition of the anatomical ROIs with a Siemens Tim Trio, 3T MRI scanner at the GSK 
Clinical Imaging Centre. The structural T1-weighted images were acquired with an inversion 
recovery prepared spoiled gradient echo sequence with TR = 3000 ms, TE = 3.66 ms, flip 
angle of 9º, TI = 1100 ms, slice thickness 1 x 1 x 1mm3 and matrix =256 x 192. 
  
5.2.4. Image Analysis 
Dynamic PET images were registered to each individual subject’s MRI image, and corrected 
for motion using a frame-to-frame registration process with a mutual information cost 
function. Regional analysis was facilitated by manual delineation of ROIs on the T1-MR 
image according to strict anatomical criteria (Tziortzi et al. 2010). The ROIs included the 
hypothalamus (HypoTH), substantia nigra and ventral tegmental area (SN&VTA), ventral 
pallidum substantia innominata (VPSI), globus pallidus (GP), ventral striatum (VST), 
thalamus (TH), caudate (CD) and putamen (PU).  The cerebellum (CER) was defined via 
nonlinear registration (using SPM5; Wellcome Trust Centre for Neuroimaging, London, UK) 
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of a template MR image and corresponding cerebellar brain atlas to each individual’s MR 
image. The derived sub-cortical and cerebellum ROIs were applied to the motion corrected 
dynamic image data to generate regional time activity curves (TACs).  A basis function 
implementation of the simplified reference tissue model (SRTM) (Gunn et al. 1997; 
Lammertsma and Hume 1996), with the cerebellum as the reference tissue, was applied to the 
TACs to derive regional estimates of non-displaceable binding potential ( ) estimates. 
 is proportional to the available concentration of receptor sites (Innis et al. 2007). 
 
5.2.5. Estimation of the effects of amphetamine 
The relative change in  elicited by amphetamine ( ) was calculated for each ROI 
as the difference between   measured in the baseline condition ( ) and that 
measured in the post-amphetamine condition ( ), expressed as a percentage of 
: 
   Eq.1 
 
5.2.6. Statistical Analysis 
Within-subjects comparison of  between radioligands was performed using repeated 
measures analysis of variance (RM ANOVA), with  as the dependent variable, the 
tracer as the repeated condition, and the ROI as a cofactor. The significance levels of the 
condition and the condition by region interaction are reported. A significance level of p = 
0.05 was selected for all statistical tests. Post-hoc comparisons of   for both ligands in 
each individual ROI were evaluated using a paired t-test (one tailed tests were used as we 
hypothesise that  will be greater for [
11
C]-(+)-PHNO). No adjustments were made for 
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multiple comparisons in the post-hoc tests. Correlations between continuous data were 
assessed using the Pearson correlation coefficient. 
5.3. Results 
Demographic and scan parameter data for all subjects are shown in Table 5 below. 
Table 5. Demographic, scan, and plasma data 
 [
11
C] raclopride (n=10) [
11
C]-(+) PHNO (n=13) 
Baseline Post-
amphetamine 
Baseline Post-
amphetamine 
Injected dose(MBq) 189±77 228±82 169±68 184±73 
Injected mass (µg) 2.77±1.73 2.24±1.23 1.62±1.15 1.51±0.8 
Plasma amphetamine 
 (0 min
#
, ng/mL) 
- 
 
55.6±5.8 
 
- 
 
59.2±7.8 
 
Plasma amphetamine 
 (90 min
#
, ng/mL) 
- 
 
52.8±8.6 
 
- 
 
54.7±7.5 
Euphoria score
##
 4.6±0.9 5.5±1*   
Alertness score
##
 4.5±1 5.5±0.9*   
Restlessness score
##
 4.1±1.3 4.7±1.1**   
Anxiety score
##
 3±1.3 3.3±1.6***   
 # refers to time post injection of radioligand in 2nd scan 
## mean score of all 23 post-amphetamine scans combined ([
11
C]raclopride and [
11
C]-(+)-
PHNO). Post amphetamine scores are at 3 hours post-dose. 
* P<0.001; **P<0.01; ***P<0.05 
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There were no significant differences between the baseline and the post-amphetamine scans 
in injected dose or injected mass for either ligand. No significant difference in amphetamine 
plasma level was observed between the post-amphetamine [
11
C]raclopride and [
11
C]-(+)-
PHNO scans (RM ANOVA p = 0.7). Amphetamine plasma levels were relatively stable 
throughout the scans for both ligands and consistent with the published literature (Narendran 
et al. 2010; Willeit et al. 2008). Changes from baseline on the Simplified Amphetamine 
Rating Scale reached a maximum at 3 hours post dose on all four domains (Table 5). 
Baseline and post-amphetamine values of [
11
C]raclopride (n = 10) and [
11
C]-(+)-PHNO 
(n = 13) are presented in Figure 10 and Table 6. Summary parametric images derived from all 
subjects are shown in Figure 10. 
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Figure 10. Summary parametric images derived from all subjects. Images shown for baseline and 
reduction in BPND following amphetamine (relative change between scan 1 and 2) for [
11
C]-(+)-
PHNO and [
11
C] raclopride in stereotaxic space overlaid onto the T1 weighted MNI template. The 
thresholds used were chosen to aid with the display of signals and their changes in sub-cortical 
regions. The actual thresholds used were not calculated as a result of any statistical tests. Tests for 
significance are presented in the thesis on a ROI level. 
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Table 6. Mean  at baseline and post-amphetamine 
 [
11
C]raclopride  [
11
C]-(+)-PHNO  
Region 
 
Baseline Post-
amphetamine % 
 
Baseline Post-
amphetamine %  
p values 
HypoTH
1 
0.20±0.06 
(0.19±0.07) 
0.14±0.11 
(0.16±0.11) 
- 1.36±0.35 
(1.54±0.34) 
0.98±0.30 
(1.09±0.33) 
-28±11 
(-29±12) 
- - 
SN&VT
A
1
 
0.32±0.05 
(0.29±0.05) 
0.30±0.06 
(0.30±0.07) 
- 1.42±0.29 
(1.51±0.33) 
1.01±0.19 
(1.12±0.17) 
-27±16 
(-22±21) 
- - 
VPSI 1.08±0.11 
(1.07±0.12) 
0.92±0.11 
(0.94±0.10) 
-14±10 
(-14±11) 
3.19±0.63 
(3.22±0.72) 
2.38±0.48 
(2.58±0.56) 
-24±14 
(-19±15) 
1.71 
(1.35) 
0.029* 
(0.096) 
GP 1.46±0.17 
(1.43±0.19) 
1.29±0.16 
(1.28±0.21) 
-11±7 
(-11±7) 
3.03±0.38 
(3.10±0.37) 
2.70±0.45 
(2.98±0.37) 
-11±11 
(-3±8) 
0.95 
(0.31) 
0.342 
(0.005*) 
VST 1.83±0.21 
(1.90±0.25) 
1.61±0.27 
(1.70±0.28) 
-13±7 
(-12±4) 
2.46±0.31 
(2.50±0.37) 
1.95±0.30 
(2.01±0.37) 
-21±6 
(-20±5) 
1.65  
(1.71) 
0.005* 
(0.0015*) 
TH 0.45±0.05 
(0.43±0.06) 
0.42±0.05 
(0.41±0.06) 
-5±5 
(-5±5) 
0.47±0.1 
(0.52±0.08) 
0.41±0.08 
(0.45±0.08) 
-14±7 
(-14±6) 
2.53 
(3.04) 
0.01* 
(0.014*) 
CD 2.21±0.30 
(2.13±0.33) 
2.05±0.28 
(2.00±0.34) 
-7±4 
(-6±5) 
1.56±0.23 
(1.46±0.26) 
1.36±0.19 
(1.34±0.26) 
-12±7 
(-8±6) 
1.65  
(1.28) 
0.0615 
(0.29) 
PU 
2.98±0.30 
(2.99±0.36) 
2.67±0.34 
(2.67±0.43) 
-11±6 
-11±6 
2.24±0.19 
(2.22±0.22) 
1.89±0.17 
(1.91±0.22) 
-16±4 
(-14±4) 
1.44  
(1.23) 
0.035* 
(0.13) 
 
 
Values in parentheses are for different day subjects only (n=7). Significance levels are of post hoc one tailed 
paired t-tests comparing ΔBPND
PHNO and ΔBPND
RAC
  
 
  
NDBP NDBP
1.Comparisons between the ligands were not made in these regions (see text)  
* denotes significant result (p<0.05) 
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[
11
C]raclopride  at baseline in the SN&VTA and hypoTH were < 0.4, and hence were 
not considered sufficiently robust to be used for the quantitation of amphetamine induced 
change.  Due to concerns about ‘carry-over’ effects of (+)-PHNO, the of “same-day 
subjects” versus that of “different-day subjects” was compared (Table 7). 
Table 7. Mean   values for all subjects (n=13), same day (n=6) and different day 
(n=7) [
11
C]-(+)-PHNO scans  
 
 
% Change: 
HypoTH SN&VT
A 
VPSI GP VST TH CD PU 
[
11
C]-PHNO all 
subjects (n=13) 
 
-28±11 -27±16 -24±14 -11±11 -21±6 -14±7 -12±7 -16±4 
[
11
C]-PHNO same 
day (n=6) 
 
-26±11 -33±6 -31±10 -19±9 -22±8 -13±8 -17±6 -18±3 
[
11
C]-PHNO 
different day (n= 7) 
-29±12 -22±21 -19±15 -3±8 -20±5 -14±6 -8±6 -14±4 
MANOVA (same day/different day comparison)  F(6,6)=1.94, p=0.22 
 
 for “same-day subjects” were higher in all regions except the TH and hypoTH, 
however this difference was not statistically significant (MANOVA, F(8,4) = 1.35, p = 0.41). 
As a result of this finding [
11
C]-(+)-PHNO data from all subjects was used in our main 
analysis. 
 
Correlations between ΔBP and change in score on the Simplified Amphetamine Rating Scale 
were examined. Change in the ‘euphoria’ score between 0 and 3 hours correlated negatively 
with VST ΔPHNO (r=-0.551, P=0.05), change in ‘restlessness’ score correlated negatively 
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with CD ΔPHNO with trend level significance (r=-0.523, P=0.07). In addition change in 
‘alertness’ score correlated negatively with TH  ΔRAC (r=-0.630, P=0.05) (Figure 11). 
 
Figure 11. Correlations between ΔBP (negative values indicate increased DA release) and 
change in scores on the Simplified Amphetamine Rating Scale (positive values indicate 
greater ‘euphoria’, restlessness’ or ‘alertness’) 
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5.3.1. Within-subjects comparison of  between radioligands 
The amphetamine-induced  was significantly higher than  (repeated 
measures ANOVA, F(1,9) = 6.58, p = 0.03; Figure 12). 
Figure 12.    Reduction in for [
11
C]-(+)-PHNO and [
11
C]raclopride following 
amphetamine. Columns represent the mean values with associated standard deviation error 
bars. 
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Post-hoc one-tailed paired t-tests revealed that  was significantly higher than 
  
 
in the VP, VST, TH and PU (Table 6). The largest displacement in [
11
C]-(+)-PHNO 
 was measured in regions with the highest D3 fraction (SN&VTA and HypoTH,  
~30%)
 
(Searle et al. 2010; Tziortzi et al. 2010), where   values were unavailable for a 
direct comparison with  The variability in these regions is clearly higher than for 
regions with lower D3 fraction. This may be due to their small size and consequent sensitivity 
to subject motion and image registration. The GP was excluded from this list of D3-rich 
regions as the results in this study for the GP were anomalous. As a D3-rich region one would 
expect the post-amphetamine change in binding potential would be significantly greater using 
PHNO than with raclopride. However there was no significant difference between 
radioligands when data from all 13 scans was examined, and a signiifant difference in the 
opposite direction from that expected (ie delta RAC>PHNO) when only the ‘different day’ 
scan data was examined.  
 
 There are several potential reasons for this. The most likely lies in the difficulties in the 
quantification of GP signal with [
11
C]-(+)-PHNO. The ligand kinetics in the GP are very 
slow, hence noise at the end of the scan can have a disproportionate effect on the 
extrapolation of the [
11
C]-(+)- PHNO time-activity curves in this region, and hence may 
affect accurate quantification of any changes in ligand binding. The GP may also be 
heterogenous in distribution of D2 and D3 receptors (Murray et al. 1994) and has indistinct 
boundaries on T1 MRI images. These factors could increase the variability in outcome 
parameters and lead to anomalous results. 
 
In order to rule out any potential influence of mass ‘carry over’ of (+)-PHNO, the within-
subjects comparison of  between radioligands was repeated using only the 7 subjects 
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who were scanned with [
11
C]-(+)-PHNO on different days. The result remained significant 
(RM ANOVA: F(1,6) = 8.043, p = 0.03; Figure 12). Post-hoc one-tailed paired t-tests 
revealed that [
11
C]-(+)-PHNO   was significantly higher than [
11
C]raclopride  
in the VST and TH (Table 6).  
 
5.3.2. Effect of order of ligand administration on  
In order to examine any potential effects of sensitisation by amphetamine, the effect of the 
order of ligand administration on the within each ROI was examined using 
independent samples t-tests. There were no significant differences in [
11
C]raclopride  
across all ROIs between those subjects who had their [
11
C]raclopride scans on the second 
study day (after a previous dose of amphetamine) and those who had their [
11
C]raclopride 
scans on the first study day.  The same lack of effect was found for [
11
C]-(+)-PHNO. In 
addition there was no significant effect of order of ligand administration when it was included 
as a covariate in the RM ANOVA comparing  between radioligands (p = 0.75). 
 
5.3.3  Relationship between regional  against the regional  
A regression was performed of regional  against the regional  (the fraction of 
the total [
11
C]-(+)-PHNO binding that can be attributed to D3) obtained from data reported by 
Tziortzi et al. (see Table 3 in the Tziortzi paper, Method A1).  In order to eliminate any 
potential bias due to (+)-PHNO mass carry-over in regions rich in D3 (such as the SN&VTA 
and the HypoTH) only the data from seven subjects who were scanned with [
11
C]-(+)-PHNO 
on separate days was examined. A significant effect of on (r = 0.325, p = 
0.014, Figure 13) was found, indicating that the interaction of dopamine with the D3 receptor 
plays a significant role in the effect of amphetamine on [
11
C]-(+)-PHNO binding. 
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Figure 13. Regression of  against  
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5.4. Discussion 
  
An administration of amphetamine induced a significantly larger change in [
11
C]-(+)-PHNO 
binding as compared to [
11
C]raclopride, with the magnitude of similar to 
that found in preclinical studies involving anaesthesia (Ginovart et al. 2006;Narendran et al. 
2006). Of the four factors identified earlier, which could explain the increased  with 
[
11
C]-(+)-PHNO compared to [
11
C]raclopride following an amphetamine challenge, the 
effects of anaesthesia do not appear to be important. Recently published data in awake and 
anaesthetised rodents implied that the greater sensitivity of agonists to amphetamine induced 
dopamine release is a side-effect of anaesthesia and is not present in conscious humans 
(McCormick et al. 2010). In this study, a direct within-subject comparison of agonist and 
antagonist ligands in conscious humans contradicts this speculation.  
 
Previous work has compared the effect of amphetamine on the binding of the D2/3 agonist 
[
11
C]NPA to that of the D2/3 antagonist [
11
C]raclopride, and found the :  to be 
~1.4 in anaesthetised primates (Narendran et al. 2004) and ~1.6 in awake humans (Narendran 
et al. 2010). As the contribution of the D3 to both the [
11
C]NPA and the [
11
C]raclopride signal 
in the striatum is negligible, the greater sensitivity of [
11
C]NPA was attributed to the greater 
sensitivity of ligands binding at the D2high sites to fluctuations in dopamine levels. While 
[
11
C]-(+)-PHNO binding is a mixture of D3 and D2 components, in the dorsal caudate and 
putamen the contribution of D3 is negligible (Searle et al. 2010; Tziortzi et al. 2010). In this 
study  = 1.53 in the dorsal caudate and putamen, consistent with 
: , suggesting that the binding of [
11
C]-(+)-PHNO to the D2high receptor may 
be a factor in its enhanced sensitivity to an amphetamine challenge. 
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In regions other than the caudate and putamen, the contribution of the D3 to [
11
C]-(+)-PHNO 
binding is significant, and any effects of amphetamine will depend on the affinity of 
dopamine for D3 as well as for D2high receptors.  
 
 In this analysis the assumption is made that the amount of dopamine released by 
amphetamine is similar in all basal ganglia regions, as well as in the TH, HypoTH and 
SN&VTA. Microdialysis literature comparing the effects of amphetamine on extracellular 
dopamine levels in these regions is not extensive, but the differences between SN and striatal 
dopamine release are minimal in one study (Robertson et al. 1991), though not in another 
(Kalivas et al. 1989). In the striatum itself, the literature does suggest that amphetamine-
induced dopamine release in the ventral striatum is approximately twice that in the dorsal 
striatum (Drevets et al. 1999). It should be stressed that the assumption of homogeneous 
regional dopamine release may not be valid, in which case the above analysis will only be an 
approximation. 
   
The corollary of this argument is that perhaps the regional differences in radioligand 
displacement are due to variations in dopamine release rather than changes in regional 
. If this is the case then it would be expected that the ratio of  
would be similar irrespective of the regional In the ROIs where a direct comparison 
of [
11
C]-(+)-PHNO and [
11
C]raclopride could be conducted, the  in the 
VST was not significantly different from that in the CD and PU, where D3 contribution to the 
[
11
C]-(+)-PHNO signal is negligible. Hence, a conclusive statement on the role of D3 in the 
sensitivity of [
11
C]-(+)-PHNO to an amphetamine challenge requires comparative data in the 
SN&VTA using a suitable high affinity D2 radioligand such as [
11
C]FLB-457 or 
[
18
F]fallypride. 
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The data allowed derivation of two incidental findings, which bear on the physiology of 
dopaminergic neurotransmission. Firstly, as [
11
C]-(+)-PHNO binds to both the D2high and D3, 
the data allow us to comment on the relative affinity of dopamine for the two sites. This 
estimation assumes that the baseline concentrations of dopamine and the amounts of 
dopamine released by amphetamine are similar in all regions. A regression of 
against provides an estimate of   2.98 (95% CI 1.34 - 4.63) (Figure 
3).  The positive value suggests that the D3 has the higher affinity, and the value of the slope 
suggests that the two dissociation constants have the same order of magnitude. While in vitro 
assessments often found higher selectivity of dopamine for the D3 over the D2 (Sokoloff et al. 
1992), most of these were conducted in receptors configured to a mixture of  D2high and D2low 
states under non-physiological conditions – which may lead to an under-estimation of the 
affinity of dopamine for the D2high. As mentioned above, this analysis assumes a similar 
magnitude of dopamine release in the various ROIs, and in addition, the baseline occupancies 
of the D2 and D3 receptors by dopamine are disregarded.  
 
Secondly it was also possible to estimate the proportion of the D2 receptors configured in the 
D2high state ( ) in the dorsal striatum, using the method developed by 
Narendran and colleagues for [
11
C]NPA and [
11
C]raclopride (Narendran et al. 2004). 
        Eq. 3 
In anaesthetised primates  was estimated at 71% (Narendran et al. 2005), while a 
subsequent study in humans found a somewhat lower estimate of ~60% (Narendran et al. 
2010). As the D3 contribution to the [
11
C]-(+)-PHNO signal in the dorsal striatum is 
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negligible, the  was estimated in this region, and found to be consistent with the 
previous estimate, at ~65%. 
  
The correlations found with the changes in score on the Simplified Amphetamine Rating 
Scale are noteworthy. The correlation found between the change in euphoria score and 
dopamine release in the VST is consistent with other studies using amphetamine, which have 
shown that has been shown its hedonic effects are associated with changes in the ventral 
regions of the striatum (Drevets et al. 2001; Martinez et al. 2003). Euphoria is the only 
subjective effect of amphetamine that has consistently been shown to correlate with 
dopamine release. Correlations between whole striatal dopamine release and measures of 
euphoria were also found in two other studies (Laruelle et al. 1995; Volkov et al. 1999). It has 
been suggested from this data that a strong neurobiologic response of the dopamine system to 
amphetamine may constitute a risk factor in the development of addiction.  The Martinez 
study also used the Simplified Amphetamine Rating Scale as a subjective measure of the 
effects of amphetamine, however they found no other correlations between other domains on 
the scale and dopamine release across several ROIs. When considering the trend-level 
significance correlation found between restlessness score and dopamine releanse in the 
caudate with [
11
C]-(+)-PHNO, it is tempting to speculate that this reflects the motor function 
of this region. Likewise, the correlation found between alertness and dopamine release in the 
thalamus with [
11
C]raclopride may reflect the fact that this region is known to be important in 
regulation of normal alertness (Balkin et al. 2002). However it is unclear why a similar 
correlation was not found with [
11
C]-(+)-PHNO in this region. 
 
Several methodological caveats of this study need to be mentioned. The first six subjects 
examined received two [
11
C]-(+)-PHNO injections ~5 hours apart, and thus their 
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estimates could be biased due to a ‘mass carry over’ effect of non-tracer amounts 
of (+)-PHNO remaining bound to the D3  during the post-amphetamine scan. This could lead 
to an overestimation of the occupancy attributed to endogenous DA. However, several lines 
of evidence suggest that this potential bias does not explain the difference between  
and  in this study. First, a separate comparison of data from the last seven subjects 
(who received their post-amphetamine [
11
C]-(+)-PHNO injection at least seven days 
following their baseline scan) revealed a notably higher than . A post-hoc 
analysis using only the 7 subjects who were scanned with [
11
C]-(+)-PHNO on different days 
indicated that the within-subject difference between
 
 and remained 
significant. The ratio of mean  for “same day” subjects was similar to that 
of that for the whole group at around 1.3 in most ROIs (Table 6). Secondly, any carry-over 
effects of (+)-PHNO from the baseline scan would be manifested only at the D3, and not at 
the D2. However,  was higher than  even in ROIs such as the dorsal caudate 
and putamen, where the contribution of the D3 is negligible. However the data did show that 
values for “same-day subjects” were higher than for “different day” subjects in all 
regions except the TH and HypoTH. Even though the difference did not reach statistical 
significance with the subject numbers in this study, when considered with what is known 
about the Kd of [11C]-(+)-PHNO at the D3 receptor (Gallezot et al. 2009), it is apparent that 
extreme caution should be exercised. If consecutive [
11
C]-(+)-PHNO scans are performed on 
the same day, account of possible carry-over effects must be included in the quantification of 
[
11
C]-(+)-PHNO binding.  
 
Non-tracer conditions during [
11
C]-(+)-PHNO scans could also lead to an underestimation of 
the occupancy by endogenous DA, due to the effects of competition between DA and (+)-
PHNO. The balance between this effect and ‘carry-over’ may be difficult to estimate, but 
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examples of the possible effects are presented in the Supplementary Information, Appendix. 
Based on these simulations, there is no evidence that any non-tracer binding of [
11
C]-(+)-
PHNO would substantially change the conclusions of this study. However it is essential that, 
in all studies using [
11
C]-(+)-PHNO, the consequences of non-tracer conditions at the D3 
receptor are considered in quantification.  The best estimate for the in vivo Kd of [
11
C]-(+)-
PHNO at the D3 receptor is ~30ng/kg (Gallezot et al. 2012). With this in mind, tracer 
conditions (i.e. occupancy of <5% of the target) would require an injection of <3ng/kg, or 
~0.2ug total dose in a 70 kg subject. The specific activity to achieve this is not attainable 
using the Grignard chemistry required to synthesise [
11
C]-(+)-PHNO. In addition, we found 
that with injected masses of over 2ug, nausea was a potential problem with [
11
C]-(+)-
PHNO.There were no documented reports of nausea when injected masses were below this 
figure. Specific activity therefore needs to be high enough to ensure that an injected mass of 
less than 2ug is possible. This is consistent with the safe dose of [
11
C]-(+)-PHNO reported by 
Mizrahi of 0.029 mg/kg, which is equivalent to approximately 2ug in a 70kg subject (Mizrahi 
et al. 2010).   Future studies with this ligand will also need to recognise that, outside the 
tracer range, [
11
C]-(+)-PHNO receptor binding is dependent on injected ligand mass as well 
as receptor density and endogenous dopamine levels. 
 
This study design required that each subject receives two doses of amphetamine, therefore 
sensitisation to amphetamine was a potential problem. However the evidence for a 
sensitisation effect with amphetamine in the literature is conflicting. Sensitisation to a single 
administration of intravenous amphetamine was examined in the course of a test-retest 
assessment of amphetamine-induced striatal dopamine release in humans using [
123
I]IBZM 
SPECT (Kegeles et al. 1999). Subjects underwent measurement of striatal dopamine release 
on 2 occasions, 16±10 days apart, following the administration of 0.3 mg/kg of amphetamine. 
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No significant differences were found between second and first administration of 
amphetamine. In contrast, both greater psychomotor response and increased dopamine release 
were seen at both 14 and 365 days after the first exposure to amphetamine in a 
[
11
C]raclopride study (Boileau et al. 2006). It is noteworthy that in this study subjects 
received oral amphetamine at the same dose (0.3 mg/kg) on three separate occasions (as 
opposed to only one previous dose in the Kegeles study above). In order to control for 
possible effects of sensitisation, the order of radioligand administration was counterbalanced 
in this study. No evidence of an amphetamine sensitisation effect was found, as for both 
ligands the  did not depend on the order of administration. 
 
The effect sizes for in the VST and PU were greater than seen in a previous human 
study (see Table 8) (Willeit et al. 2008). 
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Table 8. Effect sizes for [
11
C]-(+)-PHNO and [
11
C]NPA  after amphetamine challenge 
*Amphetamine values refer to plasma concentration measured at the start of the post-dose 
scan 
 
In addition the effect sizes in these ROIs were comparable to that of the agonist radioligand 
[
11
C]NPA (Narendran et al. 2010), even though this study used a lower dose of amphetamine 
(0.3 vs. 0.5 mg/kg). Thus [
11
C]-(+)-PHNO has at least an equal sensitivity to that of 
[
11
C]NPA to detect extracellular DA fluctuations. An added advantage of [
11
C]-(+)-PHNO is 
that it can be used to measure binding in extra-striatal regions such as the SN and hypoTH, 
which is not possible with [
11
C]NPA. Against this greater sensitivity, the methodological 
complications required to acquire well quantified data with [
11
C]-(+)-PHNO must be 
 Amphetamine 
(ng/L)* 
VST CD PU 
[
11
C]raclopride 
(this study, n=10) 
55.6±5.8 1.9 1.8 1.8 
[
11
C]PHNO (this 
study, n=13) 
59.2±7.8 3.7 1.5 3.8 
[
11
C]PHNO 
(Willeit et al., 
2008, n=11) 
53.2±24.4 1.9 1.9 2.3 
[
11
C]NPA 
(Narendren et al., 
2010, n=10) 
73.9 ± 5.4 2.3 2.6 4.5 
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acknowledged. These include complicated radiosynthesis, requirement for high specific 
activity to achieve tracer conditions and in order to avoid nausea in subjects, and the need to 
separate consecutive scans by a sufficient time gap to avoid potential carry-over effects at the 
D3 receptor. With these factors in mind, the choice of radioligand to image endogenous 
dopamine release will be conditioned by the requirements of each particular study.  
 
New data from Seeman (Seeman 2012) has suggested [
11
C]-(+)-PHNO is not selective for 
dopamine D2high receptors, but also binds to the D2low state of the dopamine receptor. This is 
not fundamentally a new finding, as it is to be expected that agonists may bind to low-affinity 
(of G-protein uncoupled) receptors, at significantly lower affinity than their binding to high-
affinity, or G-protein coupled receptors. In Figure 3 in the paper they present data suggesting 
that [
3
H]-(+)-PHNO labelled two sites; both D2high (~20%) and D2low (~80%).  Seeman 
explains this as a result of differences between (+)-PHNO binding to D2high and D2low 
receptors, however he ignores the contribution of D3 receptors. It is therefore possible that the 
two sites represent D3 and D2high instead. Previous rodent and primate work with (+)-PHNO 
suggests that the contribution of the D3 receptor to dorsal striatal (+)-PHNO binding is not 
negligible, and may constitute ~10-15%. In addition, the experiments were performed at 
[
3
H]-(+)-PHNO concentrations of 2nM. Seeman indicates that the Ki value for the “high-
affinity site” is around 0.6 nM, while  that of the “low-affinity site” is around 144 nM. Thus 
2nM concentration would block ~75-80% of the “high-affinity site” while blocking only ~3% 
of the “low-affinity site” – thus underestimating the density of the “high-affinity site”. Thus, 
overall the relevance of these data for the interpretation of in vivo studies conducted with 
[
11
C]-(+)-PHNO is unclear.   
In summary, this study used a within-subject design to provide evidence that [
11
C]-(+)-PHNO 
is more sensitive than [
11
C]raclopride in detecting the fluctuations of extracellular DA. The 
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data suggest that both the agonist nature of [
11
C]-(+)-PHNO, and its selectivity for the D3 
receptor contribute to its higher sensitivity compared to [
11
C]raclopride. It must be 
emphasised that mass effects are a potential confounding factor in imaging with [
11
C]-(+)-
PHNO, and therefore same day scans should be approached cautiously to take account of 
possible carry-over effects. 
  
Now that the increased sensitivity of [
11
C]-(+)-PHNO has been demonstrated, further studies 
are required to evaluate alternative challenge agents such as nicotine and bupropion. These 
would be useful in schizophrenia studies as they are less likely to exacerbate psychosis. With 
these, it should be possible to test whether abnormal dopamine release is an endophenotype 
or trait marker in schizophrenia. As yet, dopamine release has not been studied in those at 
increased risk of developing the condition, such as first degree relatives and those with the 
prodromal condition. Another important study would be to examine whether dopamine 
release in response to salience-generating stimuli is altered in schizophrenia. [
11
C]-(+)-PHNO 
would be the radioligand of choice, as it would allow detection of smaller changes in 
dopamine levels. Such a study would provide important evidence to back up the aberrant 
salience hypothesis of delusion formation in schizophrenia.    
Statement of student’s contribution to this chapter. 
I developed the protocol for this study, with supervision from Dr Ilan Rabiner and Professor 
Marc Laruelle. I obtained ARSAC and REC approvals for the study, performed all 
correspondence with these agencies and attended all REC meetings. I recruited all of subjects 
with the assistance of the Clinical Imaging Centre’s recruitment team. I screened all subjects 
for the study myself. I scanned all of the subjects. Image analysis scans was performed by 
myself and Andri Tziortzi.  I performed the data analysis with supervision from Dr Ilan 
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Rabiner and Professor Roger Gunn. I interpreted the results with supervison from Dr Ilan 
Rabiner and Professor Roger Gunn.  
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Appendix to Chapter 5  – Consideration of the effect of non-tracer conditions on measured 
occupancy 
In competition studies, where there are non-tracer amounts of radioligand present at each 
scan (BPscan1 and BPscan2), the measured occupancy will be different to that which would have 
been achieved by the same dose of the blocking compound under tracer conditions for the 
radioligand.  
          
It can be shown that the measured occupancy (the change in binding potential between scan I 
and scan 2 (OccM)) is related to the total true occupancy of the target by all competing species 
(here (+)-PHNO and dopamine) at the first and second scans (Occ1 and Occ2) by equation 9. 
 
          Eq 1 
 
The occupancy of a target by two competing species is given by the Gaddam Equation 
(Neubig et al. 2003); 
 
       Eq 2 
 
The following assumptions were made to estimate the potential effect of the non-tracer doses 
of (+)-PHNO used in the study on the post-amphetamine change in [
11
C]-(+)-PHNO binding.  
 
1.  DA occupies ~10% of the D2/3 receptor at baseline. 
2. A dose of amphetamine would lead to a ~16% change in the availability of the D2/3 
(i.e. increase occupancy by DA from ~10% to ~25%). This would be the measured 
occupancy if (+)-PHNO were at tracer dose. This corresponds to an increase in the 
value of   from ~0.1 to 0.33. 
3. The in vivo ED50 of (+)-PHNO for the D3 receptor is ~30 ng/kg or 2 µg. 
4. For the purpose of estimating the effects of dopamine fluctuation on the availability of 
D2/3 receptors, it was assumed that dopamine interacts with (+)-PHNO at the receptor 
in a competitive manner. Whether the exact mechanism is competition or is more 
complicated involving an internalisation of the receptor due to the action of dopamine 
may not be critical for the purposes of this simulation. Both competition and 
internalization models would predict a reduction in the availability of D2/3 receptors 
following the administration of amphetamine, and the degree of reduction would be 
dependent on the amount of dopamine released and the affinity of dopamine for the 
particular receptor. The rationale for making the assumption that internalisation is 
proportional to dopamine release is as follows; if the prolonged time course of the 
decrease in BP is proportional to the increase in dopamine (demonstrated in a 
microdialysis study (Laruelle et al. 1997)), and if internalization is the mechanism 
driving the prolonged decrease in BP, then it follows that the internalization is 
proportional to DA release. 
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The effects of (+)-PHNO were estimated for 3 doses (7, 15 and 30 ng/kg or ~0.5 µg, 1 µg and 
2 µg) representing the lowest, median and the highest dose used in this study.  
 
 Scenario 1 – No ‘carry over’ of (+)-PHNO between scans 
If it is assumed that there is no ‘carry-over’ between scans, and the occupancy of the target by 
(+)-PHNO is the same for the two scans, then the occupancy effect measured following a 
perturbation of DA levels will underestimate the true occupancy due to dopamine alone, and 
this underestimation will  increase in magnitude as the dose of (+)-PHNO increases. This is 
demonstrated in the examples below. 
It is assumed that the (+)-PHNO dose at scan 1 is the same in scan 2.  
 
Example 1 (0.5 µg (+)-PHNO, no carry over between scans) 
 
For scan 1:  
 
For scan 2:   
 
Therefore the measured occupancy will be given by the formula derived above: 
 
  
 
  
 
Example 2 (1 µg (+)-PHNO, no carry over between scans) 
 
For scan 1:  
 
For scan 2:   
 
Therefore the measured occupancy will be: 
 
  
 
Example 3 (2 µg (+)-PHNO, no carry over between scans) 
 
For scan 1:  
 
For scan 2:   
 
Therefore the measured occupancy will be: 
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Scenario 2 - The effect of carry over 
 
If there is carry over of cold (+)-PHNO between scans then this will result in an over-estimate 
of the measured occupancy, and this over-estimate will increase in magnitude as the dose of 
(+)-PHNO increases. The following examples assume that the mass dose given in the first 
scan remains fully for the second scan (i.e. 100% carry over). 
 
Example 1 - 0.5 µg dose, 100% carry over (the effective dose at scan 2 will therefore be 1 
µg) 
  
For scan 1:  
 
For scan 2:   
 
  
 
Example 2 - 1 µg dose, 100% carry over (the effective dose at scan 2 will therefore be 2 µg)  
 
For scan 1:  
 
For scan 2:   
  
 
Example 3 - 2 µg dose, 100% carry over (the effective dose at scan 2 will therefore be 4 µg)  
 
For scan 1:  
 
For scan 2:   
 
  
 
The size of the overestimate therefore increases with increasing dose of (+)-PHNO 
The table below summarises the above calculations; 
 
(+)-PHNO dose True change in 
dopamine 
occupancy 
(tracer dose) 
Estimated 
change in 
dopamine 
occupancy  
(no carry over) 
Estimated 
change in 
dopamine 
occupancy  
 (100% carry 
over) 
7 ng/kg (~0.5 µg) 16% 15% 26% 
15 ng/kg(~1 µg) 16% 11% 31% 
30 ng/kg(~2 µg) 16% 10% 38% 
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For the above study these calculations demonstrate that the results for the same day scans 
(that is with some potential carry-over) are biased towards an overestimate of the measured 
occupancy. For the different day scans (with no carry over, but with (+)-PHNO at non-tracer 
conditions) the bias would be towards an underestimate of measured occupancy. 
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Chapter 6. Quantification of [
11
C]-(+)-PHNO binding in the human brain: mass effects and 
suitability of reference region 
6.1. Introduction 
[
11
C]-(+)-propyl-hexahydro-naptho-oxazin ([
11
C]-(+)-PHNO)  is a dopamine (DA) D2/D3 
agonist radiotracer. Quantification of [
11
C]-(+)-PHNO has been formally assessed in two 
previous publications. Ginovart et al. (Ginovart et al.  2007), examined quantification of 
baseline [
11
C]-(+)-PHNO binding in six healthy subjects, using both full quantification 
(metabolite corrected arterial plasma input function and kinetic modelling) and simplified 
quantification methods, and concluded that the simplified quantification methods 
(specifically the simplified reference tissue model – SRTM) were adequate to quantify 
baseline [
11
C]-(+)-PHNO binding in humans.
  
Williet and colleagues (Williet et al. 2006), 
used the SRTM to assess test-retest (TRT) reliability of [
11
C]-(+)-PHNO in two healthy 
subjects, as well as the occupancy of a modest dose of the D2/D3 antagonist haloperidol (2 
mg). They report that the mean absolute TRT variability of SRTM BPND in two subjects 
undergoing two naive [11C]-(+)-PHNO PET at least one week apart scans was 8.5 ±0.5%, 
4.0±3.0%, and 12.5±0.5% for caudate, putamen, and globus pallidus respectively. In addition 
the cerebellar time-activity curves (TACs) were unaltered between the baseline scans and the 
post-haloperidol scans, consistent with the assumption that cerebellar radioactivity 
accumulation represents free and non-specifically bound [
11
C]-(+)-PHNO. 
 
Recent internal data acquired by the GlaxoSmithKline (GSK) molecular imaging group 
(Rabiner et al.  2009; Searle et al.  2010) brought the following potential issues to attention. 
Firstly, it was found that [
11
C]-(+)-PHNO possesses very high affinity for the D3 receptor. 
This raised the concern that most clinical studies are conducted at non-tracer conditions, with 
D3 occupancies >10%. In addition, as a result of this relatively high occupancy, it is possible 
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that significant mass carry over could occur between two scans conducted on the same day. 
Any potential mass carry over is made more likely because [
11
C]-(+)-PHNO kinetics in the 
target brain regions are moderately slow.  Secondly, and in contrast to the findings of Willeit 
et al. described above, there appears to be a significant displaceable binding component in the 
cerebellum, which, if not accounted for, could lead to a bias in the quantification of specific 
[
11
C]-(+)-PHNO binding unless accounted for properly in the model. When using a reference 
tissue model, it is generally assumed that all binding in the chosen tissue is non-specific. If 
this is not the case then the model assumptions are violated leading to bias. 
 
As the studies conducted by GSK were not focused on examining the issues described above, 
their effect on the quantitative analysis of the [
11
C]-(+)-PHNO signal is not yet well 
characterised. The purpose of this experiment was to directly test and quantify the effect of 
mass carry over between two sequential [
11
C]-(+)-PHNO scans, and also to directly test for a 
displaceable binding component in the cerebellum. In addition the test-retest reproducibility 
of [
11
C]-(+)-PHNO was formally examined. A four scan design was used in order to make the 
following comparisons; 
1. Two same day scans with as short as possible time interval between them to assess 
mass carry-over. 
2. A third scan one week later to assess test-retest reproducibility (comparison between 
scans 1 and 3). 
3. To allow quantification of the amount of displaceable binding in the cerebellum, 
which was assumed to be due to D2/D3 receptors, a fourth scan was performed four 
hours after a single 15 mg dose of aripiprazole. The differences in the binding 
potentials between scan 3 and 4 provide an index of the displaceable binding in the 
cerebellum. Aripiprazole is a D2/D3 partial agonist that allows the highest clinically 
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acceptable blockade of brain D2/D3 receptors. A review of the literature suggested that 
a single 15mg dose of aripiprazole would provide more than 50% occupancy at the D2 
receptor and would be unlikely to result in adverse events (Stahl 2001; Mallikaarjun 
et al. 2004; Mamo et al. 2008). This dose was felt to be sufficient to indicate whether 
there is (or is no) specific binding component in the cerebellum. Aripiprazole 
affinities for both D2 and D3 receptors are similar and are in the low nanomolar range 
(Shapiro et al.  2003). It acts as a partial agonist at dopamine D2-like receptors. Partial 
agonists bind to their target, but display limited intrinsic activity in comparison with 
the endogenous agonist. They characteristically behave like agonists in circumstances 
of low dopamine receptor stimulation (at autoreceptors, with high receptor reserve), 
whereas they act mainly as antagonists in conditions of high stimulation (at post-
synaptic receptors, with low receptor reserve). Partial agonism at the presynaptic D2 
autoreceptor results in decreases in dopamine synthesis, release and subsequent 
dopaminergic neurotransmission. Consequently aripiprazole has been referred to as a 
dopamine system stabilizer (Stahl, 2001; Luisi, 2002; McQuade et al., 2002); 
theoretically, it may reduce dopamine activity in areas of the brain where elevated 
dopamine is related to psychotic symptoms (the mesolimbic pathway), while 
simultaneously increasing dopamine activity where diminished levels are believed 
related to negative symptoms and cognitive dysfunction (the mesocortical pathway) 
(Stahl, 2001; Grunder et al. 2003). While partial agonists behave as antagonists post-
synaptically, they retain some intrinsic activity, thus making antagonism-related 
adverse events such as extrapyramidal symptoms less likely.   
 
Aripiprazole also has partial agonist activity at the 5HT1A receptor and antagonism at 
the 5HT2A receptor. Partial agonism at the 5HT1A receptor has been postulated as a 
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potential therapeutic mechanism in the alleviation of depression, anxiety and negative 
symptoms (Millan 2000; Meller et al. 1990; Pae et al., 2008). Aripiprazole has been 
shown to exhibit a high D2/5-HT2A binding profile in vivo, which contrasts with the 
profiles of other atypical antipsychotic drugs, which exhibit high 5-HT2A/D2 binding 
(Mamo et al. 2008). Aripiprazole’s atypical profile in vivo is therefore not related to a 
high 5-HT2/D2 binding profile. 
 
6.2. Methodology  
The study was approved by Essex 1 Research Ethics Committee. The study was conducted at 
the GSK Clinical Imaging Centre (CIC) on the Hammersmith Hospital site. 6 healthy male 
subjects participated in this study. The mean age of the participants was 42±8 years. All 
subjects were screened by history, systems review, physical examination, routine blood tests, 
urine toxicology and electrocardiogram to ensure no relevant general medical or psychiatric 
history (including drug and alcohol misuse). Subjects provided written informed consent 
following a full explanation of the study. In addition, all subjects had a structural magnetic 
resonance image (MRI) scan of the brain to provide an anatomical image for co-registration 
with the PET data. The MRI sequences performed were T1 and Fast Gray Matter Acquisition 
T1 Inversion Recovery (FGATIR) sequences. 
  
Each subject received 4 PET scans in total. Two scans were conducted on the same day with 
minimal interval to examine the effects of mass carry over (same day TRT). A third scan 
(conducted  >1 week after scans 1 and 2) determined the TRT variability without potential 
mass carry over by comparing the data to that of scan 1. The fourth scan was performed four 
hours after a single 15 mg dose of aripiprazole.  Plasma aripiprazole levels were measured 
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immediately prior to and at 4 hrs and 5.5 hours following aripiprazole administration in order 
to determine aripiprazole levels during the PET scanning period.  Each dose of radioligand 
was administered as an intravenous bolus. The MRI scan was performed on one of the PET 
scanning days. An arterial cannula was inserted before the first PET scan of the day and 
remained in situ until the last scan of the day was completed. This was used to collect 
continuous and discrete blood samples for estimation of the metabolite corrected input 
function. 
 
Three outcome measures were calculated: regional volume of distribution (VT) as estimated 
by a standard two tissue compartmental model, binding potential (BPND ) estimated from the 
two compartment model, and binding potential as derived using the simplified reference 
tissue method (BPND SRTM). The variability and reliability of the outcome measures were 
examined. In addition the change in each outcome measure following pre-treatment with 
aripiprazole was calculated. 
 
6.2.1. PET data 
In total 24 PET scans were acquired on a Siemens Biograph HiRez XVI PET scanner 
(Siemens Healthcare). A low dose CT scan (Effective Dose = 0.2 mSv) was acquired for 
attenuation and model-based scatter correction. Subjects were injected with a single 
intravenous bolus of [
11
C]-(+)-PHNO. Following bolus administration of radioligand, 
dynamic emission data were acquired for 90 minutes (frame timings: 8x15 s, 3x1 min, 5x2 
min, 5x5 min, and 5x10 min). Arterial sampling for measurement of [
11
C]-(+)-PHNO input 
function was performed. The dynamic images were reconstructed using Fourier rebinning and 
a 2D filtered back projection algorithm with a ramp filter at Nyquist cut off frequency.  
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An automatic blood sampling system was used to withdraw continuously arterial blood 
samples for the first 15min after tracer injection. In addition twelve discrete blood samples 
were acquired, the first at the 5
th
 minute post-injection until the end of the scan at regular 
intervals. Specifically the 5 earliest discrete samples were collected every 5 minutes with the 
others taken every 10 minutes. A proportion from each discrete sample was used to measure 
the whole blood radioactivity using a gamma counter. The first 3 discrete whole blood 
measurements were used to calibrate the continuous whole blood activity, which in 
conjunction with the discrete whole blood measurements were employed to generate the 
whole blood activity curve for the total scan duration. 
   
The remaining blood from each discrete sample was centrifuged to obtain the plasma 
component. A plasma aliquot was used to measure the plasma activity and the plasma-over-
blood activity ratio was estimated for each sample. A constant model was fitted to the 
measurements to estimate the average plasma-over-blood ratio. The whole blood activity 
curve was multiplied with this ratio to generate the plasma activity curve. 
   
The remaining volume of each plasma sample was used to determine the fraction of the 
unchanged radioligand (parent fraction) and its metabolites using the HPLC method.  An 
exponential plus constant model was fitted to the parent fraction data to derive the parent 
fraction curve. The product of the parent fraction curve and the plasma activity curve 
generates the metabolite corrected plasma curve, which was used as the input function for the 
kinetic analysis.    
 
 
 
122 
 
6.2.2. MRI data  
High resolution T1-weighted magnetic resonance images (MRI) and high resolution FGATIR 
(Fast Gray Matter Acquisition T1 Inversion Recovery) (Sudhyadhom et al.  2009) were 
acquired to aid in the definition of the anatomical ROIs with a Siemens Tim Trio, 3T MRI 
scanner at the GSK Clinical Imaging Centre. The T1-weighted was acquired with an 
inversion recovery prepared spoiled gradient echo sequence with TR = 3000 ms, TE = 3.66 
ms, flip angle of 9º, TI = 1100 ms, slice thickness 1 x 1 x 1mm3 and matrix =256 x 192. The 
FGATIR image which enables the definition of the globus pallidus is an MPRAGE sequence 
of TR=3000ms TE=4.39ms, TI=409ms and inversion pulse angle 180
o
. The acquisition time 
is approximately 11min.     
 
6.2.3. Image Analysis 
Dynamic PET images were registered to the subject’s MR image, and corrected for motion 
using a frame-to-frame registration process with a mutual information cost function. Regional 
analysis was performed with manually delineated regions of interest (ROIs) (Tziortzi et al.  
2009). The caudate (CD), putamen (PU), ventral striatum (VST), Hypothalamus (Hypo), and 
thalamus (TH) ROIs were defined on the structural T1-weighted images. The globus pallidus 
internal (GPi), globus pallidus external (GPe) and ventral pallidum (VP) was defined on the 
FGATIR image. Substantia Nigra (SN) was defined on the baseline PET integral image 
applying a fixed ROI size (Tziortzi et al.  2011). Subsequently the ROIs were applied to 
dynamic data to generate regional time activity curves..  The cerebellum was defined via 
nonlinear registration (using SPM5b; Wellcome Trust Centre for 
Neuroimaging,http://www.fil.ion.ucl.ac.uk/spm) of a template MR image and corresponding 
brain atlas (Tziortzi et al.  2009). 
123 
 
6.2.4. Derivation of outcome measures 
 The following outcome measures were generated from the PET data; 1) total volume of 
distribution (VT, mL cm
-3
), 2) binding potential relative to non-displaceable uptake (BPND, 
unitless), derived as; 
 
3) binding potential relative to non-displaceable uptake as calculated using the basis function 
implementation of the simplified reference tissue model (SRTM), (BPND, unitless) 
 
6.2.4.1. Derivation of distribution volumes 
VT was derived using kinetic analysis and the arterial input function. A two-tissue 
compartment model (2TCM) described the cerebellum and regions of interest (Montgomery 
et al. 2006; Mukherjee et al. 2002; Olsson et al. 1999). Model parameters were estimated 
using a curve fitting technique utilizing the least-squares minimisation method implemented 
as outlined in Laruelle et al. 1994 
 
6.2.4.2. Simplified Reference Tissue Method (SRTM) 
 The simplified reference tissue method (SRTM (Lammertsma and Hume, 1996)) was used to 
examine the feasibility of quantification of [
11
C]-(+)-PHNO BPND without collecting arterial 
plasma samples. Model fits and parameter estimates were obtained via the basis function 
implementation of SRTM (Gunn et al.  1997) 
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6.2.5. Examination of mass-carry over 
To evaluate the degree of effect of mass carry over by cold PHNO change in outcome 
measure (∆BPND, ∆SRTM BPND or ∆VT) was generated using the following formula; 
 
 
 
6.2.6. Examination of displaceable binding on the cerebellum 
The degree of displaceable binding in the cerebellum was assessed by examining the change 
in cerebellar VT between scan 3 and scan 4. 
 
6.2.7. Test-retest reproducibility: 
Test-retest reproducibility was examined using two criteria, namely variability and reliability.  
Variability was calculated as the absolute value of the difference between test and retest 
outcome measure, divided by the mean of the test and retest values. Reliability was assessed 
by the intraclass correlation coefficient (ICC) which estimates the relative contributions of 
between and within subject variability. It is calculated as;- 
 
 
where MSBS is the mean sum of squares between subjects, MSWS is the mean sum of 
squares within subjects and n is the number of repeated observations (n = 2). This coefficient 
estimates the reliability of the measurement and can vary between -1 (no reliability, ie 
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MSBS=0) and 1 (maximum reliability, achieved in case of identity between test and retest, 
i.e., MSWS = 0).  
 
6.2.8. Statistical analysis 
Results were analyzed with the paired t –test and RM ANOVA where appropriate. A 2-tailed 
probability value of 0.05 was selected as the significance level. 
 
6.3. Results 
Scan parameter data for all subjects are shown in Table 9. There were no significant 
differences in injected doses and injected masses between the four scans (Table 9).  Injected 
dose means, standard deviations and ranges were similar between scans. The injected mass of 
(+)-PHNO (range 0.45-2.08 µg) was matched between scans in each subject. Plasma 
aripiprazole levels were stable throughout the scan and were consistent with published 
literature. 
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Table 9. Scan, and plasma data 
 Scan 1 
Baseline 
Scan 2 
Baseline 
Scan 3 
Baseline 
Scan 4 Post-
aripiprazole 
Injected dose(MBq) 
Mean±SD (range in brackets) 
188±83   
(118-318) 
195±103 
(101-328) 
200±101 
(110-334) 
215±66 
(124-319) 
Time interval (hrs:mins) 
(injections 1-2 and 3-4, 
mean±sd) 
          
            
2:56±21 
 
 
 
4:47±22 (interval) 
2:58±14 (post-
aripiprazole dose) 
Injected mass (µg) 1.01±0.69 1.12±0.65 0.93±0.32 1.03±0.42 
Change in injected mass(µg) 
between scans, mean±sd 
 
- -0.02±0.15 
(sc1-sc2) 
0.17±0.47 
(sc1-sc3) 
-0.11±0.25 
(sc3-sc4) 
fP (mean±sd) 0.36±0.09 0.35±0.05 0.33±0.03 0.36±0.03 
Plasma aripiprazole 
 (4 hrs post dose, ng/mL) 
- - - 40.1±26.2 
Plasma aripiprazole 
 (5.5 hrs post dose, ng/mL) 
- 
                  
- 
                  
   -                            46.6±21 
 
6.3.1. Evaluation of mass effects of (+)-PHNO 
The mean percentage reductions in [
11
C]-(+)-PHNO binding for baseline scans conducted on 
the same day and on different days are summarised in Table 10. The same day [
11
C]-(+)-
PHNO
 
scans showed a significant reduction in the 2TC BPND in regions with a high 
including SN; (-0.41±0.34, -18±12%, p<0.03), and GP; (-1.64±1.37, -30±18%, 
p<0.03), and a trend for reduction in the TH (-0.06±0.07, -11±12%, p<0.07).  For SRTM 
BPND, the same day [
11
C]-(+)-PHNO
 
scans also showed a significant reduction  in regions 
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with a high  (Hypo; -0.03±0.19, -17±10%, p<0.01) and GP; (-0.41±0.24, -17±10%, 
p<0.01), and a trend for reduction in the SN (-0.38±0.42, -19±15%, p<0.08).  For VT, the 
same day [
11
C]-(+)-PHNO
 
scans showed a significant reduction in the GP only (-5.64±5.4, -
19±16, p<0.05). There was no significant reduction in the cerebellar VT in same-day [
11
C]-
(+)-PHNO scans (0.36±0.37, 8±8%, p<0.06). For the different day [
11
C]-(+)-PHNO
 
scans, 
only the GP showed a significant reduction in SRTM BPND (-0.41±0.24, -15±8, p<0.04). 
There were no significant reductions in the other outcome measures for the different day 
scans 
 
The correlations between injected dose of PHNO (in µg/kg body weight) and binding are 
listed in Table 11. There were significant negative correlations between injected dose and 
binding across all outcome measures, particularly in D3-rich regions (SN, Hypo and TH). 
 
Table 10. Mean percentage change in [
11
C]-(+)-PHNO binding for baseline scans conducted on the 
same day and on different days 
Occupancy 
SN Hypo GP VST PU CD TH Cerebellum 
VT 
 
Same day 
-5±11 26±83 -19±16* 1±17 5±3 2±13 4±4 8±8 
Different 
day 8±34 7±18 -7±25 13±21 8±22 5±13 4±12 6±11 
BPND 
Same day 
-18±12* 17±88 -30±18* -8±16 -4±7 -10±12 -11±12# n/a 
Different 
day 1±36 3±24 -14±27 7±17 1±14 2±15 -6±11 n/a 
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SRTM 
BPND 
Same day 
-19 ±15# -17±10* -14±8** -1±9 -4±5 -1±6 1±27 n/a 
Different 
day 
-12±19 -9±17 -5±4* -3±6 -3±4 1±7 11±11 n/a 
 
*   p<0.05;    ** p<0.01;       # p<0.1(trend) 
 
 
Table 11. Correlation between injected dose and binding 
 SN cHypo fgatir_GP TH VST PU CD 
VT -0.7** -0.71** -0.363 -0.65** -0.35 -0.55* -0.55* 
BPND -0.64** -0.68** -0.22 -0.67** -0.19 -0.45# -0.276 
SRTM BPND -0.54* -0.74** -0.06 -0.51* -0.06 -0.34 -0.47# 
 
*   p<0.05; ** p<0.01; # p<0.1(trend) 
 
6.3.2. Evaluation of a displaceable component in the cerebellum 
A single oral dose of 15 mg of aripiprazole produced a significant reduction in cerebellar VT 
between scan 3 and scan 4 (post aripiprazole). Mean cerebellar VT at scan 3 was 4.66±0.34, 
and at scan 4 was 4.15±0.36 (-0.51±0.48, -11±10%, p<0.05). This is consistent with a small 
displaceable binding component in the cerebellum. There was no reduction in fP between 
pre- and post- aripiprazole scans, which suggests that there was no aripiprazole-induced 
reduction in non-displaceable binding (Table 9).  
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6.3.3. Variability and Reliability   
6.3.3.1. Kinetic analysis 
Table 12 lists the variability and ICC between same-day and between >1 week apart TRT 
scans for VT and 2TC BPND across all regions of interest. Variability varied between regions. 
The most consistently reproducible were the striatal regions (VST, CD and PU) and the 
thalamus, with figures around 5-15%. The variability in other ROIs was between 10% and 
30%. Reliability (ICC) was generally better for the same day scans.   The most consistently 
reliable regions were the striatal regions (VST, CD and PU) and the thalamus. ICCs were 
better for VT than for 2TC BPND. 
 
6.3.3.2. SRTM analysis 
Table 12 lists the variability and ICC between same-day and between >1 week apart TRT 
scans for SRTM BPND across all ROIs. Variability varied between regions. Again the most 
consistently reproducible were the striatal regions (VST, CD and PU) with figures around 
5%. The variability in other ROIs was generally between between 15% and 20%. Variability 
was greater in the same day scans in all regions except the CD. 
  
In terms of ICCs, the most consistently reliable regions were the striatal regions (VST, CD 
and PU). Reliability for other regions was poor (<0.65). 
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Table 12. Variability and reliability for same day and different day VT, 2TC BPND and SRTM BPND 
 Same day scans VT (ml.cm
-3)  Different day scans VT(ml.cm
-3) 
 Mean BS SD 
(%CV) 
WS SD 
(%CV) 
VAR AVE± 
STD 
(%) 
ICC Mean BS SD 
(%CV) 
WS SD 
(%CV) 
VAR AVE± 
STD 
(%) 
ICC 
SN 
 
13.7 3.5 25.6 0.9 6.3 10.5 6.4 0.89 14.4 3.2 22.0 2.4 16.6 26.0 13.3 0.27 
Hypo 16.8 10.3 60.9 7.3 43.3 30.1 37.5 0.33 15.1 3.5 23.3 1.2 7.7 13.5 11.4 0.80 
fgatir_GP 23.5 5.2 22.3 3.7 15.9 23.2 20.1 0.32 24.9 4.9 19.8 3.4 13.8 23.5 10.4 0.35 
VST 23.3 5.9 25.2 1.9 8.2 14.1 6.9 0.81 25.0 8.0 31.9 2.9 11.6 18.1 10.8 0.77 
PU 16.9 2.5 14.7 0.4 2.5 4.9 2.3 0.94 17.4 2.1 12.1 1.7 9.7 14.4 13.6 0.22 
CD 12.9 1.9 14.4 0.7 5.5 10.7 4.1 0.75 13.0 1.7 13.3 0.7 5.6 10.4 6.8 0.70 
TH 6.8 0.9 13.7 0.2 2.9 4.0 3.8 0.91 6.8 0.8 11.7 0.4 5.3 9.0 6.4 0.66 
Cerebellum 4.6 0.5 9.8 0.2 5.4 8.4 6.7 0.53 4.5 0.3 6.6 0.3 5.7 10.7 4.8 0.14 
 Same day scans BP (ml.cm
-3)  
 
Different day scans BP(ml.cm-3) 
 Mean BS SD 
(%CV) 
WS SD 
(%CV) 
VAR AVE± 
STD 
(%) 
ICC Mean BS SD 
(%CV) 
WS SD 
(%CV) 
VAR AVE± 
STD 
(%) 
ICC 
SN 2.0 0.5 25.1 0.3 13.1 20.8 15.9 0.57 2.2 0.7 32.1 0.4 20.4 27.8 20.6 0.43 
Hypo 2.5 1.6 66.2 1.1 46.3 39.3 34.2 0.34 2.3 0.6 27.2 0.3 12.5 18.8 14.8 0.65 
fgatir_GP 4.1 1.0 24.2 1.0 25.0 37.6 24.3 -0.03 4.5 1.0 22.2 0.9 19.4 29.1 17.5 0.14 
VST 4.0 1.0 24.7 0.4 11.0 14.1 14.1 0.67 4.5 1.6 34.8 0.5 10.1 13.3 8.5 0.84 
PU 2.7 0.3 10.0 0.1 4.2 6.2 6.3 0.70 2.8 0.3 10.5 0.2 6.3 8.6 8.6 0.47 
CD 1.9 0.3 17.0 0.2 9.5 12.6 11.9 0.52 1.8 0.2 11.4 0.1 6.7 11.6 6.5 0.49 
TH 0.5 0.1 17.4 0.0 8.9 15.4 8.8 0.59 0.5 0.1 19.3 0.0 6.4 10.4 9.0 0.80 
Cerebellum - - - - - - - - - - - - - - - - 
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 Same day scans SRTM BP (ml.cm
-3)  
 
Different day scans SRTM BP(ml.cm-3) 
 Mean BS SD 
(%CV) 
WS SD 
(%CV) 
VAR AVE± 
STD 
(%) 
ICC Mean BS SD 
(%CV) 
WS SD 
(%CV) 
VAR AVE± 
STD 
(%) 
ICC 
SN 1.5 0.3 18.5 0.3 17.6 22.4 20.3 0.05 1.6 0.3 17.5 0.2 15.7 16.6 21.8 0.11 
Hypo 1.6 0.4 21.7 0.2 10.6 19.3 12.0 0.62 1.7 0.3 19.1 0.2 10.9 15.8 14.0 0.51 
GP 2.8 0.2 8.2 0.2 8.5 15.6 7.9 -0.03 2.9 0.2 6.6 0.1 3.3 5.7 3.5 0.59 
VST 3.0 0.4 13.3 0.1 4.1 6.7 5.4 0.82 3.0 0.4 13.7 0.1 3.1 5.0 4.0 0.90 
PU 2.4 0.2 8.7 0.1 2.8 4.3 4.3 0.81 2.4 0.2 9.3 0.1 2.4 4.3 2.6 0.87 
CD 1.6 0.2 10.6 0.0 2.8 5.2 2.4 0.87 1.6 0.2 9.4 0.1 3.3 5.7 3.7 0.78 
TH 0.5 0.1 19.7 0.1 11.9 18.2 15.7 0.47 0.5 0.1 16.9 0.0 8.5 12.3 12.0 0.60 
Cerebellum              
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6.3.4. Correlation between SRTM BPND and plasma input based BPND 
BPND derived by the SRTM was correlated with the plasma input based BPND (SRTM vs 
kinetic analysis, R = 0.98, p<0.01, n=136). Average regional BPND values derived via SRTM 
were lower than those derived by kinetic models (mean difference 15%±18). This difference 
was highly significant (P<0.0001). In addition the test/retest variability for [
11
C]PHNO was 
significantly lower with the SRTM method than with the kinetic model for both same day and 
different day TRT (RM ANOVA same day P=0.001, different day P<0.001). Examination of 
a Bland-Altman plot for the two measures shows that the differences between the two 
measures are greater at higher BPND values (r=0.57, p<0.01)(Figure 14). 
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Figure 14. Bland-Altman plot of the plasma input based BPND against the BPND derived by 
the SRTM. Bland and Altman Plot of the data obtained from 136 paired measures of BPND 
determined by kinetic analysis and by SRTM. Correlation r squared = 0.57 (P<0.01). Slope 
= 0.6 (P<0.01). Intercept = -0.7 (P<0.01) 
 
 
 
 
In order to make an estimate of the relative D2 and D3 contributions to the total aripiprazole 
occupancy, the regional occupancy values for aripiprazole obtained in this study were plotted 
against regional fractions of the [
11
C]-(+)-PHNO signal attributable to D3 ( ) derived 
from a previous study
 
(Tziortzi et al.  2011)(Figure 15).  There was a negative correlation 
between aripiprazole occupancy and (r
2
=0.6). This is consistent with a significant 
selectivity of aripiprazole for the D2 receptor over the D3 in vivo. The plot of aripiprazole-
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induced occupancy against   (Eq 1) indicated an occupancy of the D2 of ≈ 55% (y axis 
intercept) with very little D3 occupancy (gradient minus D2 occupancy ≈ 0).   
 
Equation 1. 
          
 
Figure 15. Plot of aripiprazole-induced occupancy against   
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6.4. Discussion 
6.4.1. Mass carry-over 
The primary aim of these studies was to examine the potential mass carry-over of cold PHNO 
between scans. Displaceable binding in the cerebellum was also examined using aripiprazole 
as a D2/3 blocking agent to look at the suitability of using this region as a reference tissue. 
Three different outcome measures were used, VT and BPND derived using a two tissue 
compartment kinetic model, and BPND derived using the SRTM.  
 
Examination of ∆BPND between scan 1 and scan 2 (same day scans) and scan 3 and scan 4 
(different day scans) revealed that ∆BPND was significantly greater for same day 2TC BPND 
and SRTM BPND in D3 rich regions (SN, GP and TH for 2TC BPND and SN, GP and Hypo for 
STRM BPND). Mass carry-over is a therefore significant confounder in the estimation of D3 
occupancy with [
11
C]-(+)-PHNO if the scans are conducted sequentially at the time interval 
in this study (maximum 30 mins between the end of scan 1 and start of scan 2). We are not 
able to comment on exactly how far apart the scans would need to be for mass carry over to 
no longer be an issue.  
 
.  
A small, but significant, specific binding component, attributable to D2 binding, was found in 
the cerebellum. The effect of this component may not be significant in the majority of 
studies. The presence of an additional D3 displaceable binding component cannot be 
excluded; because aripiprazole produced negligible D3 occupancy, any D3 displaceable 
binding component would not have been displaced.  
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6.4.2. Reproducibility and reliability 
As shown in Table 12 the variability was consistently lowest in the striatal regions 
(CD,PU,VST) for all outcome measures (between 5 -20%). These figures are comparable 
with those observed for [
11
C] raclopride (Mawlawi et al.  2001). In other regions the 
variability was generally higher, with figures ranging between 5 and 40%. For VT variability 
was significantly higher for different day test-retest than for same day test-retest scans, while 
the opposite was true for SRTM BPND.  
In the previous chapter it was shown that in D2 rich regions, where there is negligible D3 
binding, it is the agonist properties of the ligand which contribute to its increased sensitivity 
to DA release. However in D3 regions there was a significant correlation between fD3 and 
sensitivity to DA release.  This suggests that in the case of PHNO, D3 specificity is 
advantageous as both its agonist and D3 specificity contribute to its increased sensitivity. It is 
clear from both this study and the previous chapter that variabilty and reliability is generally 
less for D3 rich regions compared to D2 (see Table 12). In addition in this study the results for 
VT and 2TC BPND in the hypothalamus are anomalous, being in the opposite direction 
expected for a D3-rich region.  These results are likely to be due to difficulties in accurately 
defining these regions, whether due to their small size and consequent sensitivity to subject 
motion and image registration (i.e. hypothalamus) or indistinct boundaries and slow kinetics 
(GP). 
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6.4.3. SRTM analysis 
A reference tissue model such as SRTM BPND has the advantage over the 2TC model as it 
removes the need to obtain arterial blood samples to calculate the input function. Subjects 
generally find the insertion of arterial cannulae unpleasant, and the procedure can be time 
consuming for the researcher. In this study the values derived using the SRTM were lower 
than those derived using the 2TC model, although they were well correlated. One potential 
issue is that the plot of SRTM BPND to 2TC BPND had a slope less than 1 (0.73) and a small 
positive intercept (0.22) suggesting that the underestimation of BPND values with SRTM is 
greater in regions of high receptor density relative to low receptor density. This was also seen 
in the Bland-Altman plot, where the differences between the measures can be seen to be 
greater for higher BPND values. This phenomenon has been previously reported for the D2/3 
agonist radioligand [
11
C] NPA as well as the 5HT1A receptor antagonist [
11
C]WAY 100635 
(Narendran et al.  2009; Parsey et al.  2000). The cause of this underestimation, which varies 
as a function of receptor density, has not been fully elucidated.  It is likely to be a result of 
several factors including model assumption violation, contamination of cerebellar activity by 
activity in the blood and possible inadequate data set length (the underestimation is 
accentuated by shorter data sets, see Parsey et al.  2000 for discussion). Further investigation 
is required before SRTM can be considered the preferred method of quantification for 
[
11
C]PHNO. The greater differences between SRTM BPND and 2TC BPND at higher BPND 
values could affect occupancy calculations, where the important factor is that the relationship 
is between the two measures is linear.   
  
Statement of student’s contribution to this chapter. 
I developed the protocol for this study, with supervision from Dr Ilan Rabiner and Professor 
Marc Laruelle. I obtained ARSAC and REC approvals for the study, performed all 
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correspondence with these agencies and attended all REC meetings. I recruited all of subjects 
with the assistance of the Clinical Imaging Centre’s recruitment team. I screened all subjects 
for the study myself. I scanned all of the subjects. Image analysis scans was performed by 
myself and Andri Tziortzi.  I performed the data analysis with supervision from Dr Ilan 
Rabiner and Professor Roger Gunn. I interpreted the results with supervison from Dr Ilan 
Rabiner and Professor Roger Gunn.  
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Chapter 7. Conclusions and future directions 
7.1. Summary of findings 
 
The studies presented together in this thesis answer several important questions regarding 
dopaminergic function in the human brain.   
 
In the [
18
F]DOPA twin study, there was no evidence of increased striatal dopamine synthesis 
in the unaffected co-twins in twin pairs discordant for schizophrenia compared with healthy 
control twins. This contrasts with results from a previous study of first degree relatives of 
patients with schizophrenia (Huttunen et al.  2008). However, as none of the unaffected co-
twins of schizophrenia patients in the study had symptoms, whereas relatives in the Huttenen 
study had appreciable symptom levels, one interpretation of the findings together is that 
elevated dopamine synthesis capacity itself is associated with the development of psychotic 
symptoms rather than a vulnerability to psychosis itself: it is a state rather than a trait or 
endophenotype marker.    
 
An unexpected observation in our study was that there was also no elevation of striatal [
18
F] 
DOPA uptake in the twins with schizophrenia. However, it was clear that none of the patients 
was acutely psychotic at the time of scanning. This observation would be consistent with the 
conclusion that elevated dopamine synthesis capacity in schizophrenia is particularly 
associated with the acute development of psychotic symptoms. Evidence for the association 
of elevated dopaminergic function with psychosis has been found in another previous study 
(Laruelle et al.  1999). In this study only patients who were experiencing an acute 
exacerbation of their illness showed an elevation in dopamine release following an 
amphetamine challenge. Patients in remission were not different from the healthy controls. A 
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recent study examining striatal dopamine synthesis capacity in the prodrome to schizophrenia 
found that increases in dopamine synthesis were associated with the development of acute 
psychosis (Howes et al.  2011a). 
 
 In conclusion, these findings suggest that genetic vulnerability to psychosis and a shared in 
utero environment are not associated with elevation in dopamine synthesis capacity per se. It 
can also be inferred that elevated striatal dopamine function is related to the active psychotic 
phase of the illness, rather than a vulnerability marker for schizophrenia. 
 
 In the second study reported in this thesis, dopamine synthesis capacity was examined in 
healthy subjects with auditory verbal hallucinations (AVH). There was no evidence of 
increased [
18
F] DOPA uptake in the subjects with AVH compared to matched healthy 
controls subjects without a history of hallucinations. As discussed above, previous studies 
where elevations in striatal dopamine levels have been found have examined schizophrenia 
patients with a range of active psychotic symptoms including delusions, thought disorder and 
passivity phenomena.  It is notable that the abnormal salience hypothesis of dopamine and its 
relationship with delusion formation in schizophrenia focuses solely on delusion formation, 
and does not provide an adequate explanatory framework for hallucinations (Kapur et al.  
2005). This finding suggests that striatal dopamine synthesis is not increased in association 
with AVH occurring in isolation, although it is possible that abnormalities in functions of 
other neurotransmitter systems may be relevant to generation of AVH.  It may also be the 
case that the pathophysiology of AVH in healthy individuals is distinct from those seen in 
schizophrenia.  
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A challenge raised by these studies was that, while abnormal synthetic capacity was not 
associated with vulnerability to psychosis, it remains possible that abnormal dopamine 
release is associated with the trait.  However, current methods for estimating dopamine 
release quantitatively are not optimal because of the relatively low sensitivity of antagonist 
radiotracers such as [
11
C]raclopride to detect small changes in dopamine release. A more 
sensitive method would allow quantification of dopamine release in patient groups where 
increases in release, if present, might be expected to be smaller in magnitude to that seen in 
schizophrenia patients with active psychotic symptoms. Such groups would include those 
examined in this thesis, namely relatives of schizophrenia patients and healthy subjects with 
auditory hallucinations. Other potentially interesting subject groups would be individuals 
with high schizotypy scores or with the schizophrenia prodrome. 
  
A further advantage of a more sensitive measure of dopamine release is that it could allow 
use of alternative challenge agents such as nicotine or bupropion to trigger dopamine release. 
These have a much better adverse event profile than the current preferred agent, 
amphetamine, and are much safer to use in patients with or at-risk of developing psychosis. 
However they are less potent dopamine releasing agents than amphetamine (Egerton et al. 
2010, Marenco et al. 2004). In order to address this challenge, the next two studies in the 
thesis focused on the characterisation of the agonist radiotracer [
11
C]-(+)-PHNO as a new, 
more sensitive, PET marker for estimation of dopamine release. 
 
The first study compared the sensitivity to acute amphetamine challenge of [
11
C]-(+)-PHNO 
and [
11
C]raclopride. The most important finding is that an administration of amphetamine in 
conscious humans induced a significantly larger change in [
11
C]-(+)-PHNO binding as 
compared to [
11
C]raclopride. In addition to this, quantitative assessments allowed some 
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inference regarding the nature of receptor interactions.  The ratio of change in [11C]-(+)-PHNO 
binding potential to change in [11C] raclopride binding potential  ( ) was 1.53 in 
the almost exclusively D2 dorsal caudate and putamen, which is consistent with :  
found in a previous study (Narendran et al.  2010). This demonstrated that the binding of [
11
C]-(+)-
PHNO to the D2high receptor is a significant factor in its enhanced sensitivity to an amphetamine 
challenge in these regions. In regions other than the caudate and putamen, the contribution of 
the D3 to [
11
C]-(+)-PHNO binding is significant, and any effects of amphetamine depend on 
the affinity of dopamine for D3 as well as for D2high receptors. A regression of regional 
 against the regional fraction of the total [
11
C]-(+)-PHNO binding that can be 
attributed to D3 (  
) showed that there was a significant effect of on , 
suggesting that the interaction of dopamine with the D3 receptor plays the major role in 
determining effects of amphetamine on [
11
C]-(+)-PHNO binding. 
 
It was possible to estimate the proportion of the D2 receptors configured in the D2high state 
(see Chapter 5 equation 3). As the D3 contribution to the [
11
C]-(+)-PHNO signal in the dorsal 
striatum is negligible, the  was estimated in this region, was and found to be very 
consistent with estimations from previous studies at approximately 65% (Narendran et al.  
2010).  
 
As this first comparative study of [
11
C]-(+)-PHNO for dopamine release was being carried 
out, we became aware of anomalous results that suggested the possibility of slow off-kinetics 
or another factor that would lead to “mass carry-over” effects from one scan to another if 
conducted consecutively within a short time frame.  To further investigate this last point, a 
test-retest study was designed to further examine the issues of mass carry over when using 
[
11
C]-(+)-PHNO. In addition, the question of whether the cerebellar reference region contains 
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a measurable and displaceable specific binding component was considered. Characterisation 
and quantification of these effects is important for accurate interpretation of [
11
C]-(+)-PHNO 
binding data. In this study, consecutive [
11
C]-(+)-PHNO
 
scans showed a significant reduction 
in 2TC BPND in regions with a high . There were no significant reductions in the D2 
regions. It was concluded that mass carry-over is a significant confounder in the estimation of 
D3 occupancy with [
11
C]-(+)-PHNO, particularly in the lower range. There was no change in 
the cerebellar VT in consecutive tracer-only [
11
C]-(+)-PHNO scans.
 
A single oral dose of 15 
mg of aripiprazole produced a significant reduction in the cerebellar VT, which was 
consistent with a small displaceable binding component in the cerebellum. The effect of this 
component may not be relevant in the majority of studies. A plot of aripiprazole-induced 
occupancy against   indicated an occupancy of the D2 of ~55% with very little D3 
occupancy, suggesting that aripiprazole demonstrated a significant selectivity for the D2 over 
the D3 in vivo. 
 
While the data show that [
11
C]-(+)-PHNO provides a higher sensitivity for assessment of 
dopamine release, the complex methodology necessary to acquire well quantified data with 
[
11
C]-(+)-PHNO must be acknowledged. The radiosynthesis is difficult and a high specific 
activity is required both to achieve tracer conditions and in order to avoid nausea in subjects.  
As discussed above and in the preceding chapters, there is a need to separate consecutive 
scans by a sufficient time gap in order to avoid potential carry-over effects at the D3 receptor. 
However, the increase sensitivity of [
11
C]-(+)-PHNO to dopamine release will provide 
advantages if making single subject estimates (e.g., with pathology with which one cannot 
assume that all subjects are equivalent) or if studying a cohort that is intrinsically limited 
(e.g., first onset, medication-free patients with schizophrenia for which numbers are always 
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limited). My work does much to complete a solid foundation for use of [
11
C]-(+)-PHNO in 
furthering our understanding of schizophrenia and other neuropsychiatric conditions. 
 
7.2. Conclusions   
 
To conclude, within this thesis I found that genetic vulnerability to psychosis is not in itself 
associated with elevated dopamine synthesis capacity. It appears that elevated dopamine 
synthesis capacity is associated with the development of psychotic symptoms rather than a 
vulnerability to psychosis itself. In addition I found that striatal dopamine synthesis capacity 
is not increased in association with AVH occurring in isolation. As I found that dopamine 
synthesis capacity was not elevated in these patient groups, this led me to consider 
measurement of dopamine release, and whether a more sensitive index could be developed to 
detect increases in dopamine release in patient groups where increases in dopamine release, if 
present, might be expected to be smaller in magnitude to that in patients with active 
schizophrenia symptoms. 
 
Towards this aim, I made several important findings in the further characterisation of use of 
the D2/3 agonist radioligand [
11
C]-(+)-PHNO. Firstly [
11
C]-(+)-PHNO is more sensitive than 
[
11
C]raclopride in detecting the fluctuations of extracellular dopamine. My data suggests that 
both the agonist nature of [
11
C]-(+)-PHNO, and its selectivity for the D3 receptor contribute 
to its higher sensitivity compared to [
11
C]raclopride. Secondly, the proportion of the D2 
receptors configured in the D2high state (  ) in normal subjects was estimated at 
approximately 65%. Thirdly I found that mass carry-over is a significant confounder in the 
estimation of D3 occupancy with [
11
C]-(+)-PHNO, particularly in the lower range.  I hope 
that the results and conclusions within thesis will assist future research in schizophrenia and 
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other neuropsychiatric disorders to further our understanding and treatment of these 
conditions.  
 
7.3. Future directions 
 
The studies in this thesis represent significant progress for in vivo analysis of dopaminergic 
function in the human brain. The properties of [11C]-(+)-PHNO including D3 receptor 
selectivity, preferential binding to the D2high receptor and increased sensitivity to dopamine 
release will allow for development of new study paradigms. Some exciting potential research 
questions are considered below; 
The D3 receptor selectivity of [
11
C]-(+)-PHNO is potentially a very useful characteristic. It 
has been suggested that the D3 receptor plays a role in schizophrenia (Griffon et al.  1995; 
Joyce and Gurevich, 1999).   A post-mortem study found 2-fold elevations in the number of 
D3 receptors
 
in the basal ganglia and ventral forebrain of long-term hospitalized
 
patients with 
schizophrenia who received no antipsychotic drugs
 
for at least a month before death (n=7), 
when compared with matched
 
control subjects (n=15) (Gurevich et al.  1997). Patients with 
schizophrenia receiving
 
antipsychotic drugs less than 72 hours before death (n=8) had
 
levels 
similar to those of control subjects. They concluded that elevation of D3 receptor levels
 
in 
limbic striatum observed in patients with
 
schizophrenia may be reduced by antipsychotic 
drugs.
 
 The limbic distribution of the D3 receptor suggests that its functions are mainly related 
to the mesolimbic dopamine system, as opposed to the mesocortical. This elevation of D3 
receptor levels may be a reflection of a hyperdopaminergic state of the mesolimbic dopamine 
system, which is well documented in schizophrenia (Abi-Dargham and Laruelle, 2005; Kapur 
and Mamo, 2003). 
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This evidence has led directly to the hypothesis that the D3 receptor is a potential target of 
antipsychotic action. It has been suggested that D3 antagonists could have a beneficial effect 
on negative symptoms. Selective blockade of D3 receptors has been shown to enhance social 
interaction in rodents (Reavill et al.  2000). It is also possible that D3 antagonists could have 
an effect on cognitive function in schizophrenia. Frontocortical cholinergic pathways have a 
role in the modulation of attention and working memory, and selective D3 antagonists have 
been shown to enhance acetylcholine release in the frontal cortex (Lacroix et al.  2003). In 
parallel, behavioural studies in rodents have shown that D3 antagonists can enhance cognitive 
function in models of working memory (Millan et al.  2007). One study examined the 
relationship between D3 affinity and clinically effective dose, and no correlations were found 
for either typical or atypical antipsychotics (Richtand et al. 2007). However 5-HT2C/D3 
binding affinity ratios were correlated with clinically effective antipsychotic medication dose 
for typical antipsychotic medications. This data therefore suggests that an interaction between 
binding at serotonin 5-HT2C and DA D3 receptors is may be important in the mechanism of 
action of typical antipsychotic medications. 
 
 
   
[11C]-(+)-PHNO will allow further examination of D3 receptor function in schizophrenia, 
and will also be of use in evaluating new D3-specific therapeutic agents. A recent [
11
C]-(+)-
PHNO study in patients with schizophrenia, who had been drug free for 2 weeks, found no 
difference in [
11
C]-(+)- PHNO binding between patients and controls in D3 rich areas such as 
the substantia nigra (Graff-Guerrero et al.  2009a). However it must be remembered that the 
[
11
C]-(+)-PHNO signal consists of both D2 and D3 components, so it is theoretically possible 
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that in the study by Graff-Guerrero an increase in D3 was hidden by a simultaneous decrease 
in D2. In order to separate out the relative contributions of D2 and D3 in schizophrenia it 
would be necessary to perform a study with two [
11
C]-(+)-PHNO scans; a baseline scan and a 
second ‘blocked’ scan following administration of a D2 or D3 specific antagonist. Ideally this 
study would be performed in drug-naive patients to eliminate any effects of long-term 
neuroleptic treatment.  
 
An further study by this group examined the effects of long term-antipsychotic treatment 
(clozapine, risperidone, or olanzapine) on the high- vs high and low-affinity sites of the D2 
and D3 receptors was performed by comparing the [
11
C]-(+)-PHNO and [
11
C]raclopride 
binding in the D3 receptor–rich (globus pallidus and ventral striatum) and D2 receptor–rich 
(caudate and putamen) regions (Graff-Guerrero et al. 2009b). The most interesting finding 
was that long-term antipsychotic treatment does not decrease [11C]-(+)-PHNO binding in the 
D3 receptor–rich regions, though it clearly blocks the signal in the D2 receptor–rich regions. 
In fact there appeared to be a treatment-induced increase in [
11
C]-(+)-PHNO D3 binding in 
the GP. This finding may represent either an antipsychotic-induced increase in receptor 
numbers or an increase in affinity. It is clear from this study that antipsychotics exert a very 
different effect on the D2 receptor to the D3 receptor. Rather than arguing against a role for 
the D3 receptor in schizophrenia, the authors suggest that there may be a role for the D3 
receptor in the development of future antipsychotic treatments and that PHNO will enable the 
study of the D3 receptor in schizophrenia. 
 
 
The preferential binding of [
11
C]-(+)-PHNO to D2high would allow estimation of the ratio of 
D2high to D2low receptors in schizophrenia. There is evidence from multiple preclinical animal 
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models of psychosis (eg amphetamine sensitization, phencyclidine sensitization, ethanol 
withdrawal, hippocampal lesions) that there could be a selective elevation of the D2 receptor 
high affinity state with psychosis (Seeman et al.  2006). The method of distinguishing high- 
from low-affinity states of the D2 receptor in vitro involves the addition of high 
concentrations of G protein analogs, a method that is not feasible in humans (Seeman, 2011). 
The fact that [
11
C]-(+)-PHNO is an agonist ligand allows quantification of the percentage of 
receptors configured in the high affinity state. This study would, however, be 
methodologically difficult to perform. Subjects with schizophrenia would require 
measurement of challenge-agent induced dopamine release with both agonist and antagonist 
ligands, analogous to the study described in chapter 5 of this thesis. The ratio of change in 
binding potential then allows calculation of the percentage of D2 receptors configured as 
D2high (see Chapter 5, equation 3). As mentioned above, the risk of exacerbating psychosis is 
a significant problem when using amphetamine as a challenge agent. The increased 
sensitivity of [
11
C]-(+)-PHNO will allow the detection of dopamine release of lower 
magnitude, enabling the use of challenge agents that do not result in such large increases in 
dopamine levels and  reducing the risk of exacerbating psychosis. These agents could 
therefore potentially be used in studies with patients with schizophrenia. A recent study with 
looking at the effect of bupropion on [
11
C] raclopride binding in healthy humans was unable 
to demonstrate evidence of dopamine release on [
11
C] raclopride binding potential (Egerton et 
al.  2010). If repeated with [
11
C]-(+)-PHNO its increased sensitivity may reveal dopamine 
release not demonstrable using an antagonist ligand. In addition a similar study with nicotine 
would allow evaluation of its utility as a challenge agent. 
 
[
11
C]-(+)PHNO could be of potential use for the evaluation of behavioural challenges. The 
question whether behavioural challenges might induce sufficient changes of DA to be 
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measured with raclopride has been controversial. In a seminal paper increases in striatal DA 
release were detected with [
11
C] raclopride in humans during performance of a video game 
(Koepp et al, 1998). Using this technique, many studies have since reported increases in DA 
release during performance of behavioural tasks (reviewed in Egerton et al. 2009). However, 
other studies investigating similar tasks have found no such change in DA release (Wang et 
al. 2000; Volkow et al. 2002; Montgomery et al. 2006). It may be that the change induced by 
behavioural challenges are only marginally detectable with [
11
C]raclopride, and a more 
sensitive technique will be of greater use in this area. 
 
[
11
C]-(+)PHNO could also be useful in new paradigms to examine aberrant salience in 
schizophrenia. As discussed earlier, theories of the positive symptoms of schizophrenia 
hypothesize a role for aberrant reinforcement signalling or salience, driven by dysregulated 
dopamine transmission.  The Salience Attribution Test (SAT) is a novel paradigm that has 
been used to demonstrate evidence of aberrant reward learning in symptomatic, but not 
asymptomatic patients with schizophrenia (Roiser et al. 2009). Essentially the SAT is a 
probabilistic reward learning game that employs cues that vary across task-relevant and task-
irrelevant dimensions; it provides behavioural indices of adaptive and aberrant reward 
learning. 
 
The SAT in combination with functional magnetic resonance imaging has been already been 
used to examine the neural basis of adaptive and aberrant reward learning in healthy 
volunteers (Roiser et al. 2010). The logical next step would be to examine the molecular basis 
of this process in healthy volunteers and patients with schizophrenia using the same 
paradigm. The high sensitivity of [
11
C]-(+)-PHNO could be useful to examine changes in 
dopamine release in patients with schizophrenia during the salience task. 
150 
 
 
A further application for [
11
C]-(+)-PHNO would be in the study of other novel 
pharmacological challenge agents, particularly those where expected changes in DA 
concentration have not been found using other dopaminergic ligands. Daglish et al. examined 
whether injections of diamorphine or hydromorphone would produce DA release, as indexed 
by [
11
C]raclopride, and also whether this reduction would correlate with the subjective ‘high’ 
experience (Daglish et al. 2008). No significant changes in [
11
C]-raclopride binding potential 
were found in response to heroin or hydromorphone injection, despite marked objective 
measures of opioid effects including slow eye movements and pronounced subjective reports 
of intoxication. Previous animal studies have shown that dopamine is released in response to 
opioids, but that is much lower than that seen with stimulants, with a less that 300% increase 
compared with the increases seen with stimulants of 600-1000% (Di Chiari et al. 1988). 
Again, the increased sensitivity of [
11
C]-(+)-PHNO has the potential to allow measurement of 
changes of this comparatively small magnitude. 
 
Interaction between 5-HT and DA is an important area for research. Many antipsychotics 
have affinity for 5-HT2A and 5-HT2C receptors; this may account for some of the ‘atypical’ 
properties of these agents. Microdialysis has been used in animals to investigate the 
modulation of striatal DA release by 5-HT2A and 5-HT2C compounds. Under baseline 
conditions 5-HT2A receptor antagonists do not alter striatal DA levels (De Deuwaerdère and 
Spampinato 1999; Gobert et al. 2000); however they do markedly attenuate stimulated 
increases in DA release, for example by amphetamine (Auclair et al. 2004a,b; De 
Deuwaerdère and Spampinato 1999; Lucas and Spampinato 2000; Porras et al. 2002). 5-HT2A 
receptor agonists also have little baseline effect on DA release, but conversely enhance 
stimulated release (Gobert and Millan 1999; Lucas and Spampinato 2000). 
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5-HT2C receptors have an almost opposite role to 5-HT2A receptors in modulation of DA 
release; they have been shown to exert tonic inhibitory control over DA release from 
mesolimbic and nigrostriatal neurons (De Deuwaerdère et al. 2004). Tonic DA cell firing and 
terminal DA release is therefore enhanced by 5-HT2C antagonists/inverse agonists and 
inhibited by 5-HT2C agonists (De Deuwaerdère et al. 2004; De Deuwaerdère and Spampinato 
1999; Di Matteo et al. 1998; 1999; Gobert et al. 2000; Porras et al. 2002). 
 
In a feasibility study to examine the possibility of observing these effects using non-invasive 
measures, Egerton et al. (2008) used PET in the rat to demonstrated decreases in 
[
11
C]raclopride binding following 5-HT2C antagonism and attenuation of amphetamine-
induced decreases in [
11
C]raclopride binding following 5-HT2A antagonism. This result is in 
accordance with the opposing effects of 5-HT2A and 5-HT2C receptor antagonists on DA 
release as previously seen with microdialysis. However, high doses of ketanserin, SB 
206,553, and SR 46349B to were used in this study to maximize the probability of observing 
significant experimental effects. In addition a high dose of amphetamine (4 mg/kg) was used 
to provide a large initial effect size for potential reversal. If a similar study were repeated in 
humans it would not be possible to use such high doses. In this situation the increased 
sensitivity of [
11
C]-(+)-PHNO to changes in DA levels may prove to be invaluable.  
 
The GABAergic system has also been shown to have important effects on dopaminergic 
neurones, largely through GABAB receptors in the ventral tegmental area (VTA) (Morgan 
and Dewey, 1998). The GABAB receptor agonist baclofen has been proposed as a potential 
therapeutic agent for the clinical treatment of several forms of drug addiction. In a rat 
microdialysis study, Fadda et al. showed that pretreatment with baclofen (1.25 and 2.5 mg/kg 
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i.p.) dose-dependently reduced nicotine-, morphine-, and cocaine-evoked DA release in the 
shell of the nucleus accumbens (Fadda et al. 2003). Baclofen alone did not elicit changes in 
basal DA extracellular levels up. In a similar manner to the 5-HT studies described above, it 
would be interesting to replicate these findings using non-invasive PET techniques in 
humans. [
11
C]-(+)-PHNO would be the ligand of choice as due to its increased sensitivity to 
changes in DA levels.   
 
 
The effects of cannabis on dopamine release have also been extensively studied. Cannabis 
produces its behavioural effects via Δ9-tetrahydrocannabinol (THC) binding at cortical 
cannabinoid CB1 receptors. THC has been shown in animal studies to trigger dopamine 
releases in the ventral striatum (Cheer et al. 2004) and also to increase the rate of dopamine 
neuronal firing (Tanda et al. 1997). In a case report in humans (Voruganti et al. 2001) showed 
a 20% decrease in striatal [
11
C]IBZM binding after one volunteer used cannabis. A study 
using inhaled THC (Bossong et al. 2009) showed a 3% decrease in [
11
C]raclopride binding 
potential in the ventral striatum. These studies suggest that cannabis causes dopamine release 
in the human striatum, which is of obvious relevance for the aetiology of schizophrenia, for 
which cannabis use is a significant risk factor. Stokes et al. used [
11
C]raclopride to test the 
hypothesis that THC given orally at a dose of 10mgs would produce significant in vivo 
dopamine release in the human striatum (Stokes et al. 2009). Despite causing significant 
increases in psychosis-like symptoms on the Psychotomimetic States Inventory (PSI, Mason 
et al. 2008), there was no significant effect of THC on [
11
C]-raclopride binding in the 
striatum. Again it is tempting to speculate that if this study were repeated using [
11
C]-(+)-
PHNO the increased sensitivity may reveal evidence of striatal dopamine release.    
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The glutamate system is clearly of relevance in any discussion of dopamine and 
schizophrenia.  Non-competitive glutamate N-methyl-D-aspartate (NMDA) receptor 
antagonists such as phencyclidine and ketamine have been shown to induce transient 
schizophrenia-like symptoms in healthy humans and precipitate psychotic reactions in 
schizophrenic patients (Luby 1959; Lahti 1999). NMDA receptor antagonists have been 
shown to consistently increase extracellular DA concentrations in the rat (Lindefors et al. 
1997; Moghaddam et al. 1997). A glutamate–dopamine (DA) interaction has been 
hypothesised to explain these effects (Javitt and Zukin 1991; Carlsson et al. 1993; Olney and 
Farber 1995; Sharp et al. 2001). Three studies have shown a significant effect of ketamine on 
[
11
C]raclopride BP (Breier et al. 1998; Smith et al. 1998; Vollenweider et al. 2000). However 
3 further studies found no effect (Kegeles et al. 2000, 2002, Aalto et al. 2002). It is possible 
that the dose of ketamine is relevant; the use of high ketamine concentrations by 
Vollenweider et al. did result in a decrease in [
11
C]raclopride binding in the striatum. It may 
be that the increased sensitivity of [
11
C]-(+)-PHNO would be able to identify changes in 
dopamine concentration that were undetectable using [
11
C]raclopride.  
In addition, now that [
11
C]-(+)-PHNO has proven to be a more sensitive measure of DA 
release, it will facilitate study of the effects of other agents that may cause changes in 
endogenous dopamine concentration. These include compounds acting on other glutamatergic 
targets (α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) receptor modulators, 
metabotropic glutamate receptor (mGluR) modulators and Glycine transporter (GlyT) 
inhibitors), as well as histamine H3 receptor antagonists and M1/M4 muscarinic 
acetylcholine receptor agonists, which are all currently in development for schizophrenia and 
other therapeutic indications.  
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  The ability of [11C]-(+)-PHNO to measure smaller changes in dopamine release would also 
allow examination of patient groups where increases in dopamine release, if present,  might 
be expected to be smaller in magnitude to that in patients with active schizophrenia 
symptoms. This would include those at increased risk of the condition, such as relatives of 
schizophrenia patients and those with the schizophrenia prodrome. In this thesis no evidence 
of increased striatal dopamine synthesis capacity was found in the well twins of dizygotic 
pairs discordant for schizophrenia or in healthy subjects with auditory hallucinations. It 
would be interesting to look for evidence for increased dopamine release in these groups, as it 
could represent a potential psychosis endophenotype.  
  
155 
 
8. References 
 
 
Aalto S, Hirvonen J, Kajander J, Scheinin H, Någren K, Vilkman H, Gustafsson L, Syvälahti 
E, Hietala J (2002). Ketamine does not decrease striatal dopamine D2 receptor 
binding in man. Psychopharmacology (Berl). 164(4):401-6. 
 
Abi-Dargham, A. & Laruelle, M. (2005). Mechanisms of action of second generation 
antipsychotic drugs in schizophrenia: insights from brain imaging studies.  Eur. 
Psychiatry  20, 15-27. 
Abi-Dargham, A., Kegeles, L. S., Zea-Ponce, Y., Mawlawi, O., Martinez, D., Mitropoulou, 
V., O'Flynn, K., Koenigsberg, H. W., Van, H. R., Cooper, T., Laruelle, M. & Siever, 
L. J. (2004). Striatal amphetamine-induced dopamine release in patients with 
schizotypal personality disorder studied with single photon emission computed 
tomography and [123I]iodobenzamide.  Biol. Psychiatry  55, 1001-1006. 
Abi-Dargham, A., Mawlawi, O., Lombardo, I., Gil, R., Martinez, D., Huang, Y., Hwang, D. 
R., Keilp, J., Kochan, L., Van, H. R., Gorman, J. M. & Laruelle, M. (2002). Prefrontal 
dopamine D1 receptors and working memory in schizophrenia.  J. Neurosci.  22, 
3708-3719. 
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, 
R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., Gorman, J. M. & Laruelle, M. 
(2000). Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.  
Proc. Natl. Acad. Sci. U. S. A  97, 8104-8109. 
Allen P, Laroi F, McGuire PK, Aleman A. The hallucinating brain: a review of structural and 
functional neuroimaging studies of hallucinations. Neurosci Biobehav Rev. 
2008;32:175–191. 
 
Amunts K, Zilles K (2006) Atlases of the human brain: tools for functional neuroimaging. 
Springer, pp 566-603 
Andreasen NC, Flaum M, Arndt S. The Comprehensive Assessment of Symptoms and 
History (CASH) (1992). An instrument for assessing diagnosis and psychopathology. 
Arch Gen Psychiatry. 49:615–623. 
Ascher, J.A., Cole, J.O., Colin, J.N., Feighner, J.P., Ferris, R.M., Fibiger, H.C., Golden, 
R.N.,Martin, P., Potter, W.Z., Richelson, E., Sulser, F., 1995. Bupropion: a review of 
its mechanism of antidepressant activity. J. Clin. Psychiatry 56, 395–401 
Auclair A, Blanc G, Glowinski J, Tassin JP (2004a) Role of serotonin 2A receptors in the D-
amphetamine-induced release of dopamine: comparison with previous data on 
alpha1b-adrenergic receptors. J Neurochem 91(2):318–326 
 
156 
 
Auclair A, Drouin C, Cotecchia S, Glowinski J, Tassin JP (2004b) 5-HT2A and alpha1b-
adrenergic receptors entirely mediate dopamine release, locomotor response and 
behavioural sensitization to opiates and psychostimulants. Eur J Neurosci 
20(11):3073–3084 
Aylward, E., Walker, E. & Bettes, B. (1984). Intelligence in schizophrenia: meta-analysis of 
the research.  Schizophr. Bull.  10, 430-459. 
Balkin TJ, Braun AR, Wesensten NJ, Jeffries K, Varga M, Baldwin P, Belenky G, 
Herscovitch P (2002). The process of awakening: a PET study of regional brain 
activity patterns mediating the re-establishment of alertness and consciousness. Brain 
125(Pt 10):2308-19. 
Belmaker, R., Pollin, W., Wyatt, R. J. & Cohen, S. (1974). A follow-up of monozygotic 
twins discordant for schizophrenia.  Arch. Gen. Psychiatry  30, 219-222. 
Bhatt MH, Snow BJ, Martin WR, Pate BD, Ruth TJ, Calne DB (1991). Positron emission 
tomography suggests that the rate of progression of idiopathic parkinsonism is slow. 
Annals of Neurology 29, 673–677. 
Bischoff S, Gunst F (1997) Distinct binding patterns of [3H]raclopride and [3H]spiperone at 
dopamine D2 receptors in vivo in rat brain. Implications for pet studies. J Recept 
Signal Transduct Res 17:419-431 
Boileau I, Dagher A, Leyton M, Gunn RN, Baker GB, Diksic M, Benkelfat C (2006) 
Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission 
tomography study in healthy men. Arch Gen Psychiatry 63:1386-1395 
Bose, S. K., Turkheimer, F. E., Howes, O. D., Mehta, M. A., Cunliffe, R., Stokes, P. R. & 
Grasby, P. M. (2008). Classification of schizophrenic patients and healthy controls 
using [18F] fluorodopa PET imaging.  Schizophr. Res.  106, 148-155. 
Bossong, M.G., van Berckel, B.N., Boellaard, R., Zuurman, L., Schuit, R.C., Windhorst, 
A.D., van Gerven, J.M., Ramsey, N.F., Lammertsma, A.A., Kahn, R.S., 2009. Delta 
9-tetrahydrocannabinol induces dopamine release in the human striatum. 
Neuropsychopharmacology 34, 759–766. 
Bredeloux, P., Dubuc, I., Costentin, J., 2007. Comparisons between bupropion and 
dexamphetamine in a range of in vivo tests exploring dopaminergic transmission.Br. 
J. Pharmacol. 150, 711–719. 
Breier A, Adler CM, Weisenfeld N, Su TP, Elman I, Picken L, Malhotra AK, Pickar D 
(1998) Effects of NMDA antagonism on striatal dopamine release in healthy subjects: 
application of a novel PET approach. Synapse 29:142–147 
Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de BA, Weinberger DR, 
Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D (1997) Schizophrenia is 
associated with elevated amphetamine-induced synaptic dopamine concentrations: 
evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S 
A 94:2569-2574 
157 
 
Brown, E.E., Damsma, G.,Cumming, P., Fibiger, H.C., 1991. Interstitial 3-methoxytyramine 
reflects striatal dopamine release: an in vivo microdialysis study. J. Neurochem. 57, 
701–707. 
Cannon, T. D., Kaprio, J., Lonnqvist, J., Huttunen, M. & Koskenvuo, M. (1998). The genetic 
epidemiology of schizophrenia in a Finnish twin cohort. A population-based modeling 
study.  Arch. Gen. Psychiatry  55, 67-74. 
Cardno, A. G. & Gottesman, I. I. (2000). Twin studies of schizophrenia: from bow-and-arrow 
concordances to star wars Mx and functional genomics.  Am. J. Med. Genet.  97, 12-
17. 
Carlsson A, Svensson A, Carlsson ML (1993) Future strategies in the discovery of new 
antipsychotic agents: focus on dopamine-glutamate interactions. Karger, Basel 
Carlsson, A., Lindqvist, M. & Magnusson, T. (1957). 3,4-Dihydroxyphenylalanine and 5-
hydroxytryptophan as reserpine antagonists.  Nature  180, 1200. 
Cheer, J.F.,Wassum, K.M., Heien, M.L., Phillips, P.E., Wightman, R.M., (2004). 
Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of 
awake rats. J. Neurosci. 24, 4393–4400. 
Cherry SR (2001) Fundamentals of positron emission tomography and applications in 
preclinical drug development. J Clin Pharmacol 41:482-491 
Chugani DC, Ackermann RF, Phelps ME (1988) In vivo [3H]spiperone binding: evidence for 
accumulation in corpus striatum by agonist-mediated receptor internalization. J Cereb 
Blood Flow Metab 8:291-303 
Cohen, J. D., Forman, S. D., Braver, T. S., Casey, B. J., Servan-Schreiber, D. & Noll, D. C. 
(1994). Activation of prefrontal cortex in a non-spatial working memory task with 
functional MRI. In (Anonymous), pp. 293-304.  
Cordes M, Snow BJ, Cooper S, Schulzer M, Pate BD, Ruth TJ, Calne DB (1994). Age-
dependent decline of nigrostriatal dopaminergic function : a positron emission 
tomographic study of grandparents and their grandchildren. Annals of Neurology 36, 
667–670 
Creese I, Prosser T, Synder SH (1978) Dopamine receptor binding: specificity, localization 
and regulation by ions and guanyl nucleotides. Life Sci 23:495-499 
Creese I, Usdin TB, Snyder SH (1979) Dopamine receptor binding regulated by guanine 
nucleotides. Mol Pharmacol 16:69-76 
Daglish MR, Williams TM, Wilson SJ, Taylor LG, Eap CB, Augsburger M, Giroud C, 
Brooks DJ, Myles JS, Grasby P, Lingford-Hughes AR, Nutt DJ (2008). Brain 
dopamine response in human opioid addiction. Br J Psychiatry. 193(1):65-72. 
Damaj, M.I., Carroll, F.I., Eaton, J.B., Navarro, H.A., Blough, B.E., Mirza, S., Lukas, R.J., 
Martin, B.R., 2004. Enantioselective effects of hydroxy metabolites of bupropion on 
158 
 
behavior and on function of monoamine transporters and nicotinic receptors. Mol. 
Pharmacol. 66, 675–682. 
Daniel, D. G., Berman, K. F. & Weinberger, D. R. (1989). The effect of apomorphine on 
regional cerebral blood flow in schizophrenia.  J Neuropsychiatry Clin. Neurosci.  1, 
377-384. 
Dao-Castellana, M. H., Paillere-Martinot, M. L., Hantraye, P., ttar-Levy, D., Remy, P., 
Crouzel, C., Artiges, E., Feline, A., Syrota, A. & Martinot, J. L. (1997). Presynaptic 
dopaminergic function in the striatum of schizophrenic patients.  Schizophr. Res.  23, 
167-174. 
Davis, K. L., Kahn, R. S., Ko, G. & Davidson, M. (1991). Dopamine in schizophrenia: a 
review and reconceptualization.  Am. J. Psychiatry  148, 1474-1486. 
de Beaurepair, R., Labelle, A., Naber, D., Jones, B. D. & Barnes, T. R. (1995). An open trial 
of the D1 antagonist SCH 39166 in six cases of acute psychotic states.  
Psychopharmacology (Berl)  121, 323-327. 
De Deurwaerdère P, Spampinato U (1999) Role of 5-HT2A and 5-HT2C receptor subtypes in 
the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe 
nucleus electrical stimulation. J Neurochem 73:1033–1042 
 
De Deuwaerdère P, Navailles S, Berg KA, Clarke WP, Spampinato U (2004) Constitutive 
activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat 
striatum and nucleus accumbens. J Neurosci 24:3235–3241 
De Jesus OT, Van Moffaert GJ, Dinerstein RJ, Friedman AM (1986) Exogenous l-dopa alters 
spiroperidol binding, in vivo, in the mouse striatum. Life Sci 39:341-349 
De Mei, C., Ramos, M., Iitaka, C., and Borrelli, E. (2009) Getting specialized: presynaptic 
and postsynaptic dopamine D2 receptors. Curr Opin Pharmacol 9:53–58. 
Dempster, E. L., Pidsley, R., Schalkwyk, L. C., Owens, S., Georgiades, A., Kane, F., 
Kalidindi, S., Picchioni, M., Kravariti, E., Toulopoulou, T., Murray, R. M. & Mill, J. 
(2011). Disease-associated epigenetic changes in monozygotic twins discordant for 
schizophrenia and bipolar disorder.  Hum. Mol. Genet.  
den Boer, J. A., van Megen, H. J., Fleischhacker, W. W., Louwerens, J. W., Slaap, B. R., 
Westenberg, H. G., Burrows, G. D. & Srivastava, O. N. (1995). Differential effects of 
the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of 
schizophrenia.  Psychopharmacology (Berl)  121, 317-322. 
Di Chiara G, Imperato A (1988). Drugs abused by humans preferentially increase synaptic 
dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl 
Acad Sci USA 85: 5274–5278.  
Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E (1998). Selective blockade of 
serotonin2C/2B receptors enhances dopamine release in the rat nucleus accumbens. 
Neuropharmacology 37:265–272 
159 
 
 
Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E (1999). SB242084, a selective 
serotonin2c receptor antagonist, increases dopaminergic transmission in the 
mesolimbic system. Neuropharmacology 38:1195–1205 
Diederen KM, Daalman K, de Weijer AD, Neggers SF, van Gastel W, Blom JD, Kahn RS, 
Sommer IE.Auditory Hallucinations Elicit Similar Brain Activation in Psychotic and 
Nonpsychotic Individuals. Schizophr Bull. 2011 Apr 28. 
 
Diederen KM, Neggers SF, Daalman K, Blom JD, Goekoop R, Kahn RS, Sommer IE. 
Deactivation of the parahippocampal gyrus preceding auditory hallucinations in 
schizophrenia. Am J Psychiatry. 2010;167:427–435. 
 
Dolan, R. J., Fletcher, P., Frith, C. D., Friston, K. J., Frackowiak, R. S. & Grasby, P. M. 
(1995). Dopaminergic modulation of impaired cognitive activation in the anterior 
cingulate cortex in schizophrenia.  Nature  378, 180-182. 
Doot RK, Scheuermann JS, Christian PE, Karp JS, Kinahan PE (2010) Instrumentation 
factors affecting variance and bias of quantifying tracer uptake with PET/CT. Med 
Phys 37:6035-6046 
Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA, Price JL, Mathis CA 
(2001) Amphetamine-induced dopamine release in human ventral striatum correlates 
with euphoria. Biol Psychiatry 49:81-96 
Drevets WC, Price JC, Kupfer DJ, Kinahan PE, Lopresti B, Holt D, Mathis CA (1999) PET 
measures of amphetamine-induced dopamine release in ventral versus dorsal striatum. 
Neuropsychopharmacology 21(6):694-709. 
 
Egerton A, Ahmad R, Hirani E, Grasby PM (2008) Modulation of striatal dopamine release 
by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat. 
Psychopharmacology (Berl). 2008 Nov;200(4):487-96 
 
Egerton A, Mehta MA, Montgomery AJ, Lappin JM, Howes OD, Reeves SJ, Cunningham 
VJ, Grasby PM. (2009). The dopaminergic basis of human behaviors: A review of 
molecular imaging studies. Neurosci Biobehav Rev. 33(7):1109-32. 
 
Egerton, A., Shotbolt, J. P., Stokes, P. R., Hirani, E., Ahmad, R., Lappin, J. M., Reeves, S. J., 
Mehta, M. A., Howes, O. D. & Grasby, P. M. (2010). Acute effect of the anti-
addiction drug bupropion on extracellular dopamine concentrations in the human 
striatum: an [11C]raclopride PET study.  Neuroimage.  50, 260-266. 
Ehrin
 
E, Gawell
 
L, Högberg T, de Paulis
 
T, Ström
 
P (1987) Synthesis of [methoxy-
3
H]- and 
[methoxy-
11
C]- labelled raclopride. J Labelled Compounds  Radiopharm 24(8):931–
940 
Eidelberg D, Takikawa S, Dhawan V, Chaly T, Robeson W, Dahl R, Margouleff D, Moeller 
JR, Patlak CS, Fahn S (1993). Striatal 18F-dopa uptake: absence of an aging effect. 
Journal of Cerebral Blood Flow and Metabolism 13, 881–888. 
160 
 
Elkashef, A. M., Doudet, D., Bryant, T., Cohen, R. M., Li, S. H. & Wyatt, R. J. (2000). 6-
(18)F-DOPA PET study in patients with schizophrenia. Positron emission 
tomography.  Psychiatry Res.  100, 1-11. 
Endicott, J., Spitzer, R. L., Fleiss, J. L. & Cohen, J. (1976). The global assessment scale. A 
procedure for measuring overall severity of psychiatric disturbance.  Arch. Gen. 
Psychiatry  33, 766-771. 
Fadda P, Scherma M, Fresu A, Collu M, Fratta W (2003). Baclofen antagonizes nicotine-, 
cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat. 
Synapse 50(1):1-6. 
Ferris, R.M., Beaman, O.J., (1983). Bupropion: a new antidepressant drug, the mechanism of 
action of which is not associated with down-regulation of postsynaptic betaadrenergic, 
serotonergic (5-HT2), alpha 2-adrenergic, imipramine and dopaminergic receptors in 
brain. Neuropharmacology 22, 1257–1267 
Finnema SJ, Halldin C, Bang-Andersen B, Gulyas B, Bundgaard C, Wikstrom HV, Farde L 
(2009) Dopamine D(2/3) receptor occupancy of apomorphine in the nonhuman 
primate brain--a comparative PET study with [11C]raclopride and [11C]MNPA. 
Synapse 63:378-389 
Fish, B. & Hagin, R. (1972). Visual-motor disorders in infants at risk for schizophrenia.  
Arch. Gen. Psychiatry  27, 594-598. 
Gallezot JD, Beaver JD, Gunn RN, Nabulsi N, Weinzimmer D, Singhal T, Slifstein M, 
Fowles K, Ding YS, Huang Y, Laruelle M, Carson RE, Rabiner EA (2012). Affinity 
and selectivity of [
11
C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey 
brain in vivo. Synapse, 66 (6); 489-500, 2012. 
Gazzara, R.A., Andersen, S.L., (1997). The effects of bupropion in vivo in the neostriatum of 
5-day-old and adult rats. Brain Res. Dev. Brain Res. 100, 139–142. 
Gerfen C.R. (2000) Molecular effects of dopamine on striatal-projection pathways. Trends 
Neurosci 23:S64–S70. 
Ginovart N, Galineau L, Willeit M, Mizrahi R, Bloomfield PM, Seeman P, Houle S, Kapur S, 
Wilson AA (2006) Binding characteristics and sensitivity to endogenous dopamine of 
[11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 
receptors in vivo using positron emission tomography. J Neurochem 97:1089-1103 
Ginovart, N., Willeit, M., Rusjan, P., Graff, A., Bloomfield, P. M., Houle, S., Kapur, S. & 
Wilson, A. A. (2007). Positron emission tomography quantification of [11C]-(+)-
PHNO binding in the human brain.  J. Cereb. Blood Flow Metab  27, 857-871. 
 
Gobert A, Millan MJ (1999) Serotonin (5-HT)2A receptor activation enhances dialysate 
levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-
moving rats. Neuropharmacology 38(2):315–317 
 
161 
 
Gobert A, Rivet J-M, Lejeune F, Newman-Tancredi A, Adhumeau-Auclair A, Nicolas JP 
(2000) Serotonin 2C receptors tonically suppress the activity of mesocortical 
dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and 
electrophysiological analysis in the rat. Synapse 36:205–221 
Gold, J. M., Carpenter, C., Randolph, C., Goldberg, T. E. & Weinberger, D. R. (1997). 
Auditory working memory and Wisconsin Card Sorting Test performance in 
schizophrenia.  Arch. Gen. Psychiatry  54, 159-165. 
Graff-Guerrero A, Mizrahi R, Agid O, Marcon H, Barsoum P, Rusjan P, Wilson AA, 
Zipursky R, Kapur S. (2009a). The dopamine D2 receptors in high-affinity state and 
D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study.  
Neuropsychopharmacology  34, 1078-1086. 
 
Graff-Guerrero A, Mamo D, Shammi CM, Mizrahi R, Marcon H, Barsoum P, Rusjan P, 
Houle S, Wilson AA, Kapur S (2009b) The effect of antipsychotics on the high-
affinity state of D2 and D3 receptors: a positron emission tomography study with 
[11C]-(+)-PHNO. Arch Gen Psychiatry 66(6):606-15. 
Green MV, Seidel J, Stein SD, Tedder TE, Kempner KM, Kertzman C, Zeffiro TA (1994) 
Head movement in normal subjects during simulated PET brain imaging with and 
without head restraint. J Nucl Med 35:1538-1546 
Greisenger, W. (1861). Die Pathologie und Therapie der Psychischen Krankheiten. Krabbe, 
Stuttgart. 
Griffon, N., Sokoloff, P., Diaz, J., Levesque, D., Sautel, F., Schwartz, J. C., Simon, P., 
Costentin, J., Garrido, F., Mann, A. & . (1995). The dopamine D3 receptor and 
schizophrenia: pharmacological, anatomical and genetic approaches.  Eur. 
Neuropsychopharmacol.  5 Suppl, 3-9. 
Grunder G, Carlsson A, Wong DF (2003). Mechanism of new antipsychotic medications: 
occupancy is not just antagonism. Arch Gen Psychiatry 60(10):974-7. 
 
Grunder G, Vernaleken I, Muller MJ, Davids E, Heydari N, Buchholz HG, Bartenstein P, 
Munk OL, Stoeter P, Wong DF, Gjedde A, Cumming P (2003). Subchronic 
haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic 
patients in vivo.Neuropsychopharmacology 28, 787–794. 
Guiramand, J., Montmayeur, J. P., Ceraline, J., Bhatia, M. & Borrelli, E. (1995). Alternative 
splicing of the dopamine D2 receptor directs specificity of coupling to G-proteins. J. 
Biol. Chem. 270, 7354±7358. 
Gunn RN, Gunn SR, Cunningham VJ (2001) Positron emission tomography compartmental 
models. J Cereb Blood Flow Metab 21:635-652 
Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ (1997) Parametric imaging of 
ligand-receptor binding in PET using a simplified reference region model. 
Neuroimage 6:279-287 
162 
 
Guo N, Guo W, Kralikova M, Jiang M, Schieren I, Narendran R, Slifstein M, Abi-Dargham 
A, Laruelle M, Javitch JA, Rayport S (2010). Impact of D2 receptor internalization on 
binding affinity of neuroimaging radiotracers. Neuropsychopharmacology 35(3):806-
17. 
Gurevich, E. V., Bordelon, Y., Shapiro, R. M., Arnold, S. E., Gur, R. E. & Joyce, J. N. 
(1997). Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with 
schizophrenia. A postmortem study.  Arch. Gen. Psychiatry  54, 225-232. 
Haddock, G., McCarron, J., Tarrier, N. & Faragher, E. B. (1999). Scales to measure 
dimensions of hallucinations and delusions: the psychotic symptom rating scales 
(PSYRATS).  Psychol. Med.  29, 879-889. 
Hammers, A., Allom, R., Koepp, M. J., Free, S. L., Myers, R., Lemieux, L., Mitchell, T. N., 
Brooks, D. J. & Duncan, J. S. (2003). Three-dimensional maximum probability atlas 
of the human brain, with particular reference to the temporal lobe.  Hum. Brain Mapp.  
19, 224-247. 
Hardin, J. W. &. H. J. M. (2003). Generalized Estimating Equations.  Chapman & Hall/CRC: 
Boca Raton, FL . 
Harding, C. M., Zubin, J. & Strauss, J. S. (1992). Chronicity in schizophrenia: revisited.  Br. 
J Psychiatry Suppl , 27-37. 
Hartvig P, Torstenson R, Tedroff J, Watanabe Y, Fasth KJ, Bjurling P, Langstrom B (1997) 
Amphetamine effects on dopamine release and synthesis rate studied in the Rhesus 
monkey brain by positron emission tomography. J Neural Transm 104:329-339 
Hietala, J., Syvalahti, E., Vuorio, K., Rakkolainen, V., Bergman, J., Haaparanta, M., Solin, 
O., Kuoppamaki, M., Kirvela, O., Ruotsalainen, U. & . (1995). Presynaptic dopamine 
function in striatum of neuroleptic-naive schizophrenic patients.  Lancet  346, 1130-
1131. 
Hirvonen, J., van Erp, T. G., Huttunen, J., Aalto, S., Nagren, K., Huttunen, M., Lonnqvist, J., 
Kaprio, J., Hietala, J. & Cannon, T. D. (2005). Increased caudate dopamine D2 
receptor availability as a genetic marker for schizophrenia.  Arch. Gen. Psychiatry  
62, 371-378. 
Honig, A., Romme, M. A., Ensink, B. J., Escher, S. D., Pennings, M. H. & deVries, M. W. 
(1998). Auditory hallucinations: a comparison between patients and nonpatients.  J. 
Nerv. Ment. Dis.  186, 646-651. 
Houston GC, Hume SP, Hirani E, Goggi JL, Grasby PM (2004) Temporal characterisation of 
amphetamine-induced dopamine release assessed with [11C]raclopride in 
anaesthetised rodents. Synapse 51:206-212 
Howes OD, Bose SK, Turkheimer F, Valli I, Egerton A, Valmaggia LR, Murray RM, 
McGuire P (2011a). Dopamine synthesis capacity before onset of psychosis: a 
prospective [18F]-DOPA PET imaging study. Am J Psychiatry 168(12):1311-7 
163 
 
Howes O, Bose S, Turkheimer F, Valli I, Egerton A, Stahl D, Valmaggia L, Allen P, Murray 
R, McGuire P (2011b). Progressive increase in striatal dopamine synthesis capacity as 
patients develop psychosis: a PET study. Mol Psychiatry 16(9):885-6. 
Howes, O. D., Egerton, A., Allan, V., McGuire, P., Stokes, P. & Kapur, S. (2009a). 
Mechanisms underlying psychosis and antipsychotic treatment response in 
schizophrenia: insights from PET and SPECT imaging.  Curr. Pharm. Des  15, 2550-
2559 
Howes, O. D. & Kapur, S. (2009b). The dopamine hypothesis of schizophrenia: version III--
the final common pathway.  Schizophr. Bull.  35, 549-562. 
Howes, O. D., Montgomery, A. J., Asselin, M. C., Murray, R. M., Valli, I., Tabraham, P., 
Bramon-Bosch, E., Valmaggia, L., Johns, L., Broome, M., McGuire, P. K. & Grasby, 
P. M. (2009c). Elevated striatal dopamine function linked to prodromal signs of 
schizophrenia.  Arch. Gen. Psychiatry  66, 13-20. 
Huttunen, J., Heinimaa, M., Svirskis, T., Nyman, M., Kajander, J., Forsback, S., Solin, O., 
Ilonen, T., Korkeila, J., Ristkari, T., McGlashan, T., Salokangas, R. K. & Hietala, J. 
(2008). Striatal dopamine synthesis in first-degree relatives of patients with 
schizophrenia.  Biol. Psychiatry  63, 114-117. 
Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, 
Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, 
Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey 
R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE (2007). 
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J 
Cereb Blood Flow Metab 27(9):1533-9. 
Ishikawa T, Dhawan V, Kazumata K, Chaly T, Mandel F,Neumeyer J, Margouleff C,  
Babchyck B, Zanzi I, Eidelberg D (1996). Comparative nigrostriatal dopaminergic 
imaging with iodine-123-beta CIT-FP/ SPECT and fluorine-18-FDOPA/PET. Journal 
of Nuclear Medicine 37, 1760–1765. 
Ito H, Takano H, Takahashi H, Arakawa R, Miyoshi M, Kodaka F, Okumura M, Otsuka T, 
Suhara T (2009). Effects of the antipsychotic risperidone on dopamine synthesis in 
human brain measured by positron emission tomography with L-[beta-11C]DOPA: a 
stabilizing effect for dopaminergic neurotransmission? Journal of Neurosciences 29, 
13730–13734. 
 Jardri R, Pouchet A, Pins D, Thomas P. Cortical activations during auditory verbal 
hallucinations in schizophrenia: a coordinate-based meta-analysis. Am J Psychiatry. 
2011;168:73–81. 
 
Jaskiw, G. E., Juliano, D. M., Goldberg, T. E., Hertzman, M., Urow-Hamell, E. & 
Weinberger, D. R. (1994). Cerebral ventricular enlargement in schizophreniform 
disorder does not progress. A seven year follow-up study.  Schizophr. Res.  14, 23-28. 
Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. 
Am J Psychiatry 148:1301–1308 
164 
 
Johns, L. C. (2005). Hallucinations in the general population.  Curr. Psychiatry Rep.  7, 162-
167. 
Johnstone, E. C., Crow, T. J., Frith, C. D., Husband, J. & Kreel, L. (1976). Cerebral 
ventricular size and cognitive impairment in chronic schizophrenia.  Lancet  2, 924-
926. 
Joyce, J. N. & Gurevich, E. V. (1999). D3 receptors and the actions of neuroleptics in the 
ventral striatopallidal system of schizophrenics.  Ann. N. Y. Acad. Sci.  877, 595-613. 
Kahn, R. S., Harvey, P. D., Davidson, M., Keefe, R. S., Apter, S., Neale, J. M., Mohs, R. C. 
& Davis, K. L. (1994). Neuropsychological correlates of central monoamine function 
in chronic schizophrenia: relationship between CSF metabolites and cognitive 
function.  Schizophr. Res.  11, 217-224. 
Kalivas PW, Bourdelais A, Abhold R, Abbott L (1989) Somatodendritic release of 
endogenous dopamine: in vivo dialysis in the A10 dopamine region. Neurosci Lett 
100:215-220 
Kapur, S. & Mamo, D. (2003). Half a century of antipsychotics and still a central role for 
dopamine D2 receptors.  Prog. Neuropsychopharmacol. Biol. Psychiatry  27, 1081-
1090. 
Kapur, S., Mizrahi, R. & Li, M. (2005). From dopamine to salience to psychosis--linking 
biology, pharmacology and phenomenology of psychosis.  Schizophr. Res.  79, 59-68. 
Karle, J., Clemmesen, L., Hansen, L., Andersen, M., Andersen, J., Fensbo, C., Sloth-Nielsen, 
M., Skrumsager, B. K., Lublin, H. & Gerlach, J. (1995). NNC 01-0687, a selective 
dopamine D1 receptor antagonist, in the treatment of schizophrenia.  
Psychopharmacology (Berl)  121, 328-329. 
Karlsson, P., Smith, L., Farde, L., Harnryd, C., Sedvall, G. & Wiesel, F. A. (1995). Lack of 
apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in 
acutely ill schizophrenic patients.  Psychopharmacology (Berl)  121, 309-316. 
Kay, S. R., Fiszbein, A. & Opler, L. A. (1987). The positive and negative syndrome scale 
(PANSS) for schizophrenia.  Schizophr. Bull.  13, 261-276. 
Kebabian, J. W. & Calne, D. B. (1979). Multiple receptors for dopamine.  Nature  277, 93-
96. 
Kegeles LS, Slifstein M, Xu X, Urban N, Thompson JL, Moadel T, Harkavy-Friedman JM, 
Gil R, Laruelle M, Abi-Dargham A (2010). Striatal and extrastriatal dopamine D2/D3 
receptors in schizophrenia evaluated with [18F]fallypride positron emission 
tomography. Biol Psychiatry 68(7):634-41. 
Kegeles LS, Martinez D, Kochan LD, Hwang D-R, Huang Y, Mawlawi O, Suckow RF, Van 
Heertum RL, Laruelle M (2002). NMDA antagonist effects on striatal dopamine 
release: positron emission tomography studies in humans. Synapse 43:19–29 
 
165 
 
Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, 
Cooper TB, Carlsson A, Laruelle M (2000)  Modulation of amphetamine-induced 
striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol 
Psychiatry 48:627–640 
Kegeles LS, Zea-Ponce Y, bi-Dargham A, Rodenhiser J, Wang T, Weiss R, Van Heertum 
RL, Mann JJ, Laruelle M (1999) Stability of [123I]IBZM SPECT measurement of 
amphetamine-induced striatal dopamine release in humans. Synapse 31:302-308 
Kim, Y., Zerwas, S., Trace, S. E. & Sullivan, P. F. (2011). Schizophrenia genetics: where 
next?  Schizophr. Bull.  37, 456-463. 
Koepp MJ, Gunn RN, Lawrence AD, Cunningham VJ, Dagher A, Jones T, Brooks DJ, Bench 
CJ, Grasby PM. (1998) Evidence for striatal dopamine release during a video game. 
Nature 21;393(6682):266-8. 
Koeppe RA, Holthoff VA, Frey KA, Kilbourn MR, Kuhl DE (1991) Compartmental analysis 
of [11C]flumazenil kinetics for the estimation of ligand transport rate and receptor 
distribution using positron emission tomography. J Cereb Blood Flow Metab 11:735-
744 
Lacroix, L. P., Hows, M. E., Shah, A. J., Hagan, J. J. & Heidbreder, C. A. (2003). Selective 
antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic 
neurotransmission in the rat anterior cingulate cortex.  Neuropsychopharmacology  
28, 839-849. 
Lahti AC, Holcomb HH, Gao X-M, Tamminga CA (1999) NMDA sensitive glutamate 
antagonism: a human model for psychosis.Neuropsychopharmacology 21:S158–S169 
 
Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor 
studies. Neuroimage 4:153-158 
Laruelle M, Slifstein M, Huang Y (2003) Relationships between radiotracer properties and 
image quality in molecular imaging of the brain with positron emission tomography. 
Mol Imaging Biol 5:363-375 
Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition 
techniques: a critical review. J Cereb Blood Flow Metab 20:423-451 
Laruelle, M., Abi-Dargham, A., Gil, R., Kegeles, L. & Innis, R. (1999). Increased dopamine 
transmission in schizophrenia: relationship to illness phases.  Biol. Psychiatry  46, 56-
72.  
Laruelle M, Iyer RN, al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, Baldwin RM, 
Kung HF, Charney DS, Hoffer PB, Innis RB, Bradberry CW (1997) Microdialysis 
and SPECT measurements of amphetamine-induced dopamine release in nonhuman 
primates. Synapse 25:1-14 
166 
 
Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS, 
Baldwin RM, Charney DS, Hoffer PB, Kung HF, Innis RB (1995) SPECT imaging of 
striatal dopamine release after amphetamine challenge. J Nucl Med 36:1182–1190 
Launay, G., Slade, P.D., (1981). The measurement of hallucinatory predisposition in male 
and female prisoners. Personality and Individual Differences 2, 221–234.  
Lenth, R. V. (2006).  Java Applets for Power and Sample Size [Computer software].  
Retrieved from http://www.stat.uiowa.edu/~rlenth/Power. 
Leyton M, Boileau I, Benkelfat C, Diksic M, Baker G, Dagher A (2002) Amphetamine-
induced increases in extracellular dopamine, drug wanting, and novelty seeking: a 
PET/[11C]raclopride study in healthy men. Neuropsychopharmacology 27:1027-1035 
Li, S.X., Perry, K.W., Wong, D.T., 2002. Influence of fluoxetine on the ability of bupropion 
to modulate extracellular dopamine and norepinephrine concentrations in three 
mesocorticolimbic areas of rats. Neuropharmacology 42, 181–190. 
Lindefors N, Barati S, O’Connor WT (1997) Differential effects of single and repeated 
ketamine administration on dopamine, serotonin, and GABA transmission in rat 
prefrontal cortex. Brain Res 759:202–212 
 
Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959). Study of a new 
schizophrenomimetic drug: serenyl. Arch Neurol Psychiatry 71:363–369 
 
Lucas G, Spampinato U (2000) Role of striatal serotonin2A and serotonin2C receptor 
subtypes in the control of in vivo dopamine outflow in the rat striatum. J Neurochem 
74:693–701 
 
Luisi AF (2002). Aripiprazole: first of a new class of antipsychotics. Formulary 37;575–587 
Mallikaarjun S, Salazar DE, Bramer SL (2004). Pharmacokinetics, tolerability, and safety of 
aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin 
Pharmacol. 2004 Feb;44(2):179-87. 
Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S. Differential effects of 
aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with 
schizophrenia: a triple tracer PET study (2007). Am J Psychiatry 164(9):1411-7. 
Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G 
(2004). A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in 
patients with schizophrenia treated with therapeutic doses of ziprasidone. American 
Journal of Psychiatry 161, 818–825. 
Marenco S, Carson RE, Berman KF, Herscovitch P, Weinberger DR (2004). Nicotine-
induced dopamine release in primates measured with [11C]raclopride PET. 
Neuropsychopharmacology 29(2):259-68. 
Martin WR, Palmer MR, Patlak CS, Calne DB (1989). Nigrostriatal function in humans 
studied with positron emission tomography. Annals of Neurology 26, 535–542. 
167 
 
Martinez, D., Slifstein, M., Broft, A., Mawlawi, O., Hwang, D. R., Huang, Y., Cooper, T., 
Kegeles, L., Zarahn, E., bi-Dargham, A., Haber, S. N. & Laruelle, M. (2003). Imaging 
human mesolimbic dopamine transmission with positron emission tomography. Part 
II: amphetamine-induced dopamine release in the functional subdivisions of the 
striatum.  J. Cereb. Blood Flow Metab  23, 285-300. 
Mason, O.J., Morgan, C.J., Stefanovic, A., Curran, H.V. (2008). The Psychotomimetic States 
Inventory (PSI): measuring psychotic-type experiences from ketamine and cannabis. 
Schizophr. Res. 103, 138–142. 
Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, Huang Y, Simpson 
N, Ngo K, Van HR, Laruelle M (2001) Imaging human mesolimbic dopamine 
transmission with positron emission tomography: I. Accuracy and precision of D(2) 
receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 
21:1034-1057 
McCormick PN, Ginovart N, Wilson AA (2010) Isoflurane Anaesthesia Differentially 
Affects the Amphetamine Sensitivity of Agonist and Antagonist D2/D3 Positron 
Emission Tomography Radiotracers: Implications for In Vivo Imaging of Dopamine 
Release. Mol Imaging Biol 
McCormick PN, Kapur S, Seeman P, Wilson AA (2008) Dopamine D2 receptor radiotracers 
[(11)C](+)-PHNO and [(3)H]raclopride are indistinguishably inhibited by D2 agonists 
and antagonists ex vivo. Nucl Med Biol 35:11-17 
McGowan, S., Lawrence, A. D., Sales, T., Quested, D. & Grasby, P. (2004). Presynaptic 
dopaminergic dysfunction in schizophrenia: a positron emission tomographic 
[18F]fluorodopa study.  Arch. Gen. Psychiatry  61, 134-142. 
McQuade R, Burris KD, Jordan S, Tottori K, Kurahashi N, Kikuchi T (2002). Aripiprazole: a 
dopamine-serotonin system stabilizer. Int. J. Neuropsychopharmacol 5 (suppl.);S176 
 
Meller E, Goldstein M, Bohmaker K: Receptor reserve for 5-hydroxytryptamine 1A-mediated 
inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5-
hydroxytryptamine 1A agonists. Mol Pharmacol 1990; 37:231–237. 
 
Millan, M. J., Di, C. B., Dekeyne, A., Panayi, F., De, G. L., Sicard, D., Cistarelli, L., Billiras, 
R. & Gobert, A. (2007). Selective blockade of dopamine D(3) versus D(2) receptors 
enhances frontocortical cholinergic transmission and social memory in rats: a parallel 
neurochemical and behavioural analysis.  J Neurochem.  100, 1047-1061. 
 
Millan MJ: Improving the treatment of schizophrenia: focus on serotonin 5-HT1A receptors. J 
Pharmacol Exp Ther 2000; 295:853–861 
Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ (1984) A quantitative model 
for the in vivo assessment of drug binding sites with positron emission tomography. 
Ann Neurol 15:217-227 
Missale C, Nash SR, Robinson SW, Jaber M, and Caron MG (1998) Dopamine receptors: 
from structure to function. Physiol Rev 78:189–225. 
168 
 
Mizrahi R, Houle S, Vitcu I, Ng A, Wilson AA (2010). Side effects profile in humans of 
(11)C-(+)-PHNO, a dopamine D(2/3) agonist ligand for PET. J Nucl Med. 51(3):496- 
Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic 
neurotransmission by ketamine: a novel step in the pathway from NMDA receptor 
blockade to dopaminergic and cognitive disruptions associated with the prefrontal 
cortex. J Neurosci 17:2921–2927 
Montgomery AJ, Lingford-Hughes AR, Egerton A, Nutt DJ, Grasby PM (2007). The effect of 
nicotine on striatal dopamine release in man: a [11C]raclopride PET study. Synapse 
61, 637–645. 
Montgomery AJ, Thielemans K, Mehta MA, Turkheimer F, Mustafovic S, Grasby PM (2006) 
Correction of head movement on PET studies: comparison of methods. J Nucl Med 
47:1936-1944 
Montgomery, A.J., Mehta, M.A., Grasby, P.M., (2006). Is psychological stress in man 
associated with increased striatal dopamine levels? A [11C]raclopride PET study. 
Synapse 60, 124–131. 
Montmayeur, J. P., Guiramand, J. & Borrelli, E. (1993) Preferential coupling between 
dopamine D2 receptors and G-proteins. Mol. Endocrinol. 7, 161±170. 
Morgan AE, Dewey SL. 1998. Effects of pharmacologic increases in brain GABA levels on 
cocaine-induced changes in extracellular dopamine. Synapse 28:60–65. 
Mukherjee J, Christian BT, Dunigan KA, Shi B, Narayanan TK, Satter M, Mantil J. (2002). 
Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, 
test-retest studies, and preliminary assessment of sensitivity to aging effects on 
dopamine D-2/D-3 receptors. Synapse 46(3):170-88. 
 
Munro CA, McCaul ME, Wong DF, Oswald LM, Zhou Y, Brasic J, Kuwabara H, Kumar A, 
Alexander M, Ye W, Wand GS (2006) Sex differences in striatal dopamine release in 
healthy adults. Biol Psychiatry 59:966-974 
Murray AM, Ryoo HL, Gurevich E, Joyce JN (1994): Localization of dopamine D3 receptors 
to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc Natl 
Acad Sci U S A 91:11271–11275 
Narendran R, Mason S, Laymon C, Lopresti B, Velasquez N, May M, Kendro S, Martinez D, 
Mathis C, Frankle G (2010) A comparative evaluation of the dopamine D2/3 agonist 
radiotracer [11C]NPA and antagonist [11C]raclopride to measure amphetamine-
induced dopamine release in the human striatum. J Pharmacol Exp Ther 
Narendran, R., Frankle, W. G., Mason, N. S., Laymon, C. M., Lopresti, B. J., Price, J. C., 
Kendro, S., Vora, S., Litschge, M., Mountz, J. M. & Mathis, C. A. (2009). Positron 
emission tomography imaging of D(2/3) agonist binding in healthy human subjects 
with the radiotracer [(11)C]-N-propyl-norapomorphine: preliminary evaluation and 
reproducibility studies.  Synapse  63, 574-584. 
 
169 
 
Narendran R, Slifstein M, Guillin O, Hwang Y, Hwang DR, Scher E, Reeder S, Rabiner E, 
Laruelle M (2006) Dopamine (D2/3) receptor agonist positron emission tomography 
radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse 
60:485-495 
Narendran, R., Hwang, D.R., Slifstein, M., Hwang, Y., Huang, Y., Ekelund, J., Guillin, O., 
Scher, E., Martinez, D., Laruelle, M. (2005) Measurement of the proportion of D2 
receptors configured in state of high affinity for agonists in vivo: a positron emission 
tomography study using [11C]N-propyl-norapomorphine and [11C]raclopride in 
baboons. J Pharmacol Exp Ther. 315(1):80-90. 
Narendran R, Hwang DR, Slifstein M, Talbot PS, Erritzoe D, Huang Y, Cooper TB, Martinez 
D, Kegeles LS, Abi-Dargham A, Laruelle M (2004) In vivo vulnerability to 
competition by endogenous dopamine: comparison of the D2 receptor agonist 
radiotracer (-)-N-[11C]propyl-norapomorphine ([11C]NPA) with the D2 receptor 
antagonist radiotracer [11C]-raclopride. Synapse 52:188-208 
Navari S, Dazzan P (2009). Do antipsychotic drugs affect brain structure ? A systematic and 
critical review of MRI findings. Psychological Medicine 39, 1763–1777. 
Neve, K. A., Seamans, J. K. & Trantham-Davidson, H. (2004). Dopamine receptor signaling.  
J Recept. Signal. Transduct. Res.  24, 165-205.  
Niehoff DL, Palacios JM, Kuhar MJ (1979) In vivo receptor binding: attempts to improve 
specific/non-specific ratios. Life Sci 25:819-826 
Nomikos, G.G., Damsma, G., Wenkstern, D., Fibiger, H.C., 1989. Acute effects of bupropion 
on extracellular dopamine concentrations in rat striatum and nucleus accumbens 
studied by in vivo microdialysis. Neuropsychopharmacology 2, 273–279. 
Olney JW, Farber NB (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen 
Psychiatry 52:998–1007 
Olsson H, Halldin C, Swahn CG, Farde L (1999). Quantification of [11C]FLB 457 binding to 
extrastriatal dopamine receptors in the human brain. J Cereb Blood Flow Metab. 
19(10):1164-73. 
 
Oswald LM, Wong DF, McCaul M, Zhou Y, Kuwabara H, Choi L, Brasic J, Wand GS 
(2005) Relationships among ventral striatal dopamine release, cortisol secretion, and 
subjective responses to amphetamine. Neuropsychopharmacology 30:821-832 
Pae CU, Serretti A, Patkar AA, Masand PS (2008). Aripiprazole in the treatment of 
depressive and anxiety disorders: a review of current evidence. CNS Drugs 22;367–
388 
Park, S. & Holzman, P. S. (1992). Schizophrenics show spatial working memory deficits.  
Arch. Gen. Psychiatry  49, 975-982. 
Parsey, R. V., Slifstein, M., Hwang, D. R., bi-Dargham, A., Simpson, N., Mawlawi, O., Guo, 
N. N., Van, H. R., Mann, J. J. & Laruelle, M. (2000). Validation and reproducibility 
of measurement of 5-HT1A receptor parameters with [carbonyl-11C]WAY-100635 in 
170 
 
humans: comparison of arterial and reference tisssue input functions.  J. Cereb. Blood 
Flow Metab  20, 1111-1133. 
 
Patlak CS, Blasberg RG, Fenstermacher JD (1983) Graphical evaluation of blood-to-brain 
transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 3:1-7 
Peters E, Joseph S, Day S, Garety P. Measuring delusional ideation: the 21-item Peters et al. 
Delusions Inventory (PDI). Schizophr Bull. 2004;30:1005–1022. 
 
Peters, E. R., Joseph, S. A. & Garety, P. A. (1999). Measurement of delusional ideation in the 
normal population: introducing the PDI (Peters et al. Delusions Inventory).  
Schizophr. Bull.  25, 553-576. 
Phelps ME (2006) PET : physics, instrumentation and scanners. Springer. 
Pidoplichko VI, DeBiasi M, Williams JT, Dani JA (1997) Nicotine activates and desensitizes 
midbrain dopamine neurons. Nature 390(6658):401-4. 
Pontieri FE, Tanda G, Orzi F, Di Chiara G (1996). Effects of nicotine on the nucleus 
accumbens and similarity to those of addictive drugs. Nature 382: 255–257.  
Porras G, Di Matteo V, Fracasso C, Lucas G, De Deurwaerdère P, Caccia S, Esposito E, 
Spampinato U (2002) 5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine 
release induced in vivo by amphetamine and morphine in both the rat nucleus 
accumbens and striatum. Neuropsychopharmacology 26:311–324 
Rabe-Hesketh, S. &. S. A. (2010). Multilevel and Longitudinal Modeling using Stata.  Stata 
Press: College Station, TX . 
Rabiner EA, Slifstein M, Nobrega J, Plisson C, Huiban M, Raymond R, Diwan M, Wilson 
AA, McCormick P, Gentile G, Gunn RN, Laruelle MA (2009) In vivo quantification 
of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-
human primates and transgenic mice. Synapse 63:782-793 
Raine, A. (1991). The SPQ: a scale for the assessment of schizotypal personality based on 
DSM-III-R criteria.  Schizophr. Bull.  17, 555-564. 
Rankin, M.L., Hazelwood, L.A., Free, R.B., Namkung, Y., Rex, E.B., Roof, R.A. and Sibley 
D.R.(2010) Molecular pharmacology of the dopamine receptors, in Dopamine 
Handbook (Iversen LL, Dunnett SB, Iversen SD, Bjorklund A ed) pp 63–87, Oxford 
University Press, New York. 
Reavill, C., Taylor, S. G., Wood, M. D., Ashmeade, T., Austin, N. E., Avenell, K. Y., 
Boyfield, I., Branch, C. L., Cilia, J., Coldwell, M. C., Hadley, M. S., Hunter, A. J., 
Jeffrey, P., Jewitt, F., Johnson, C. N., Jones, D. N., Medhurst, A. D., Middlemiss, D. 
N., Nash, D. J., Riley, G. J., Routledge, C., Stemp, G., Thewlis, K. M., Trail, B., 
Vong, A. K. & Hagan, J. J. (2000). Pharmacological actions of a novel, high-affinity, 
and selective human dopamine D(3) receptor antagonist, SB-277011-A.  J 
Pharmacol. Exp. Ther.  294, 1154-1165. 
171 
 
Richtand NM, Welge JA, Logue AD, Keck PE Jr, Strakowski SM, McNamara RK (2007). 
Dopamine and serotonin receptor binding and antipsychotic efficacy. 
Neuropsychopharmacology 32(8):1715-26. 
Robertson GS, Damsma G, Fibiger HC (1991) Characterization of dopamine release in the 
substantia nigra by in vivo microdialysis in freely moving rats. J Neurosci 11:2209-
2216 
Roiser JP, Stephan KE, den Ouden HE, Barnes TR, Friston KJ, Joyce EM (2009). Do patients 
with schizophrenia exhibit aberrant salience? Psychol Med. 39(2):199-209.  
 
Roiser JP, Stephan KE, den Ouden HE, Friston KJ, Joyce EM. (2010). Adaptive and aberrant 
reward prediction signals in the human brain. Neuroimage 50(2):657-64.  
Rondou P, Haegeman G, and Van Craenenbroeck K (2010) The dopamine D4 receptor: 
biochemical and signalling properties. Cell Mol Life Sci 67:1971–1986. 
Ross, C. A., Margolis, R. L., Reading, S. A., Pletnikov, M. & Coyle, J. T. (2006). 
Neurobiology of schizophrenia.  Neuron  52, 139-153. 
Ruttimann UE, Andreason PJ, Rio D (1995) Head motion during positron emission 
tomography: is it significant? Psychiatry Res 61:43-51 
Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak RS (1990). Striatal 
function in normal aging : implications for Parkinson’s disease. Annals of Neurology 
28, 799–804. 
Schotte A, Janssen PF, Bonaventure P, Leysen JE (1996) Endogenous dopamine limits the 
binding of antipsychotic drugs to D3 receptors in the rat brain: a quantitative 
autoradiographic study. Histochem J 28:791-799 
Schotte A, Janssen PF, Gommeren W, Luyten WH, Leysen JE (1992) Autoradiographic 
evidence for the occlusion of rat brain dopamine D3 receptors in vivo. Eur J 
Pharmacol 218:373-375 
Schultz, W. (1999). The Reward Signal of Midbrain Dopamine Neurons.  News Physiol Sci.  
14, 249-255. 
Searle G, Beaver JD, Comley RA, Bani M, Tziortzi A, Slifstein M, Mugnaini M, Griffante C, 
Wilson AA, Merlo-Pich E, Houle S, Gunn R, Rabiner EA, Laruelle M (2010) Imaging 
dopamine D3 receptors in the human brain with positron emission tomography, 
[11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry 68:392-399 
Seeman P.(2012). Dopamine agonist radioligand binds to both D2High and D2Low receptors, 
explaining why alterations in D2High are not detected in human brain scans. Synapse 
66(1):88-93.  
Seeman, P. (2011). All roads to schizophrenia lead to dopamine supersensitivity and elevated 
dopamine D2(high) receptors.  CNS. Neurosci. Ther.  17, 118-132. 
172 
 
Seeman, P. (2011). All roads to schizophrenia lead to dopamine supersensitivity and elevated 
dopamine D2(high) receptors.  CNS. Neurosci. Ther.  17, 118-132. 
Seeman, P., Schwarz, J., Chen, J. F., Szechtman, H., Perreault, M., McKnight, G. S., Roder, 
J. C., Quirion, R., Boksa, P., Srivastava, L. K., Yanai, K., Weinshenker, D. & 
Sumiyoshi, T. (2006). Psychosis pathways converge via D2high dopamine receptors.  
Synapse  60, 319-346. 
Seeman, P., Schwarz, J., Chen, J. F., Szechtman, H., Perreault, M., McKnight, G. S., Roder, 
J. C., Quirion, R., Boksa, P., Srivastava, L. K., Yanai, K., Weinshenker, D. & 
Sumiyoshi, T. (2006). Psychosis pathways converge via D2high dopamine receptors.  
Synapse  60, 319-346. 
Seeman P (2006) Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther 
Targets 10:515–531 
Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L. X., Sibley, D. R., Roth, B. 
L. & Mailman, R. (2003). Aripiprazole, a novel atypical antipsychotic drug with a 
unique and robust pharmacology.  Neuropsychopharmacology  28, 1400-1411. 
 
Sharp FR, Tomitaka M, Bernaudin M, Tomitaka S (2001). Psychosis: pathological activation 
of limbic thalamocortical circuits by psychomimetics and schizophrenia? Trends 
Neurosci 26:330–334 
Sibley DR (1999) New insights into dopaminergic receptor function using antisense and 
genetically altered animals. Annu Rev Pharmacol Toxicol 39:313–341. 
Sibley DR, De LA, Creese I (1982) Anterior pituitary dopamine receptors. Demonstration of 
interconvertible high and low affinity states of the D-2 dopamine receptor. J Biol 
Chem 257:6351-6361 
Sidhpura, N., Redfern, P., Rowley, H., Heal, D., Wonnacott, S., (2007). Comparison of the 
effects of bupropion and nicotine on locomotor activation and dopamine release in 
vivo. Biochem. Pharmacol. 74, 1292–1298. 
Skinbjerg M, Liow JS, Seneca N, Hong J, Lu S, Thorsell A, Heilig M, Pike VW, Halldin C, 
Sibley DR, Innis RB (2010) D2 dopamine receptor internalization prolongs the 
decrease of radioligand binding after amphetamine: a PET study in a receptor 
internalization-deficient mouse model. Neuroimage 50(4):1402-7.  
Smieskova R, Fusar-Poli P, Allen P, Bendfeldt K, Stieglitz RD, Drewe J, Radue EW, 
McGuire PK, Riecher-Rossler A, Borgwardt SJ (2009). The effects of antipsychotics 
on the brain : what have we learnt from structural imaging of schizophrenia ? – a 
systematic review. Current Pharmacological Design 15,2535–2549. 
Smith GS, Schloesser R, Brodie JD, Dewey SL, Logan J, Vitkun SA, Simkowitz P, Hurley A, 
Cooper T, Volkow ND, Cancro R (1998). Glutamate modulation of dopamine 
measured in vivo with positron emission tomography (PET) and [
11
C]raclopride in 
normal human subjects. Neuropsychopharmacology 18:18–25 
173 
 
Sokoloff P, Andrieux M, Besancon R, Pilon C, Martres MP, Giros B, Schwartz JC (1992) 
Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: 
comparison with D2 receptor. Eur J Pharmacol 225:331-337 
Sokoloff P., Diaz J., Le Foll B., Guillin O., Leriche L., Bezard E., and Gross C. (2006) The 
dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric 
disorders. CNS Neurol Disord Drug Targets 5:25–43. 
 Sommer IE, Diederen KM, Blom JD, et al. Auditory verbal hallucinations predominantly 
activate the right inferior frontal area. Brain. 2008;131(pt 12):3169–3177. 
 
Sommer, I. E., Daalman, K., Rietkerk, T., Diederen, K. M., Bakker, S., Wijkstra, J. & Boks, 
M. P. (2008). Healthy Individuals With Auditory Verbal Hallucinations; Who Are 
They? Psychiatric Assessments of a Selected Sample of 103 Subjects.  Schizophr. 
Bull.  
Spitzer, R. L., Williams, J. B., Gibbon, M. & First, M. B. (1992). The Structured Clinical 
Interview for DSM-III-R (SCID). I: History, rationale, and description.  Arch. Gen. 
Psychiatry  49, 624-629. 
Spitzer, R. L., Williams, J. B., Gibbon, M. & First, M. B. (1992). The Structured Clinical 
Interview for DSM-III-R (SCID). I: History, rationale, and description.  Arch. Gen. 
Psychiatry  49, 624-629. 
Stahl SM (2001). Dopamine system stabilizers, aripiprazole, and the next generation of 
antipsychotics: part 1. J Clin Psychiatry, 62: 841–842 
 
Stahl SM (2001). Dopamine system stabilizers, aripiprazole, and the next generation of 
antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry 
62:923-4 
 
Stokes PR, Mehta MA, Curran HV, Breen G, Grasby PM (2009). Can recreational doses of 
THC produce significant dopamine release in the human striatum? Neuroimage 
15;48(1):186-90. 
Studholme, C., Hill, D. L. & Hawkes, D. J. (1997). Automated three-dimensional registration 
of magnetic resonance and positron emission tomography brain images by 
multiresolution optimization of voxel similarity measures.  Med. Phys.  24, 25-35. 
Studholme, C., Hill, D. L. & Hawkes, D. J. (1997). Automated three-dimensional registration 
of magnetic resonance and positron emission tomography brain images by 
multiresolution optimization of voxel similarity measures.  Med. Phys.  24, 25-35. 
Sudhyadhom, A., Haq, I. U., Foote, K. D., Okun, M. S. & Bova, F. J. (2009). A high 
resolution and high contrast MRI for differentiation of subcortical structures for DBS 
targeting: the Fast Gray Matter Acquisition T1 Inversion Recovery (FGATIR).  
Neuroimage.  47 Suppl 2, T44-T52. 
 
Sullivan, P. F., Kendler, K. S. & Neale, M. C. (2003). Schizophrenia as a complex trait:  
evidence from a meta-analysis of twin studies.  Arch. Gen. Psychiatry  60, 1187-1192. 
174 
 
Tanda, G., Pontieri, F.E., Di Chiara, G., (1997). Cannabinoid and heroin activation of 
mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. 
Science 276, 2048–2050. 
Tsuang, M. T., Woolson, R. F. & Fleming, J. A. (1979). Long-term outcome of major 
psychoses. I. Schizophrenia and affective disorders compared with psychiatrically 
symptom-free surgical conditions.  Arch. Gen. Psychiatry  36, 1295-1301. 
Turkheimer, F. E., Aston, J. A., Asselin, M. C. & Hinz, R. (2006). Multi-resolution Bayesian 
regression in PET dynamic studies using wavelets.  Neuroimage.  32, 111-121. 
Turkheimer, F. E., Brett, M., Visvikis, D. & Cunningham, V. J. (1999). Multiresolution 
analysis of emission tomography images in the wavelet domain.  J. Cereb. Blood 
Flow Metab  19, 1189-1208. 
Tziortzi AC, Searle GE, Tzimopoulou S, Salinas C, Beaver JD, Jenkinson M, Laruelle M, 
Rabiner EA, Gunn RN (2010) Imaging dopamine receptors in humans with [(11)C]-
(+)-PHNO: Dissection of D3 signal and anatomy. Neuroimage 54(1):264-77 
Tziortzi, A. C., Searle, G. E., Tzimopoulou, S., Salinas, C., Beaver, J. D., Jenkinson, M., 
Laruelle, M., Rabiner, E. A. & Gunn, R. N. (2011). Imaging dopamine receptors in 
humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy.  Neuroimage.  
54, 264-277. 
 
Tziortzi, A., Searle, G., Tzimopoulou, S., Beaver, J., Rabiner, E. & Gunn, R. (2009). Imaging 
the dopamine D3/D2 receptor with [11C]PHNO: Development and validation of 
manual and automated regional analyses.  J Nucl Med.  50 (Supplement 2), 531. 
 
Usiello A., Baik J.H., Rouge´-Pont F., Picetti R., Dierich A., LeMeur M., Piazza P.V., and 
Borrelli E. (2000) Distinct functions of the two isoforms of dopamine D2 receptors. 
Nature 408:199–203. 
Vallone D, Picetti R, and Borrelli E (2000) Structure and function of dopamine receptors. 
Neurosci Biobehav Rev 24:125–132. 
Vallone D, Picetti R, and Borrelli E (2000) Structure and function of dopamine receptors. 
Neurosci Biobehav Rev 24:125–132. 
Van Kammen DP, Murphy DL (1975). Attenuation of the euphoriant and activating effects of 
d- and l-amphetamine by lithium carbonate treatment. Psychopharmacologia 44: 215-
224. 
 
Vernaleken I, Kumakura Y, Cumming P, Buchholz HG, Siessmeier T, Stoeter P, Müller MJ, 
Bartenstein P, Gründer G (2006). Modulation of [18F]fluorodopa (FDOPA) kinetics 
in the brain of healthy volunteers after acute haloperidol challenge. Neuroimage 
30(4):1332-9. 
Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Wong C, Hitzemann R, Pappas NR 
(1999) Reinforcing effects of psychostimulants in humans are associated with 
increases in brain dopamine and occupancy of D(2) receptors. J Pharmacol Exp Ther  
291:409–415 
175 
 
Volkow, N.D., Wang, G.J., Fowler, J.S., Logan, J., Jayne, M., Franceschi, D., Wong, C., 
Gatley, S.J., Gifford, A.N., Ding, Y.S., Pappas, N., 2002. ‘‘Nonhedonic’’ food 
motivation in humans involves dopamine in the dorsal striatum and methylphenidate 
amplifies this effect. Synapse 44, 175–180. 
 
Vollenweider FX, Vontobel P, Oye I, Hell D, Leenders KL (2000) Effects of (S)-ketamine on 
striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. J 
Psychiatr Res 34:35–43 
 
Voruganti, L.N., Slomka, P., Zabel, P., Mattar, A., Awad, A.G., (2001). Cannabis induced 
dopamine release: an in-vivo SPECT study. Psychiatry Res. 107, 173–177. 
 
Wang, G.J., Volkow, N.D., Fowler, J.S., Franceschi, D., Logan, J., Pappas, N.R., Wong, 
C.T., Netusil, N., (2000). PET studies of the effects of aerobic exercise on human 
striatal dopamine release. J. Nucl. Med. 41, 1352–1356. 
Watt, N. F. (1972). Longitudinal changes in the social behavior of children hospitalized for 
schizophrenia as adults.  J Nerv. Ment. Dis  155, 42-54. 
Weinberger, D. R., Berman, K. F. & Illowsky, B. P. (1988). Physiological dysfunction of 
dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a 
monoaminergic mechanism.  Arch. Gen. Psychiatry  45, 609-615. 
Weinberger, D. R., Torrey, E. F., Neophytides, A. N. & Wyatt, R. J. (1979). Lateral cerebral 
ventricular enlargement in chronic schizophrenia.  Arch. Gen. Psychiatry  36, 735-
739. 
 
Willeit M, Ginovart N, Graff A, Rusjan P, Vitcu I, Houle S, Seeman P, Wilson AA, Kapur S 
(2008) First human evidence of d-amphetamine induced displacement of a D2/3 
agonist radioligand: A [11C]-(+)-PHNO positron emission tomography study. 
Neuropsychopharmacology 33:279-289 
Willeit, M., Ginovart, N., Kapur, S., Houle, S., Hussey, D., Seeman, P. & Wilson, A. A. 
(2006). High-affinity states of human brain dopamine D2/3 receptors imaged by the 
agonist [11C]-(+)-PHNO.  Biol. Psychiatry  59, 389-394Aalto S, Hirvonen J, 
Kajander J, Scheinin H, Någren K, Vilkman H, Gustafsson L, Syvälahti E, Hietala J 
(2002). Ketamine does not decrease striatal dopamine D2 receptor binding in man. 
Psychopharmacology (Berl) 164(4):401-6.  
Williams, R. L. (2000). A note on robust variance estimation for cluster-correlated data.  
Biometrics  56, 645-646. 
 
Wilson AA, McCormick P, Kapur S, Willeit M, Garcia A, Hussey D, Houle S, Seeman P, 
Ginovart N (2005) Radiosynthesis and evaluation of [11C]-(+)-4-propyl-
3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential 
radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron 
emission tomography. J Med Chem 48:4153-4160 
176 
 
Wolf ME and Roth RH (1990) Autoreceptor regulation of dopamine synthesis. Ann NY Acad 
Sci 604:323–343. 
 
Woods, S. W. (2003). Chlorpromazine equivalent doses for the newer atypical antipsychotics.  
J. Clin Psychiatry  64, 663-667. 
 
Wooltorton JR, Pidoplichko VI, Broide RS, Dani JA. Differential desensitization and 
distribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas. 
J Neurosci 2003; 23: 3176–85 
Yang, Y. (2011). Schizotypy trait and striatal dopamine receptors in healthy volunteers. 
Psychiatry Research: Neuroimaging 
 
Zahniser NR, Molinoff PB (1978) Effect of guanine nucleotides on striatal dopamine 
receptors. Nature 275:453-455 
 
 
 
